In Vitro-In Silico Methods For Risk Assessment Of Organophosphate Pesticides (OPs) As Found In Commonly Consumed Vegetables In Kenya

Isaac Mokaya Omwenga
Propositions

1. The presence of organophosphate pesticide residues in vegetables from Peri-urban Nairobi, Kenya requires risk management actions. (this thesis)
2. Physiologically based kinetic modeling is essential for a novel approach in risk assessment of organophosphate pesticides. (this thesis)
3. Antimicrobial resistance poses an existential threat to humanity.
4. Epigenetics holds the key in unraveling the possible factors behind health and disease.
5. The wellbeing of a society is largely dependent on consistent political decisions made.
6. Persistence and endurance are the most essential virtues in a PhD journey.

Propositions belonging to the thesis, entitled
In vitro-in silico methods for risk assessment of organophosphate pesticides (OPs) as found in commonly consumed vegetables in Kenya

Isaac Mokaya Omwenga

Wageningen, 7 January 2022
In vitro-in silico methods for risk assessment of organophosphate pesticides (OPs) as found in commonly consumed vegetables in Kenya

Isaac Mokaya Omwenga
Thesis committee:

Promotor
Prof. Dr. I.M.C.M. Rietjens
Professor of Toxicology
Wageningen University & Research
Wageningen, The Netherlands

Co-promotors
Dr. J. Louisse
Scientific Researcher Toxicology
Wageningen Food safety Research
Wageningen, The Netherlands

Dr. Hans Mol
Senior Scientist pesticides, natural toxins, food safety & exposure
Wageningen Food safety Research
Wageningen, The Netherlands

Other members
Prof. Dr. Violette Geissen, Wageningen University & Research
Dr. Jessica Broeders, Board for the Authorization of Plant Protection Products and Biocides (CTGB)
Dr. Paul Scheepers, Radboud University Medical Center, Nijmegen
Dr. Remco Westerink, Utrecht University

This research was conducted under the auspices of the Graduate School VLAG (Advanced studies in Food Technology, Agrobiotechnology, Nutrition and Health Sciences).
In vitro-in silico methods for risk assessment of organophosphate pesticides (OPs) as found in commonly consumed vegetables in Kenya

Isaac Mokaya Omwenga

Thesis

submitted in fulfilment of the requirements for the degree of doctor

at Wageningen University

by the authority of the Rector Magnificus,

Prof. Dr. A.P.J. Mol,

in the presence of the

Thesis Committee appointed by the Academic Board

to be defended in public

on Friday 7 January 2022

at 13:30 p.m. in the Aula.
Isaac Mokaya Omwenga

In vitro-in silico methods for risk assessment of organophosphate pesticides (OPs) as found in commonly consumed vegetables in Kenya

296 pages

PhD thesis, Wageningen University, Wageningen, the Netherlands (2022)

With references, with summary in English


DOI-link: https://doi.org/10.18174/553680
Contents

Chapter 1 ........................................................................................................................................ 7
General Introduction

Chapter 2 ...................................................................................................................................... 55
Organophosphate and Carbamate Pesticide Residues and accompanying risks in Commonly Consumed Vegetables in Kenya

Chapter 3 ..................................................................................................................................... 95
Prediction of dose-dependent in vivo acetylcholinesterase inhibition by profenofos in rats and humans using physiologically based kinetic (PBK) modeling-facilitated reverse dosimetry

Chapter 4 .................................................................................................................................... 147
Prediction of in vivo acetylcholinesterase inhibition upon acute combined exposure to profenofos and chlorpyrifos by using a combined in vitro and in silico approach

Chapter 5 .................................................................................................................................... 189
Predicting interindividual differences in profenofos detoxification based on in vitro kinetic data and a physiologically based kinetic (PBK) and Monte Carlo modelling approach

Chapter 6 .................................................................................................................................... 221
General Discussion and Future Perspectives

Chapter 7 ..................................................................................................................................... 281
Summary

Appendices ................................................................................................................................... 289
Acknowledgements, About the Author, Overview of Completed Training Activities
CHAPTER 1.

General Introduction
GENERAL INTRODUCTION, AIM AND OUTLINE OF THE THESIS

1.1 Background

Pesticides are indispensable in improving the efficiency of food production processes, increasing crop yields, reducing the costs of food, as well as providing high-quality produce for the ever increasing world population. Previous reports have indicated that up to 40% of food production globally is lost annually due to pests, weeds and diseases (Oerke, 2006). In addition, pesticide use has shown to be beneficial in controlling pests of infrastructural and public health significance such as termites, mosquitoes, ants, roaches, rats, and other pests (Suratman et al., 2015). Pesticides distribution from targeted sites may follow different routes during spraying, allowing toxic chemicals access to beneficial and non-target organisms in the environment (Ngolo, 2019). Organophosphate pesticides (OPs) are esters of phosphoric acid, thiophosphoric acid, or other phosphoric acids and are applied in many insecticides, certain herbicides, and nerve agents (Edwards, 1973; Kus hwaha et al., 2016). These chemicals were introduced to replace persistent and hazardous organochlorine pesticides (Chapalamadugu and Chaudhry, 1992; Pogačnik and Franko, 2003), becoming popular initially in the United States (Bonner et al., 2007) and then globally. However, most OPs have been classified by the World Health Organization (WHO) Food and Agriculture Organisation (FAO) and US Environmental Protection Agency (EPA) to be moderately or highly hazardous to non-target organisms including humans (WHO, 2009). OPs have been extensively used for the control of agricultural and household pests globally (Kumari and John, 2019). Exposure to these pesticides has been reported for various segments of the population, including agriculture workers and their families, household members during home application of pesticides, people that live in proximity to farms, or the general public via residues on food (Bradman et al., 2011; Lu et al., 2010). Studies worldwide reveal that infants and adults are exposed to OPs and carbamate pesticide residues as a consequence of their presence in food (Amaroli et al., 2013).
Furthermore, several studies have demonstrated that maternal exposure to food containing pesticides residues in the neonatal period as well as early infancy exposure can alter the development and function of the immune, nervous, endocrine and reproductive systems (Glynn et al., 2008; Grandjean et al., 2008; Borchers et al., 2010). In all these events, acetylcholinesterase (AChE) has been found to play a role in the modulation of cell proliferation (Angelini et al., 2004), apoptosis (Aluigi et al., 2010), cell-substrate interaction and messages mediated by ion changes (Aluigi et al., 2005). Recent studies provide insights on the mechanisms underlying the toxicity of neurotoxic pesticides, including, for example, AChE inhibitors (organophosphorus and carbamates) (Aardema et al., 2008) found in the environment and food from agricultural sites (Abdel Rasoul et al., 2008). A particular example is chlorpyrifos, whose exposure during the neonatal period and early infancy have been reported to alter the development and function of the nervous, immune, endocrine and reproductive systems (Glynn et al., 2008; Grandjean et al., 2008; Borchers et al., 2010), and has been shown to increase the risk of delays in mental and motor development and to cause an increased occurrence of pervasive developmental disorders such as Attention Deficit Hyperactivity Disorder (ADHD) (Rauh et al., 2006) following exposure of children while in the womb (Amaroli, 2013). Epidemiological studies have linked chronic OP exposure to reproductive disorders, developmental toxicity, birth defects, cancer, Parkinson’s disease, Alzheimer’s disease, diabetes, chronic respiratory disease, cardiovascular diseases, chronic nephropathies and amyotrophic lateral sclerosis (ALS) (Mostafalou & Abdollahi, 2013). The critical effects of OPs in animal studies are related to neurotoxicity (acute and chronic), of which some are mediated through inhibition of AChE, the enzyme that terminates the action of the neurotransmitter acetylcholine (ACh) within neuromuscular junctions and nerve tissue, leading to overstimulation of the post-synaptic membrane (Timchalk and Poet, 2008). Whereas acute OP toxicity is generally thought to be mediated by overstimulation of nicotinic and muscarinic
acetylcholine receptors due to AChE inhibition, chronic OP neurotoxicity is hypothesized to be due to receptor down-regulation. This leads to long-term neurological and neurobehavioral deficits (Costa, 2006; Costa, 2018), called organophosphorus ester-induced delayed neurotoxicity (OPIDN) or organophosphorus ester-induced chronic neurotoxicity (OPICN). OPs have not been found to be genotoxic, nor carcinogenic or teratogenic in chronic studies in rats (Ghorab and Khalil, 2015).

In the hazard and risk assessment of OPs, in vivo animal studies on OP-induced inhibition of brain or red blood cells (RBC) AChE have been used for various OPs to derive a point of departure (POD) such as a BMDL10 to set safe exposure levels, such as an Acute Reference Dose (ARfD). In these in vivo studies, AChE activity is usually measured in blood and sometimes also brain tissue after OP exposure. ARfDs for, for example, profenofos, chlorpyrifos, acephate, methamidofos and omethoate as reported by organizations as the European Food Safety Authority (EFSA), the United States Environmental Protection Authority (EPA), and the Joint FAO/WHO Meeting on Pesticide Residues (JMPR), have been derived from data on OP-induced AChE inhibition from animal studies (JMPR, 2007; EPA, 2006; EPA, 2011; EPA, 2016; EFSA, 2019). For example, PODs for profenofos and chlorpyrifos have been derived by estimation of exposure levels resulting in 10% RBC AChE inhibition following acute (single day, 24 hours) exposure. However, the reliance on approaches consisting of live animal experimentation has its drawbacks in terms of economical, ethical and scientific considerations (Van Norman, 2020; Wang et al., 2020; Huang et al., 2021). Consequently, the so-called principles of the 3Rs have been propagated in the later 1950s and reinforced in the European Union (Directives of the European Parliament), with the aim to Replace, Reduce and Refine (3Rs) the use of animals in scientific research (Russell and Burch, 1959; Flecknell, 2002; Amaroli et al., 2013; Kendall et al., 2018; Arck, 2019; Huang et al., 2021). Besides aiming for a reduction of animal use for toxicity testing, application of the 3Rs
are moving the field of chemical risk assessment to more mechanism-based in vitro and in silico approaches (Flecknell, 2002; Amaroli et al., 2013; Arck, 2019; Kendall et al., 2018). Furthermore, based on available data on pharmaceuticals, there have been concerns about the lack of concordance between animal and human toxicity and efficacy studies, which led scientists to question the value of animal studies requirement in determining drugs that should enter the last stage of trials (USFDA, 2006; Ewert et al., 2014; Milman, 2015; Van Norman, 2019; Abi-Gerges et al., 2019; Greenfieldboye, 2019; Van Norman, 2020). Although human data are in general lacking for non-pharmaceuticals, it can be expected that also for these chemicals, toxicity data obtained in animals may not always be representative for the human situation. Consequently, in vitro human tissue-based and in silico models have been developed as a replacement for animal in vivo models in testing of various compounds (Yang and Xiong, 2012). Indeed, in vitro approaches with cell cultures, organs-on-a-chip, organoids, 3D printed tissues (additive manufacturing), in silico computational biomodelling, and ex vivo tests using tissue from dead animals and humans have been developed to replace the use of live animals (Taylor, 2019; Huang et al., 2021; Van Norman, 2020). These models offer promise in overcoming the lack of correlation between animal and human toxicity studies (MacGregor et al., 2001; Thasler et al., 2006; Yang and Xiong, 2012). Moreover, in vitro studies facilitate exploration of cellular and molecular mechanisms underlying toxicity (Kendall, 2018). Consequently, the term “new approach methodologies” (NAMs) has emerged as a descriptive reference to these in silico or in vitro methods that can be utilized to predict data required for chemical hazard and risk assessment (Parish et al., 2020). These new approaches include integrated approaches to testing and assessment (IATAs), defined approaches for data interpretation, and performance-based evaluation of test methods (Parish et al., 2020).

With this view in mind, the present thesis aimed to assess whether in vivo dose-dependent OP-induced AChE inhibition can be predicted by a combined in vitro-in silico approach, allowing
to set an ARfD for OPs by an animal-free approach. To estimate the amount of OP that reaches the target (AChE), so-called physiologically based kinetic (PBK) models can be used. A PBK model is a set of mathematical equations that describe the absorption, distribution, metabolism, and excretion (ADME) characteristics of a chemical within an organism (Krewski et al., 1994; Chiu et al., 2007; Louisse et al., 2017). It is based on physiological and anatomical, physicochemical, and kinetic parameters (Louisse et al., 2017). A PBK model permits the simulation of the chemical’s in vivo kinetics (ADME) and can relate external exposure to internal exposure at the target sites. Translating effect concentrations of chemicals obtained in relevant in vitro models representing in vivo target sites (internal exposure) with a PBK model allows the prediction of dose levels that cause toxicity (external exposure), also referred to as quantitative in vitro to in vivo extrapolation (QIVIVE) or PBK modelling facilitated reverse dosimetry. Indeed, the quantitative interpretation of toxic effects of compounds in in vitro studies, using in silico approaches including PBK modelling is a necessary component of the American National Academy of Sciences’ vision on toxicity testing in the 21st century (Krewski et al., 2010).

Besides the use of PBK models for QIVIVE, PBK models are also of use for the interpretation of human biomonitoring data (Brown et al., 2015; Clewell et al., 2008; Campbell et al., 2011) and to better understand possible species differences in toxicokinetics and related differences in sensitivity to the chemical of interest. Only a handful of PBK models have been built for commonly used OPs (chlorpyrifos (Timchalk et al., 2002; Bouchard et al., 2005; Mosquin et al., 2009; Lu et al., 2010), malathion (Bouchard et al., 2003; Bogen and Singhal, 2017; Bouchard et al., 2017), parathion (Sultatos, 1990) and diazinon (Poet et al., 2004)), while for many more OPs PBK models are lacking.

The current thesis aimed at developing a non-animal approach for OP hazard assessment, that can be applied in next generation risk assessment (NGRA). The novel method developed allows
to quantitatively predict the potential of OP pesticides to inhibit AChE in vivo upon acute exposure, also taking combined exposure into account. Furthermore, this thesis aimed to obtain data on the occurrence of OPs on commonly consumed vegetables in Kenya, as such data, and related estimations of human exposure, are lacking. Kenya, a member of the East Africa community in the African continent, is a middle income country whose economy relies heavily on agricultural produce (including horticulture where vegetables are grown and floriculture). The use of chemical pesticides is indispensable in Kenya due to the hot and humid tropical environmental conditions that are conducive to the development of pests, weeds, and disease vectors (Omwenga et al., 2016).

1.2 Human exposure to OPs

Exposure to OPs may be through the gastrointestinal tract following consumption of residues in food, via skin, or inhalation (Risher and Navarro, 1997; Smegal, 2000). Exposure to these pesticides has been reported for various segments of the population, including agricultural workers and their families, household members during home application of pesticides, people that live in proximity to farms, or the general public via residues on food (Quandt et al., 2004; Bradman et al., 2011). Consequently, OPs and their metabolites have been found in human blood, serum, urine, and breast milk (Hardt and Angerer, 2000; Liu et al., 2014; Zhang et al., 2014: Naksen et al., 2016; Nishihama, et al., 2021).

Consumption of conventionally grown fruits and vegetables provides the major pesticide exposure route for the general population (Bradman et al., 2015). In order to monitor the risk and adverse effects following exposure to pesticides, various pesticide monitoring programs have been implemented by various authorities in different countries and regions of the world. While the developed countries such as the USA, Canada and countries in the EU have implemented pesticide monitoring programs, providing information that can be used to estimate human exposure, in developing countries such information is lacking and health risk
assessments cannot be performed (Ecobichon, 2001). Furthermore, recent studies have shown that people of all ages especially in developing countries are increasingly being exposed to higher levels of OP pesticides as a consequence of the increased quantity of pesticide residues in food (Amaroli et al., 2013). Indeed, exponential increase in the use of these pesticides over the last 40 years has been reported globally, with an average rise up from 0.49 kg per hectare in 1961 to 2 kg in 2004, leading to the presence of these substances in the daily diet (Amaroli et al., 2013; Zhang, 2018). In other regions of the world such as the EU, there has been a reduction in pesticide use, accompanied by a decline in regulatory approvals of chemical substances used as pesticides, while the demand is increasing in many developing countries, which together account for a quarter of global pesticide use (UNICEF, 2018). Various studies have reported on the levels of pesticide residues in various food products, including milk products (Golge et al., 2018; Muhammad Arif et al., 2021), other animal products such as poultry and sheep fat (EFSA, 2019), cereals (Lozowicka et al., 2014; EFSA, 2019), olive oils (Razzaghi et al., 2018), fish (Sapozhnikova, 2014) and fruit and vegetables from various countries including Korea (Lee and Lee 2012) Chile (Elgueta et al., 2019) Indonesia (Bhandari et al., 2019), China (Wang et al., 2019; Jiang et al., 2021), EU (EFSA, 2019), Turkey (Hepsağ and Kizildeniz, 2021), Canada (Wang et al., 2019) and USA (Baker et al., 2002; Hu et al., 2016; Chiu et al., 2018). However, few data are available on the presence and levels of pesticide residues on vegetables consumed in African countries, including Kenya. This thesis therefore includes a study on the levels of organophosphate and carbamate pesticide residues and accompanying calculated risks in commonly consumed vegetables in Kenya.

1.3 The model compounds of the present thesis: profenofos and chlorpyrifos

In the present thesis two OPs, profenofos and chlorpyrifos (Figure 1) were studied to develop the proof-of-concept regarding the development of non-animal approaches to predict in vivo
dose-dependent effects on AChE activity upon single and combined exposure. These OPs were selected based on the findings of the study on the presence of OPs (and carbamates) on commonly consumed vegetables in Kenya (Chapter 2). Profenofos and chlorpyrifos are members of the OP group that have been extensively used for the control of agricultural and household pests globally (Kumari & John, 2019). They have been used extensively in agriculture and their residues have been detected concurrently in various vegetables (Kunyanga et al., 2018; Omwenga et al., 2021), indicating their relevance for consideration of combination effects. Generally, the toxicity of OPs and especially their oxon forms is related to phosphorylation of the serine residue of the AChE enzyme at the active site, leading to diminished ability to hydrolyze the neurotransmitter, acetylcholine (ACh).

Profenofos (O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate) is a thiophosphate OP pesticide (O=P-S-C) that exists in an active oxon form. The pesticide was developed for pest strains resistant to chlorpyrifos and other OPs (Gotoh et al., 2001). Profenofos has been classified as a moderately hazardous (Toxicity Class II) pesticide by the WHO with a moderate level of acute toxicity (LD50 of 358 to 1178 mg/kg in rat) following oral administration (Reported in JMPR (2007)) (Table 1). Dietary intake of profenofos is the primary exposure route for humans (Greish et al., 2011) and residue levels exceeding EU maximum residue levels (MRLs) have been found in various vegetables in Kenya (Karanja et al., 2012).

Chlorpyrifos (chlorpyrifos, O, O-diethyl O-3,5,6-trichloropyridin-2-yl phosphorothioate, O, O-diethyl O-3,5,6-trichloro-2-pyridyl phosphorothioate, chlorpyrifos-ethyl) is a widely used thionophosphate OP (S=P-O-C) pesticide (Eaton et al., 2018). It has an LD50 of 82–270 mg/kg bw (Qiao, 2010) following oral administration (Table 1). Chlorpyrifos’s in vivo toxicity is a result of its bioactivation by cytochrome P450 (CYP)-mediated monooxygenases to a more potent AChE inhibitor, chlorpyrifos-oxon (CPO). This oxidation reaction, which proceeds
through a possible phosphoxythiiran intermediate, can result in either a desulfuration reaction that generates the oxon or a dearylation reaction that degrades the parent compound (Chambers, 1992; Timchalk et al., 2001).

Figure 1. Chemical structures of profenofos (A), chlorpyrifos (B) and chlorpyrifos’ toxic metabolite chlorpyrifos oxon (C).

1.4 Absorption, Distribution, Metabolism and Excretion (ADME) of profenofos and chlorpyrifos

Following exposure, organophosphate pesticides such as chlorpyrifos require bioactivation by cytochrome P-450s (CYPs) to form the (more) active oxon metabolites which are potent AChE inhibitors, with the exception of a few OPs including profenofos which are already in an oxon form (Figure 1) (Ma and Chambers, 1994). Therefore, unlike other OPs that require metabolic activation, the parent compound profenofos is itself responsible for the AChE inhibition activity.
In general, profenofos exhibits rapid absorption and distribution with extensive metabolism and no accumulation in tissues (EPA, 2016). In a profenofos kinetic study in rats, recovery of radioactivity in fecal and urine samples ranged from 97-108% of the administered dose, with >97% of the radioactivity excreted in the urine within 48 hours (EPA, 2016, JMPR, 2007). Only less than 0.2% of the radioactivity was expired through air in volatile form. Furthermore, analysis of fecal material revealed that <4% of the parent compound or its metabolites remained unabsorbed or were excreted via the biliary system into the intestinal tract (JMPR, 2007). As shown in Figure 2 profenofos appears to be metabolized primarily by hydrolysis of its thiophosphate ester followed by dephosphorylation to form 4-bromo-2-chlorophenol (BCP), which undergoes sulfate or glucuronide conjugation (FAO, 2012; Dadson et al., 2013; EPA, 2016). Previous in vivo studies in rat identified conjugated and unconjugated 4-bromo-2-chlorophenol (BCP), O-ethyl-O-(2-chloro-4-bromo-phenyl)-phosphate, and thiophosphoric acid O-(4-bromo-2-chloro-phenyl) ester O´-ethyl ester (Figure 2) (Cho et al., 2002; EPA, 2016). Currently, no apparent sex or dose related differences in the absorption, distribution, metabolism, or excretion of profenofos have been demonstrated. In in vitro studies, also CYP-mediated formation of other metabolites has been reported (in the presence of inhibitors of hydrolysis enzymes) (Dadson et al., 2013), but these are considered less relevant, since based on these in vitro studies the hydrolysis reaction is expected to be more efficient than the CYP-mediated oxidations.

In a kinetic study involving young adult male rhesus monkeys, approximately 0.5 mg/kg bw of profenofos was administered and the results showed rapid profenofos absorption with significant concentrations measured in the blood and plasma at the first blood measurement (30 minutes post-dose) (EPA, 2016). The time to reach maximum concentration in the blood (Tmax) was 1 hour post-dose with a rapid decline in the blood concentration thereafter. In that study, the terminal phase elimination half-life (t1/2) was approximately 4 hours. Up to 68% of
the administered dose was recovered in the excreta (urine, faeces, and cage wash after 168 hours) with the majority recovered in the urine (49%) (US EPA, 2016), with ultimately complete excretion following treatment. The glucuronide conjugate of BCP was the main metabolite.

Figure 2. Metabolic pathways for metabolism of profenofos (A) based on data reported in previous studies (Gotoh et al., 2001; Dadson et al., 2013). Metabolites include desethylated profenofos (B), desthiopropylprofenofos (C), hydroxypropyl profenofos (D), 4-bromo-2-chlorophenyl dihydrogen phosphate (E), and 4-bromo-2-chlorophenyl (BCP) (F).
Chlorpyrifos kinetic data in experimental animals indicate that following oral exposure absorption is rapid. About 70% of the administered dose is absorbed following oral administration. Metabolism is complete, with 3,5,6-trichloro-2-pyridinol and its glucuronide and possibly sulfate conjugates being excreted. As shown in figure 3, once absorbed into the body, chlorpyrifos can be metabolized by CYP enzymes through diarylation (oxidative ester cleavage), forming 3,5,6-trichloro-2-pyridinol (TCPy) and diethylthiophosphate (DETP), or oxidative desulfuration, forming CPO which is the active form inhibiting AChE (Kamataki et al., 1976; Timchalk et al., 2002). These conversions are catalyzed by CYP enzymes, with CYP2B6 being the most active CYP for conversion of chlorpyrifos into CPO, and CYP2C19 being the most active CYP for conversion of chlorpyrifos into TCPy and DETP, whereas CYP3A4 is involved in both pathways (Foxenberg et al., 2007; Tang et al., 2001). CPO is converted by A-esterases, with paraoxonase 1 (PON1) as the main A-esterase involved, resulting in formation of TCPy and diethyl phosphate (DEP) (Furlong et al., 1989; Timchalk et al., 2002).

In general, chlorpyrifos has a short biological half-life of approximately 18 h in plasma and 62 h in fat tissue (Qiao, 2010). However, due to its very wide use, chlorpyrifos metabolites are commonly found in human tissue (fat tissue) (Bakke et al., 1976; Eaton et al., 2008). Excretion of chlorpyrifos metabolites as well as traces of chlorpyrifos occurs mainly through urine. In a chlorpyrifos kinetic study, a single dose of radioactive chlorpyrifos administered to rats (unspecified strain) at a dose of 50 mg/kg bw by gavage showed a 90.1% excretion of the administered radioactivity in 26 h, with 90% of the excreted material being in urine and 10% in feces. The metabolites excreted were [36Cl]-3,5,6-trichloro-2-pyridyl phosphate (75–80%)(DETP), 3,5,6-trichloro-2-pyridinol (TCPy) (15–20%), and traces of unmetabolized chlorpyrifos, indicating that deethylation is the main metabolic pathway in rats (Figure 3).
Furthermore, tissue residues of chlorpyrifos with a radioactive half-life of about 62 h were found mainly in fat tissue (Smith et al., 1967).

Figure 3. Metabolic pathways for metabolism of chlorpyrifos (A) based on data reported in previous studies (Eaton et al., 2008; Tang, et al., 2001). Metabolites include chlorpyrifos oxon (CPO) (B), 3,5,6-trichloro-2-pyridinol (TCPy) (C), diethyl thiophosphate (DETP) (D) and diethyl phosphate (DEP) (E).
1.5 Organophosphate Toxicity

OPs are primarily neurotoxicants, and exert their toxicity on the nervous systems of the target species (Casida, 2009). The OPs are non-species specific in their toxic effect, hence a wide range of mammals, humans included, are susceptible to their adverse effects. OP neurotoxicity can be broadly classified into two types: acute cholinergic toxicity and, in few instances, delayed neurotoxicity (Aldridge, 1981). A possible third type that falls in between acute and delayed neurotoxicity, referred to as the intermediate syndrome, characterised by muscular weakness, and developing once acute cholinergic symptoms have subsided, has been described in humans following severe OP poisoning.

The critical effects of OPs in animal studies are related to neurotoxicity, which has been reported to be related to, amongst others, inhibition of acetylcholinesterase (AChE), neuropathy target esterase (NTE) (Costa, 2018), acylpeptide hydrolase (APH) (Richards et al., 2000), fatty acid amide hydrolase (FAAH) (Quistad et al., 2001; Buntyn et al., 2017) muscarinic M2 receptors (Costa, 2006), and a variety of lipases (Quistad et al., 2006). Inhibition of AChE is one of the mechanisms by which OPs cause acute neurotoxicity (Jamal et al., 2002; Farahat et al., 2003). AChE inhibition occurs following hydroxyl group phosphorylation of the serine-OH in the enzyme active site by the P=O moiety of the OP, thus impeding its action on the physiological substrate. The hydrolysis of the phosphorylated enzyme proceeds at a very slow rate. Although some hydroxylamine derivatives have been found to facilitate reactivation of AChE, and hence are clinically used in the therapy of OP poisoning (Eyer, 2003), the dephosphorylation of the phosphorylated AChE fails once the enzyme-inhibitor complex loses one of the 2 alkyl (R) groups (by nonenzymatic hydrolysis) otherwise referred to as aging (Figure 4) (Quinn et al., 2017). The aged phosphorylated AChE is considered to be irreversibly inhibited, and de novo synthesis is the only possibility of replacing its activity, a process that takes days to occur (Sultatos, 2006).
AChE inhibition is characterized by decreased hydrolysis of acetylcholine in both central and peripheral cholinergic synapses, resulting initially in overstimulation of nicotinic and muscarinic receptors, followed by receptor down-regulation on post-synaptic membranes (Costa, 2006). Acute or repeated exposure to OPs can lead to a delayed neurotoxicity referred to as organophosphate ester-induced polyneuropathy (OPIDP), a neurodegenerative disorder caused by inhibition and aging of at least 70% of the activity of the neuropathy target esterase (NTE) present in nerve tissues as well as other tissues (e.g., lymphocytes, testis) (Johnson and Glynn, 1995; Johnson and Glynn, 2001; Costa, 2018). OPIDP is characterized by tingling of the feet and hands, followed by sensory loss, flaccidity of the distal skeletal muscles and upper extremities resulting from progressive muscle weakness and ataxia (Lotti and Moretto, 2005). These effects are encountered 2–3 weeks following OP exposure, mostly when eventual cholinergic toxicity signs have subsided.

Pathologically, OPIDP can be designated as a distal sensorimotor axonopathy, characterized by bilateral degenerative lesions in distal levels of axons and their terminals as the primary lesions, mainly affecting longer myelinated peripheral and central nerve fibers, eventually resulting in breakdown of myelin sheaths and neuritic segments (Ehrich and Jortner, 2010). Furthermore, OPs whose chemical structure leads to aging of phosphorylated NTE (by a chemical process similar to that for AChE) can cause OPIDP, implying that the aging of NTE is a key event in the initiation of OPIDP. Moreover, OPIDP is only initiated following phosphorylation and subsequent aging of at least 70% of NTE, a two-step pathway occurring hours following poisoning.
Figure 4. AChE inhibition by the organophosphorus nerve agent sarin based on previous studies (Quinn et al., 2017). The figure shows phosphorylation of the AChE enzyme (A), AChE enzyme reactivation (B) and AChE aging (Loss of one alkyl group through dealkylation) (C)

1.6 Hazard assessment of OPs

In the hazard assessment of OPs, in vivo animal studies on OP-induced inhibition of RBC AChE have been used to derive a point of departure (POD) to set safe exposure levels, such as an Acute Reference Dose (ARfD) (Table 1). ARfDs for chlorpyrifos, acephate, methamidofos, omethoate and profenofos as reported by organizations as the European Food Safety Authority (EFSA), United States Environmental Protection Authority (EPA), and the Joint FAO/WHO Meeting on Pesticide Residues (JMPR) have been derived from data on OP-induced RBC or brain AChE inhibition from animal studies (EPA, 2006; JMPR, 2007; EPA, 2011; EPA, 2016;
EFSA, 2019). For chronic exposure, in vivo animal studies with repeated-dosing have been conducted, with measurement of OP induced AChE inhibition as the end point (EPA, 2016). Although these in vivo studies do not measure complex neurotoxicity endpoints, the information on OP-induced inhibition of AChE in vivo is considered adequate in the hazard characterization to assess acute effects. In risk assessment of profenofos, JMPR used a NOAEL value of 100 mg/kg bw to derive an ARfD, based on a dataset on profenofos-induced inhibition of brain AChE in rats (upon a single exposure to profenofos). This NOAEL was then divided by a default uncertainty factor of 100 (10 for interspecies differences and 10 for intraspecies difference) to derive an ARfD of 1 mg/kg bw. Furthermore, the US EPA considered erythrocyte (RBC) AChE inhibition to be more suitable to derive a POD for human safety assessment, since it is more sensitive than brain AChE inhibition in case of profenofos exposure (EPA, 2016). A 10% RBC inhibition of AChE has been adopted by the US EPA to obtain a POD to define the ARfD for profenofos (EPA, 2016). The US EPA reported a BMDL10 of 1.99 mg/kg bw for profenofos-induced RBC AChE inhibition in adult rats upon a single exposure to profenofos. This BMDL10 was divided by a default uncertainty factor of 100 (10 for interspecies differences and 10 for intraspecies difference) to derive an ARfD of 0.0199 mg/kg/day. Furthermore, recent epidemiological studies have consistently identified associations between OP exposure and neurodevelopmental outcomes, for example attention problems, autism spectrum disorder in early childhood, delays in mental development in infants (24-36 months) as well as intelligence decrements in school age children. Consequently, there is a need for protection of children from OP exposures that could cause these effects. Based on this consideration the Food Quality Safety Act (FQPA) safety factor of 10 for interindividual viability has been added by the US EPA for some OPs including chlorpyrifos and profenofos for the population subgroups consisting of infants, children, women of childbearing age and youth for all exposure scenarios, resulting to an ARfD of 0.00199 mg/kg bw/day (EPA, 2016).
However, the FQPA safety factor does not apply in dietary exposures for the adult population subgroup 50-99 years old where the FQPA safety factor does not apply (total uncertainty factor = 100).

In a recent report from EFSA (EFSA, 2019), an ARfD for profenofos of 0.005 mg/kg bw was reported, based on a German evaluation in 2001 that defined an ARfD based on a NOAEL in a dog study using inhibition of brain cholinesterase activity as critical effect. Unfortunately, no further information (e.g. NOAEL) on that particular dog study is publicly available.

For chronic toxicity testing of profenofos, EPA (2016) conducted a 91-day repeated-dose study with RBC AChE inhibition as the end point in rats. In this study, data were obtained for both chronic effects as well as for tests on the ability of profenofos to induce carcinogenicity. A BMDL10 of 0.12 mg/kg bw/day associated with RBC AChE inhibition in male and female adult rats at the 13 week interim measurement was selected as a suitable POD for the steady-state dietary exposure scenario for all populations (Table 2). In the next step, an uncertainty factor of 1000 (10 to account for interspecies extrapolation, 10 for intraspecies variation, and 10 as an extra FQPA safety factor to account for uncertainty in the human dose-response relationship for neurodevelopmental effects) was applied to the BMDL10 to obtain a steady-state population-adjusted dose (ssPAD) of 0.00012 mg/kg bw/day for exposure scenarios with infants, children, youths, and women of childbearing age. Again, the FQPA safety factor does not apply in dietary exposures for the adult population subgroup 50-99 years old where the FQPA safety factor does not apply (total uncertainty factor = 100), hence the ssPAD for this population subgroup is 0.0012 mg/kg bw/day (EPA, 2016).

On the other hand, JMPR (2007) established an ADI of 0.03 mg/kg bw/day based on an overall NOAEL of 2.9 mg/kg bw/day derived from inhibition of brain AChE activity in three short-term studies in dogs and using a safety factor of 100. This ADI was supported by the NOAEL of 5.1 mg/kg bw/day identified based on inhibition of maternal and pup brain AChE activity in
a study of developmental neurotoxicity in rats and a NOAEL of 4.5 mg/kg bw per day identified on the basis of inhibition of brain AChE activity in a 2-year study in mice (JMPR, 2007).

For chlorpyrifos risk assessment, 20% inhibition of AChE has initially been described by EFSA to derive a suitable POD to define the acute reference dose for chlorpyrifos (EFSA, 2014). However, EPA in its risk assessment of chlorpyrifos derived a BMDL10 of 0.36 mg/kg bw resulting in 10% RBC AChE inhibition as POD (BfR, 2012; Koshlukova and Reed, 2014; Fan, 2014) (Table 1). Moreover, in the recent past, EPA indicated that 10% RBC AChE inhibition may not be adequately protective for human health since several studies suggest that adverse effects could occur even at lower levels of RBC AChE inhibition (EPA, 2016).

EFSA adopted an ARfD value of 0.005 mg/kg bw/ day based on a NOAEL of 0.5 mg/kg bw derived from rat RBC AChE inhibition, and applying an uncertainty factor of 100 (EFSA, 2014). On the other hand, US EPA used the Benchmark Dose (BMDL10) approach to derive reference values resulting in slightly lower values of 0.36 mg/kg bw using inhibition of RBC AChE as the critical effect (BfR, 2012; Fan, 2014; Koshlukova and Reed, 2014). Using the default factor of 100, the resulting ARfD is 0.0036 mg/kg bw/day.

For chronic exposure, the Acceptable Daily Intake (ADI) and Acceptable Operator Exposure Level (AOEL) were derived to be 0.01 mg/kg bw per day, based on long- and short-term studies respectively, in all species tested, with the application of an uncertainty factor (UF) of 100. The most sensitive end point the inhibition of RBC AChE was used to derive the ADI. In order to derive the Acceptable operator exposure levels (AOEL), a repeated dose study in juvenile and adult rats was used. In this study a NOAEL of 0.1 mg/kg bw per day based on RBC AChE inhibition was identified and an UF of 100 applied, resulting in an AOEL of 0.001 mg/kg bw per day, similar to the ADI.
As discussed above, the PODs for OPs including profenofos and chlorpyrifos have been derived by estimation of exposure levels resulting in 10% RBC AChE inhibition following acute oral exposure (single day, 24 hours). However, repeated exposures generally result in more AChE inhibition at a given administered dose compared to single exposures. Moreover, AChE inhibition in repeated dosing toxicological studies with OPs exhibit a consistent pattern of inhibition that reaches a steady state at approximately 2-3 weeks of exposure in adult laboratory animals (U.S. EPA, 2016). This phenomenon observed in repeated dosing results from the equilibrium achieved between the inhibited enzyme and the de novo synthesis of new enzyme. Consequently, AChE short term studies of 2-3 weeks generally exhibit inhibition activity similar to those of longer duration (i.e., up to 2 years of exposure)

Table 1. PODs as derived by various regulatory bodies.

<table>
<thead>
<tr>
<th>Study type</th>
<th>Species</th>
<th>LD50 (mg/kg bw)</th>
<th>NOAEL (mg/kg bw/day)</th>
<th>LOAEL (mg/kg bw/day)</th>
<th>Endpoint used</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chlorpyrifos</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short term</td>
<td>Rat, dog</td>
<td>0.5</td>
<td>RBC AChE</td>
<td>EFSA, 2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 year</td>
<td>Rat</td>
<td>0.1</td>
<td>RBC AChE</td>
<td>EFSA, 2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short term, oral</td>
<td>Rat females</td>
<td>82–155</td>
<td>1.0</td>
<td>5</td>
<td>Sins of Cholinergic poisoning</td>
<td>Clegg and Gemert, 1999</td>
</tr>
<tr>
<td>Short term, oral</td>
<td>Rat</td>
<td>1</td>
<td>RBC AChE inhibition</td>
<td>JMPR, 1999</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short term, oral</td>
<td>human</td>
<td>0.5</td>
<td>RBC AChE inhibition</td>
<td>Clegg and Gemert, 1999</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repeated dosing</td>
<td>human</td>
<td>0.1</td>
<td>RBC AChE inhibition</td>
<td>Clegg and Gemert, 1999</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Profenofos</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short term, oral</td>
<td>Rat</td>
<td>358–1178</td>
<td>Sins of Cholinergic poisoning</td>
<td>JMPR, 2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short term</td>
<td>Rat</td>
<td>100</td>
<td>Brain AChE inhibition</td>
<td>JMPR, 2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 year toxicity</td>
<td>Rat</td>
<td>5.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 2. Profenofos and chlorpyrifos BMD10 and BMDL10 results (mg/kg bw/day) for RBC AChE inhibition over time in adult rats (profenofos data are taken from EPA, 2016 while data for chlorpyrifos are from BfR, 2012 and EFSA, 2014)

<table>
<thead>
<tr>
<th>Dosing days</th>
<th>Profenofos</th>
<th>Chlorpyrifos</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td></td>
<td>BMD10 (mg/kg bw/day)</td>
<td>BMDL10 (mg/kg bw/day)</td>
</tr>
<tr>
<td>1</td>
<td>13.49</td>
<td>11.24</td>
</tr>
<tr>
<td>10</td>
<td>NMF</td>
<td>NMF</td>
</tr>
<tr>
<td>35</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>90</td>
<td>0.33</td>
<td>0.29</td>
</tr>
<tr>
<td>91</td>
<td>0.14</td>
<td>0.12</td>
</tr>
<tr>
<td>364</td>
<td>0.17</td>
<td>0.15</td>
</tr>
<tr>
<td>1 (BfR, 2012) 10% RBC AChE inhibition</td>
<td></td>
<td>0.36</td>
</tr>
<tr>
<td>1 (EFSA, 2014) 20% RBC AChE inhibition</td>
<td></td>
<td>0.5</td>
</tr>
</tbody>
</table>

NMF- No model fit
NA- Not applicable

1.7 PBK modelling-based reverse dosimetry

The concentration-response curves obtained from in vitro models are inadequate for human risk and safety assessment because risk assessment requires in vivo dose-response curves from which points of departure (PODs) can be derived for defining safe exposure levels. Consequently, the use of current non-animal based testing strategies requires a method to translate the in vitro concentration-response curves to in vivo dose-response curves that can replace the data from animal bioassays (Archibald et al., 2011). As earlier discussed (see background section), experimental animals may not be good models to predict toxicity effects in humans (Shanks et al., 2009; Crump et al., 2010) hence the vivo dose-response curves defined should relate closely to humans rather than to rodents (Louisse et al., 2017). To bridge the gap between in vitro alternative testing strategies and the needs of modern risk assessment for in vivo data, the application of so-called physiologically based kinetic (PBK) modeling-
general reverse dosimetry provides the solution. The principle is based on the use of PBK models to translate in vitro concentration-response curves to in vivo dose-response curves for various species including human. This approach can provide dose-response curves for toxicity in human provided that the PBK models used, and preferably also the cell models used, relate to the human situation.

The PBK model is used in the reverse order when the PBK modeling-based reverse dosimetry is applied. In that case the PBK model is used to calculate the dose level that would be needed to obtain the concentration of a compound or of its metabolite in the blood or in a tissue of interest. Reverse dosimetry has been successfully used to estimate exposure using biomonitoring data (e.g. chemical levels in blood and urine). Examples include estimation of exposure to chlorpyrifos in rats and humans (Timchalk et al., 2002), and chlorpyrifos in children (Rigas et al., 2001). Furthermore, these models can be used for reverse dosimetry of in vitro toxicity data, thereby translating in vitro effect concentrations to in vivo doses, enabling prediction of in vivo dose-dependent toxicity, as has been shown for the OP chlorpyrifos (Zhao et al., 2019). Such PBK modeling-facilitated reverse dosimetry of in vitro toxicity data is considered crucial in the transition to non-animal based new approach methodologies (NAMs) for the safety assessment of chemicals (Louisse et al., 2017). Scientific approaches for risk assessment prefer the use of human data, and this requires the development of novel human in vivo testing strategies (Krewski et al., 2010). Therefore, this thesis also aims to develop an approach using in vitro toxicity data combined with PBK modelling facilitated reverse dosimetry to predict in vivo acute AChE inhibition. For the reverse dosimetry approach to be performed, in vitro concentrations of the chemical need to be set equal to a relevant dose metric in the PBK model, such as a maximal blood concentration or the area under the concentration-time curve (AUC) in the blood or in a specific target tissue (Rietjens et al., 2019; USEPA, 2014b). Since the aim here is to predict OP-induced RBC AChE inhibition upon acute exposure,
the relevant dose metric chosen for reverse dosimetry in this thesis was the maximum concentration in blood. This is in line with previous studies that have demonstrated that PBK modeling-facilitated reverse dosimetry of OP in vitro toxicity data may adequately predict inhibition of OP based RBC AChE, as demonstrated for the OP chlorpyrifos (Zhao et al., 2019).

Figure 5. Schematic diagram of the PBK model for profenofos for rats and humans as developed in this thesis (Chapter 3).
1.8 Taking combination exposure into account in risk assessment

Since a variety of pesticides is being used, environmental, occupational and dietary exposures are primarily to pesticide mixtures. As a result, there is lifelong combined exposure to various pesticides from, for example, one food item containing multiple compounds or combinations of food items, each containing different residues (Boobis et al., 2008). If these pesticides have a similar mode of action and toxic end point, assessing the dietary risk of exposure for each pesticide separately may lead to underestimation of the health risk (Boon et al., 2008). Also, the EU Scientific Committees on Health and Environmental Risks (SCHER), on Consumer Safety (SCCS), and on Emerging and Newly Identified Health Risks (SCENIHR) have recently indicated that the health effect from combination exposure could be greater than the effect from individual compound exposure (SCCS, SCHER, SCENIHR, 2012). For this reason, current approaches in pesticide risk assessment include cumulative and probabilistic approaches in order to include the amount and variety of pesticide residues likely to be present in the vegetable sample (Jensen et al., 2015; Boon et al., 2015; Elgueta et al., 2019). The first step in assessing effects of combined exposure to pesticide mixtures is to identify substances with a similar mode of toxicity (Gallagher et al., 2015; EFSA, 2019). For example, AChE inhibitors, such as OPs and carbamates have been assigned the same cumulative assessment group (CAG) by the United States Environmental Protection Agency (US EPA) as well as by the European Food Safety Authority (EFSA) (USEPA, 2006, 2007, 2011; EFSA, 2019). For chemicals in the same CAG, the current scientific and regulatory recommendations for the risk assessment of mixtures follows a test strategy based on a component-based assessment, a concept with dose addition as the default model (Kortenkamp et al., 2009; EFSA et al., 2013; Bopp et al., 2015; EFSA et al., 2019).

On the other hand, substances with a different mode of action are assumed to have independent action since these substances induce effects through different modes of action devoid of
interaction with each other (Drescher and Boedeker, 1995; Medlock Kakaley et al., 2019). Therefore, response addition principles can be applied, hence it is assumed that there is no need for a combined risk assessment if exposure of the respective chemicals is for each chemical in the mixture below levels that cause adverse effects when testing the chemical in isolation. However, when no information on the mode of action is available, dose/concentration addition should be considered (Staal and van der Ven, 2016). When the dose additivity approach is used, the hazard index (HI) and toxic equivalency factor (TEF) are commonly applied to facilitate the combined risk assessment (Staal and van der Ven, 2016). The HI is the sum of the hazard quotients (HQs) for compounds that affect the same target organ or organ system. HQs are defined as the ratio of the exposure (for example, EDI) and a safe dose (an acceptable or tolerable daily intake (ADI or TDI) for chronic exposure (te Biesebeek et al., 2021) or an ARfD for acute exposure (Boobis et al., 2008; OECD, 2018). If the HI is lower than 1, it implies that the levels of the toxicants are not likely to elicit the adverse effect even during a lifetime exposure (when based on an ADI/TDI), whereas a HI higher than 1, implies that adverse effects cannot be excluded and should therefore be evaluated case by case to see which exposure adds the most to the HI and exceedance of relevant health based guidance values (HBGVs) and to direct potential risk management actions (Boobis et al., 2008; te Biesebeek et al., 2021).

For evaluation of combined exposure by dose addition also the so-called toxic equivalency (TEQ) approach applying toxic equivalency factors (TEFs) is preferred to evaluate the combined exposure to structurally related compounds with a similar mode of action but different potency (Delistraty, 1997). The TEQ method takes into consideration the differences in toxicity between congeners. The TEF for each individual congener is expressed as the ratio of the dose or concentration inducing a defined level of toxicity, such as for example the EC50, from the compound of interest and from the reference compound;

\[
\text{TEF} = \frac{\text{EC50 reference compound}}{\text{EC50 compound X}}
\]
The total value called the toxic equivalency (TEQ) value for a mixture is calculated by the sum of each compound’s dose or concentration multiplied by its corresponding TEF value. Both profenofos and chlorpyrifos share a similar mode of toxicity, hence belong to the same CAG related to brain and/or RBC AChE inhibition (EFSA et al., 2019). Therefore, a dose additivity approach can be used. For this dose additivity approach, the hazard index (HI) and toxic equivalency factor (TEF) may also be used to perform the combined risk assessment (Staal and van der Ven, 2016).

1.9 Goal of the research and thesis overview

The main aim of the research was to develop a non-animal based combined in vitro and in silico approach to predict in vivo AChE inhibition upon acute exposure to single pesticides as well as to a combined exposure to pesticides. To define the model compounds for the studies, first organophosphate and carbamate pesticide residues were determined in commonly consumed vegetables in Kenya. Only OP pesticides were detected of which profenofos was most abundant in the samples assessed. Therefore, profenofos PBK models were developed based on in silico and in vitro input data for rats and humans, and the models were applied for reverse dosimetry of in vitro data on profenofos-induced AChE inhibition. Chlorpyrifos was found to be present on some of the vegetable samples together with profenofos. In a next step, a combined in vitro-in silico approach was developed to predict the effects of combined acute exposure to profenofos and chlorpyrifos on in vivo AChE activity. Finally, human interindividual differences in profenofos detoxification were assessed in vitro and these data were combined with a Monte Carlo simulation approach, to predict human interindividual differences in internal profenofos exposure and related consequences on AChE activity, all without the need for in vivo studies.

Chapter 1 of the thesis (this chapter) starts with providing background information on OP use in agriculture, the exposure of non-target species to OPs and a description of the characteristics
and toxicity of the OPs studied in this thesis, profenofos, and chlorpyrifos. This chapter also presents background information on the hazard assessments for profenofos and chlorpyrifos and presents the concepts of PBK modelling-based reverse dosimetry and approaches used to assess combined exposure.

**Chapter 2** analyses the occurrence of OPs in commonly consumed vegetables in Kenya and assesses the accompanying exposure and health risks. A total of 90 samples were analysed by liquid chromatography/high-resolution tandem mass spectrometry. Exposure analysis and risk characterization was conducted using the acute/short-term hazard quotient (aHQ) for potential health risks emanating from short term intake and the chronic/long-term hazard quotient (cHQ) for potential health risks from long term consumption of contaminated vegetables. The risk assessment of the cumulative chronic exposure to residues was performed by summing the chronic Hazard Quotients (cHQ) for the individual pesticide residues as Hazard Index (HI) = ΣcHQ.

**Chapter 3** proposes a combined in vitro-in silico approach to predict AChE inhibition by the OP profenofos in rats and humans by applying PBK modelling-facilitated quantitative in vitro to in vivo extrapolation (QIVIVE). A PBK model was developed for both species. Parameter values for profenofos conversion to 4-bromo-2-chlorophenol (BCP) were derived from in vitro incubations with liver microsomes, liver cytosol, and plasma from rats and humans whereas other chemical-related parameter values were derived using in silico calculations. The PBK model predictions were evaluated by comparison to literature data on profenofos kinetics in rats following oral exposure (Cho et al., 2002). Following model evaluation, the concentration-dependent inhibition of rat and human AChE was determined in vitro and these data were translated with the PBK models to predicted dose-dependent AChE inhibition in rats and humans in vivo.
Chapter 4 investigates the combination effects of two selected OPs (profenofos and chlorpyrifos), by studying the combined effects of profenofos and chlorpyrifos’s toxic metabolite chlorpyrifos oxon (CPO) on AChE inhibition in vitro, as well as the effects of chlorpyrifos and CPO on profenofos biotransformation (detoxification) by human liver microsomes, cytosol, and human plasma. The profenofos physiologically based kinetic (PBK) model developed in chapter 3 was extended to include the description of chlorpyrifos kinetics, using also in vitro kinetic data from the literature and in silico calculations. The profenofos concentrations in the model are expressed as CPO-equivalents (i.e., using a TEF/RPF approach) allowing prediction of total internal CPO-equivalents (and related effects on AChE activity) upon combined exposure to profenofos and chlorpyrifos.

Chapter 5 aimed to predict human interindividual differences in profenofos detoxification based on a combined in vitro-in silico approach to account for human variability in toxicokinetics. To that end, profenofos conversion to BCP was studied in in vitro incubations with S9 liver fractions of 25 different Caucasian donors and with plasma samples of 25 different Caucasian donors. The obtained information on the variation in the in vitro kinetic constants Vmax and Km, was applied in the PBK model developed in Chapter 3 using a Monte Carlo simulation modelling approach. Internal concentrations were estimated for the geometric mean (GM), the 90th, 95th and 99th percentiles of the simulated virtual population. The model was then used for reverse dosimetry of the in vitro data on profenofos-induced AChE inhibition of Chapter 3. Also, the interindividual variability in profenofos toxicokinetics was quantified by dividing the internal Cmax concentrations of profenofos for the 90th or 99th percentile by that of the GM, which was compared to the default uncertainty factor for interindividual differences in kinetics (IPCS 2005). The predicted BMDL10 for the 99th percentile was compared to PODs of the regulatory bodies.
Finally, Chapter 6 summarizes the main outcomes of this thesis and compiles the overall discussion. The chapter discusses: (i) the potential health concerns raised by OP exposure through consumption of vegetables contaminated by OP pesticide residues in peri-urban Nairobi, Kenya, (ii) the benefits and challenges of using PBK modelling-based reverse dosimetry to predict OP-derived neurotoxicity endpoints, (iii) OPs and long term effects considering neurodegenerative diseases including Parkinsonism and (iv) risk assessment of combined exposure to OPs and to OPs and other types of pesticides. Finally, the chapter provides further considerations for further studies on OPs and their effects in humans and assessment of exposure through contaminated foodstuff such as vegetables globally as well as locally (i.e., Kenya).
REFERENCES


BfR., 2012. Reconsideration of the human toxicological reference values (ARfD, ADI) for


Lozowicka, B., Kaczynski, P., Paritova, A.E., Kuzembekowa, G.B., Abzhalieva, A.B.,


OECD. (2018). Considerations for assessing the risks of combined exposure to multiple chemicals. Series on Testing and Assessment No. 296. Paris Cedex 16, France


pesticides in vegetable samples by a photothermal biosensor,” *Biosensors and Bioelectronics*, vol. 18:1–9.


Razzaghi, N., Ziarati, P., Rastegar, H., Shoeibi, S., Amirahmadi, M., Conti, G.O., Ferrante,


CHAPTER 2.
Organophosphate and Carbamate Pesticide Residues and accompanying risks in Commonly Consumed Vegetables in Kenya

Isaac Omwenga
Laetitia Kanja
Paul Zomer
Jochem Louisse
Ivonne M.C.M. Rietjens
Hans Mol

Published in: Food Additives & Contaminants: Part B (2021)
14(1):48-58
ABSTRACT

The current study was conducted to assess the levels of organophosphates and carbamates in vegetables in Kenya, and to examine potential consumer health risks. A total of 90 samples were analysed by liquid chromatography/high resolution tandem mass spectrometry. Residues of acephate, chlorpyrifos, methamidophos, omethoate and profenofos were found in 22% of the samples, ranging from 10 to 1343 μg/kg. The EU MRL was exceeded in 21%, 10%, 8% and 22% of the samples of French beans, kales, spinach, and tomatoes respectively. Chlorpyrifos in spinach had an acute HQ of 3.3 and 2.2 for children and adults, respectively, implying that potential health risks with respect to acute dietary exposure cannot be excluded. For chronic dietary exposure, all chronic HQs were below 1. The HI for the pesticides was 0.54 and 0.34 for children and adults. Routine monitoring of OPs and carbamates in vegetables is recommended to minimize consumer’s health risks.
2.1 Introduction

Pesticide use is essential for control of pests in horticultural crops and adequate production of food supplies for the ever increasing world population as well as for control of vector-borne diseases. Most developing countries with a rapidly growing population require pesticides to improve food production (Akoto et al., 2015). However, the extensive use of pesticides has led to adverse effects to human health as well as other non-target species and the environment (Bravo et al., 2011; Stadlinger et al., 2013; Li et al., 2017; Bhandari et al., 2019).

Organophosphates (OPs) and carbamates were considered safer than their predecessors, the persistent organochlorine insecticides like aldrin, dieldrin and DDT (Fernández et al., 2000; Pogačnik and Franko, 2003). However, over 40 OP pesticides, including the most commonly used ones such as chlorpyrifos have been classified by the WHO Food and Agriculture Organization and US Environmental Protection Agency (EPA) to be moderately or highly hazardous to human health (WHO, 2009; Roberts and Reigart, 2013). The intensive use of OP pesticides in various crops may lead to accumulation of levels higher than those permitted, and subsequently affect quality of agricultural products, and raise concerns with respect to human health and international trade (EC, 2005; Boobis et al., 2008). The OPs and carbamates produce their effects by inhibiting acetylcholinesterase (AChE), the enzyme that terminates the action of the neurotransmitter acetylcholine (ACh) within neuromuscular junctions and nerve tissue, leading to overstimulation of the post-synaptic membrane (Timchalk and poet, 2008). Reported effects related to exposure to OPs vary from mild short-term impacts such as nausea and headaches to chronic effects such as infertility, birth defects, blood disorders, nerve disorders, endocrine disruption and reproductive effects (Mansour, 2004; Alavanja et al., 2013).

Consumption of conventionally grown fruits and vegetables provide the major pesticide exposure route for the general population (Bradman et al., 2015). Consequently, biomonitoring
studies have found pesticides and their metabolites in biospecimens in several countries including USA and Canada (CDC, 2017; Haines et al., 2017).

Despite regulation of pesticides through maximum residues limits (MRLs), there is lifelong combined exposure to low amounts of hundreds of various pesticides from one food item containing multiple compounds or combinations of food items, each containing different residues (Boobis et al. 2008). If these pesticides have a similar mechanism of action and end point, assessing the dietary risk of exposure differently may lead to underestimation of the health risk (Boon et al., 2008). Consequently, recent approaches in pesticide risk assessment include cumulative and probabilistic approaches in order to include the amount and variety of pesticide residues likely to be present in the vegetable sample (Boon et al., 2015; Jensen et al., 2013, 2015; Elgueta et al., 2019). The initial step in assessing pesticide mixtures is to identify substances with a similar mechanism of toxicity (Gallagher et al., 2015). For example, acetylcholinesterase inhibitors such as OPs and carbamates have been assigned the same cumulative assessment group by the United States Environmental Protection Agency (USEPA, 2006, 2007, 2011) hence their choice in this study.

The use of chemical pesticides is still indispensable in Kenya due to the hot and humid tropical environmental conditions that are conducive to the development of pests, weeds, and disease vectors (Omwenga et al., 2016). There is increased use of chemicals, especially fertilizers, veterinary chemicals and pesticides, since agriculture accounts for 60% of Kenya’s foreign exchange earnings and provides raw materials for the industries (NIP, 2006). Many small-scale farmers are not aware of the hazards associated with these chemicals. For example, a previous study in Ghana revealed that up to 45% and 20 % of farmers wore partial or no personal protective equipment at all when applying pesticides to cocoa plants hence increasing their risks of exposure to pesticides (Okoffo et al., 2016). In addition, the study reported other poor operational habits such as talking, eating, drinking, stirring pesticides with bare hands and
smoking among others during the process of pesticides application (Okoffo et al., 2016). Other indiscreet practices, such as application of higher than recommended doses of pesticides on crops and failure to implement the pre-harvest time frame after application, may lead to consumers’ exposure to pesticides at levels of concern (Akoto et al., 2015). Furthermore, OP pesticides of environmental and human health concern that have been banned in developed countries such as EU, USA and Canada are still used in developing countries (Picciotto et al., 2018). For example, pesticides such as chlorpyrifos, profenofos, acephate, metamidophos, dimethoate and omethoate which are banned in Europe and other countries are still in use in developing countries such as Costa Rica, Guatemala (Bravo et al., 2011), Mexico (Gonzales et al., 2018) and Kenya (PCPB, 2019). The focus of occupational and public health institutions in developing countries have been on acute poisonings, as delayed and chronic effects remain undetermined (Wesseling et al., 2005; Toe, 2010; Bravo et al., 2011).

Vegetables provide vitamins, minerals and active compounds known to reduce the effect of cardiovascular diseases (Ivey et al. 2015). According to the WHO, vegetables and fruits constitute on average 30% of food consumption (WHO, 2003). However, in Kenya, it is estimated that fresh fruits and vegetables constitute 25% and >80% of the diets in the urban and the rural areas, respectively (Mungai et al., 2000; Kunyanga et al., 2018). Among them, kales (Brassica oleracea var acephala), spinach (Spinacia oleracea), tomatoes (Solanum lycopersicum) and to a lesser extent French beans (Phaseolus vulgaris) are the most common vegetables used in various dishes (Karanja et al., 2012; Okello et al., 2012: Mutai et al., 2015: RSA, 2015; Njuguna et al., 2019). In general, it is reported that the amounts of pesticides used in vegetable crops are three times higher than what is used for cereal crops (Fan et al., 2015), which are staple foods in many other countries. Consequently, it is expected that vegetables contain higher pesticide residue levels as compared to cereal-based foodstuffs, not only because of the large amount of pesticide usage but also because some, like tomatoes, are eaten raw in
salads (Baig et al., 2009; Knežević et al., 2012). Monitoring pesticide residues in vegetables is therefore key in determining and mitigating possible risks to human health from daily dietary pesticide exposure of consumers (Curl et al., 2003).

Developed countries such as USA, Canada and in the EU have implemented pesticide monitoring programmes. However, little effort has focused on long-term adverse health effects of pesticides on the agricultural workers and local consumers in developing countries (Ecobichon, 2001). Many studies have reported on the levels of pesticide residues in various food products, including milk products (Golge et al., 2018), poultry and sheep fat (EFSA 2019), cereal (Lozowicka et al., 2014; EFSA, 2019), olive oils (Razzaghi et al., 2018), fish (Sapozhnikova, 2014), and fruit and vegetables from various countries (Lee and Lee, 2012; Jensen et al., 2013; Zhao et al., 2014; Quijano et al., 2016; Muñoz et al., 2017; EFSA, 2019). However, few data are available on the presence and levels of pesticide residues in vegetables consumed in Kenya (Ngatia and Kabaara, 1976; Karembu, 1991; Karanja et al., 2012; Mutai et al., 2015; Kunyanga et al., 2018).

The objective of this study was therefore to determine OP pesticides and carbamates in tomatoes, kales, spinach and French beans and evaluate the associated dietary exposure and the associated potential health risks to children and adults upon acute and chronic exposure.

2.2 Materials and Methods

2.2.1 Chemicals and Reagents

Pesticide reference standards for organophosphate pesticides were obtained from Restek (Restek Corporation, Bellefonte, USA) while carbamate standards were from LGC standards (Teddington UK) and Sigma Aldrich (Zwijndrecht, the Netherlands) with certified purity ranging from 97% to 99%. Acetonitrile and acetic acid were obtained from Rankem (New
Delhi, India), and anhydrous magnesium sulfate, primary and secondary amine from Phenomenex (Phenomenex Inc, California, USA). All the other organic solvents used were high performance liquid chromatography (HPLC) grade.

2.2.2 Study site and Study design

This study was conducted in urban and peri-urban Nairobi. Nairobi is the capital city of Kenya and is very likely to reflect what is anticipated in other counties in the country. With an altitude of 1,670 meters (5,480 feet) above the sea level, urban and peri-urban Nairobi receive 1,050 millimeters of rainfall, twice a year with the long rains between March and May. The short rains occur between October and December. The mean annual temperature is 62.6 F (17°C), with mean daily maximum and minimum temperatures of 73.4 F (23°C) and 53.6 F (12°C), respectively.

A total of 90 vegetable samples consisting of 19 French beans, 29 kales, 24 spinach and 18 tomatoes samples were collected from Mkulima, Kangemi, Kawangware, Limuru, N-market and Kiambu open air markets in the months of April, May and June 2018. The selection of these vegetables for this study was based on their high consumption and commercial significance in Kenya (Karanja et al., 2012; Okello et al., 2012; Mutai et al., 2015; RSA, 2015; Njuguna et al., 2019).

The sampling was performed in accordance with the general principles and methods of the European Commission (EC) directive 2002/63/EC (EC, 2002) for compliance verification with MRLs in food commodities. Dust from the samples was removed with light brushing, without washing prior to placing them into the collection bags. Only fresh, high-quality vegetables that were free from blemishes or rot were sampled. Samples were double packed and transported on ice from the markets to the Department of Public health, Pharmacology and Toxicology,
University of Nairobi, Kenya. In the laboratory, samples were placed in the refrigerator at 4°C and extracted within 5 days of collection.

### 2.2.3 Extraction Procedure

The extraction and clean-up method used was based on QuEChERS (quick easy cheap effective rugged and safe) sample preparation method for pesticides (Anastassiades et al., 2003). About 1 kg of each vegetable sample was homogenized in a blender (SM1030 SANYO Electric Co., Ltd. Japan) and 15 g of the homogenized sample was accurately weighed and transferred into a 50-mL polypropylene centrifuge tube with screw cap. Extraction was conducted according to the AOAC Official Method 2007.01. Briefly, a 15-mL volume of 1% acetic acid in acetonitrile was added as an extraction solvent and the tube was tightly capped and vigorously mixed for 5 min by hand shaking. The tube was opened and 6 g of anhydrous MgSO₄ and 1.5 g sodium acetate were added. The tube was closed immediately after addition and vigorously mixed by hand for 1 minute to avoid formation of salt lump. The mixture was centrifuged at 4000 rpm (Sorvall ST 16, Thermo scientific, MA, USA). The acetonitrile phase was transferred into cryotubes and stored in the freezer (-80°C). Samples were transported at ambient temperature to the Netherlands for instrumental analysis. After centrifugation, an aliquot of the acetonitrile phase was diluted 1:1 with water and filtered. The final extract contained 0.5 g of matrix equivalent per ml.

### 2.2.4 LC-hrMS screening

Applying the method described by Zomer and Mol (2015), the extracts were first analysed using LC-hrMS. Following a non-targeted measurement, the extracts were screened in a targeted manner for a total of 118 cholinesterase-inhibiting compounds (organophosphate and carbamate pesticides) including some of their metabolites. Suspect screening was done based on expected retention time, a protonated molecule (NH₄⁺ or Na-adduct in some cases) and a
fragment ion. The compound specific parameters that were used for data processing during the pesticide screening can be made available upon request. As quality control, a mix solution of pesticides at 10 ng/ml was included in the sample batch to verify the detection capabilities of the method. These QC samples confirmed that similar detection limits were obtained as described by Zomer and Mol (2015) (typically ≤10 µg/kg). The sample extracts in which pesticides were detected during screening were re-analysed for confirmation and quantification, using an LC-MS/MS method.

2.2.5 LC-MS/MS confirmation and quantification

An Acquity UPLC system (Waters, Millford, MA, USA) was coupled to a TQ-S triple quad MS system (Waters). Chromatography was performed on a HSS-T3 C18 column (1.7 µm, 2.1x100 mm, Waters) using water (eluent A) and MeOH:H2O 95:5 (eluent B), both containing 5 mM ammonium formate and 0.1 % formic acid. The LC flow rate was 0.4 ml/min, column temperature 45°C, and injection volume 5 µl. The LC gradient started with 100% A for 1 min, followed by a two-step linear increase to eluent B (45% B at 2.5 min, 100% B at 8.5 min), which was maintained 3 min and then back initial conditions in 30 s, allowing a equilibration for 2 min before the next injection.

The MS was used in positive MRM mode with the following source parameters; capillary (3 kV), source offset (50 V), source temperature (150 °C), desolvation temperature (590 °C), cone gas flow (150 L/Hr), desolvation gas flow (1000 L/Hr) and nebuliser gas flow (7 bar). The transitions were grouped into two scan events to enable use of longer dwell times for each transition. Table 1 shows the two transitions measured for each compound. The second transition (Ql) was used to calculate an ion ratio between Qn and Ql. In positive samples this value was compared to the average ratio in the standards and used for identification. The linear range was established by injecting a calibration curve in solvent. Positive samples were
quantified by 1-point bracketed calibration using a standard in matrix prepared from a blank sample from the corresponding matrix. As QC samples the same spiked samples as used in the LC-hrMS screening were measured.

### 2.2.6 Data processing

For suspect screening by LC-hrMS, the software package Tracefinder (version 3.2 SP1, Thermo Scientific) was used to process the data. For confirmatory LC-MS/MS analysis, Masslynx was used. Calculations were further conducted using Microsoft Excel 2010.

### 2.2.7 Exposure analysis and risk characterisation

Exposure to pesticide residues through the consumption of tomatoes, kales, spinach and French beans was estimated by multiplying the residue concentration detected in the vegetables by food consumption data.

Dietary exposure (µg/kg bw/day)

\[
\text{Dietary exposure (µg/kg bw/day)} = \frac{\text{Concentration of chemical in food (µg/kg) x Food consumption (kg/person/day)}}{\text{Body weight (kg bw/person)}}
\]

Consumption of vegetables contaminated with pesticides can have acute and chronic risks which can be quantified using hazard quotient (HQ) and hazard index (HI) approaches. The following equations were used for determination of HQs:

#### 2.2.7.1 Acute/short-term Hazard Quotient (aHQ)

The aHQ was calculated based on the estimated short-term intake (ESTI) and the acute reference dose (ARfD) as follows:

\[
\text{ESTI} = (\text{the highest level of residue x the highest large portion of food consumption per day/body weight})
\]

\[
\text{aHQ} = \frac{\text{ESTI}}{\text{ARfD}}
\]
2.2.7.2 Chronic/long-term Hazard Quotient (cHQ)

The cHQ was calculated based on the estimated daily intake (EDI) and the acceptable daily intake (ADI) as follows:

\[
\text{EDI} = \frac{\text{mean level of residue } \times \text{average portion of food consumption per day}}{\text{body weight}}
\]

\[
\text{cHQ} = \frac{\text{EDI}}{\text{ADI}}
\]

Information on ARfDs and ADIs was obtained from the EU pesticides database. (https://ec.europa.eu/food/plant/pesticides/eu-pesticides-database/public/?event=activesubstance.selection&language=EN)

When HQs exceed 1, a health risk cannot be excluded.

3. Results and discussion

In Kenya, vegetables play an important role in the nutrition and health of both the urban and rural population and their intake is estimated to constitute up to 80% of the diets (Mungai et al., 2000; Kunyanga et al., 2018). Therefore, potential exposure to vegetable contaminants such as pesticide residues is likely to be high. The mean consumptions of kales, spinach, tomatoes and French beans per day are 200, 100, 200 and 10 g/day respectively (Karanja et al., 2012; Kariathi et al., 2016; Kunyanga et al., 2018; Njuguna et al., 2019). As data of Kenyan large portion consumption of the vegetables were not available, for aHQ, the maximum consumption value was assumed to be 560 (g/day) for tomatoes, kales and spinach based on a study conducted in Tanzania (Kariathi et al., 2016) and an estimate of 50 g/day for French beans was made. The dietary exposure was calculated for both the consumer groups of adults (aged above 18 years) and children (3–10 years old). For dietary exposure assessment, a body weight of 70 kg for adults (aged above 18 years) and 23 kg for children (aged 3–10 years) was applied as recommended by EFSA (EFSA, 2012). In children, the vegetables consumption (g/day) was assumed to be half that of an adults’ daily vegetable consumption.
Major sources of uncertainties in the exposure assessment are food consumption rate, body weight, sampling, processing factors, analytical bias and variation, and left-censored data (non-detects) (EFSA, 2006c). Processing factors were not considered during exposure assessment in this study.

The substitution method was applied for non-detects as described in the EFSA scientific report (EFSA, 2010b). The non-detect results were replaced with zero and the value of the LOQ (10 µg/kg), according to a Lower and Upper Bound (LB and UB) scenario, respectively.

The risk assessment of the cumulative chronic exposure to residues was performed by using the Hazard Index (HI) method, which is calculated by summing the chronic Hazard Quotients (cHQ) for the individual pesticide residue as described by Reffstrup et al., (2010):

\[
\text{Hazard Index (HI)} = \Sigma \text{cHQ}
\]

An HI exceeding 1 indicates that a health risk related to the combined exposure cannot be excluded.
Table 1: Compound specific parameters LC-MS/MS measurement

<table>
<thead>
<tr>
<th>Name</th>
<th>Precursor ion</th>
<th>Product ion</th>
<th>Cone [V]</th>
<th>Coll. En [V]</th>
<th>Dwell [s]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methamidophos Qn</td>
<td>142.2</td>
<td>94</td>
<td>20</td>
<td>13</td>
<td>0.05</td>
</tr>
<tr>
<td>Methamidophos Ql</td>
<td>142.2</td>
<td>125</td>
<td>20</td>
<td>13</td>
<td>0.05</td>
</tr>
<tr>
<td>Acephate Ql</td>
<td>184</td>
<td>125</td>
<td>10</td>
<td>20</td>
<td>0.1</td>
</tr>
<tr>
<td>Acephate Qn</td>
<td>184</td>
<td>143</td>
<td>10</td>
<td>17</td>
<td>0.1</td>
</tr>
<tr>
<td>Omethoate Ql</td>
<td>214</td>
<td>155</td>
<td>22</td>
<td>17</td>
<td>0.05</td>
</tr>
<tr>
<td>Omethoate Qn</td>
<td>214</td>
<td>183</td>
<td>22</td>
<td>10</td>
<td>0.05</td>
</tr>
<tr>
<td>Fenthion Qn</td>
<td>279</td>
<td>169</td>
<td>30</td>
<td>18</td>
<td>0.01</td>
</tr>
<tr>
<td>Fenthion Ql</td>
<td>279</td>
<td>247</td>
<td>30</td>
<td>12</td>
<td>0.01</td>
</tr>
<tr>
<td>Pirimiphos-methyl QI</td>
<td>306</td>
<td>108</td>
<td>30</td>
<td>25</td>
<td>0.01</td>
</tr>
<tr>
<td>Pirimiphos-methyl Qn</td>
<td>306</td>
<td>164</td>
<td>30</td>
<td>25</td>
<td>0.01</td>
</tr>
<tr>
<td>Triazophos Qn</td>
<td>314</td>
<td>119</td>
<td>25</td>
<td>35</td>
<td>0.01</td>
</tr>
<tr>
<td>Triazophos QI</td>
<td>314</td>
<td>162</td>
<td>25</td>
<td>20</td>
<td>0.01</td>
</tr>
<tr>
<td>Azinphos-ethyl Qn</td>
<td>346</td>
<td>132</td>
<td>10</td>
<td>15</td>
<td>0.01</td>
</tr>
<tr>
<td>Azinphos-ethyl Ql</td>
<td>346</td>
<td>160</td>
<td>10</td>
<td>10</td>
<td>0.01</td>
</tr>
<tr>
<td>Chlorpyrifos Qn</td>
<td>350</td>
<td>198</td>
<td>20</td>
<td>17</td>
<td>0.01</td>
</tr>
<tr>
<td>Chlorpyrifos Ql</td>
<td>352</td>
<td>200</td>
<td>20</td>
<td>17</td>
<td>0.01</td>
</tr>
<tr>
<td>Profenofos Ql</td>
<td>373</td>
<td>97</td>
<td>30</td>
<td>33</td>
<td>0.01</td>
</tr>
<tr>
<td>Profenofos Qn</td>
<td>373</td>
<td>303</td>
<td>30</td>
<td>18</td>
<td>0.01</td>
</tr>
</tbody>
</table>

3.1 Occurrence of OP pesticides and carbamates in Kenyan vegetables

In this survey, 118 organophosphate and carbamate pesticides were screened in vegetable samples comprising of French beans, kales, spinach, and tomatoes to assess health risk. After the screening, acephate, azinphos-ethyl, chlorpyrifos, fenthion, methamidophos, omethoate, pirimiphos-methyl, profenofos, triazophos, aldicarb, carbaryl, carbetam, carbofuran,
ethiofencarb, methiocarb and pirimicarb were tentatively detected. However, during confirmatory quantitative analysis, only chlorpyrifos, profenofos, acephate, metamidophos and omethoate had levels above the default limit of quantification of 10 µg/kg. Out of 90 vegetable samples analysed, 20 (22%) were found to contain residues of the targeted pesticide.

The most frequently detected pesticides in the positive samples were profenofos (40%) (only in tomatoes), followed by chlorpyrifos (35%), acephate (30%), metamidophos (30%), and omethoate (15%). The concentration of profenofos in tomato ranged from 10 to 958 µg/kg (44% of samples) while chlorpyrifos had a range of 78 to 107 µg/kg in tomato (11% of samples), 26 to 315 µg/kg in kales (7% of samples), and 24-1,343 µg/kg (8% of samples) in spinach respectively (Table 2). Concentrations of omethoate ranged from 11 to 98 µg/kg in tomato while acephate was found between 41 to 66 µg/kg (21% of samples). The metamidophos concentration ranged from 20 to 25 µg/kg (21% of samples), 182 µg/kg, and 13 µg/kg in French beans, tomato and kales respectively. The findings are summarised in Table 2.

The presence of multiple residues in French beans and tomatoes were 17%. Acephate and metamidophos were found in three French beans while the fourth had acephate, metamidophos and chlorpyrifos (Table 2). Methamidophos can be used as an insecticide as such, but is also a metabolite of acephate. Since it was always found together with acephate (in a ratio of 0.3 - 0.5) it was concluded that its presence was the result of acephate applications. Omethoate is another OP pesticide that can be applied as such but also is a degradation product of dimethoate. Dimethoate was not detected, indicating that it might have been applied as such or it was a metabolite of dimethoate as observed in a previous study (Bhandari et al, 2018; Kunyanga et al., 2018). Most of the pesticide residues were found in tomatoes followed by French beans, kales and lastly spinach.

Chlorpyrifos is one of the most used pesticides worldwide due to its effectiveness against a wide range of pests and rapid action (Angioni et al., 2011) and also still registered for use in
vegetable crops as well as soil treatment in Kenya (Mutai et al., 2015; PCPB, 2019). It is registered for use in pineapples, roses, cotton, coffee, barley and wheat to control various pests. Its presence in French beans, kales, spinach, and tomatoes could be due to plant uptake from the soil where it is applied to control soil based pests (Zhang et al., 2015), spray drift, or direct application on vegetables. Poor compliance of the pre-harvest interval due to high market demand for the vegetables has also been reported to result in high residue levels as observed in Ghana (Ntow et al., 2006; Darko & Akoto, 2008; Akoto et al., 2015). Ngigi et al. (2011) made a similar observation in Kenya among 85 percent of peri-urban farmers. Furthermore, other studies have indicated that farmers with low perception of harmful effects of pesticides may use them at higher than recommended doses on crops leading to higher pesticide residues (Horna et al., 2008).

In the current study, OP pesticides were detected in 22% of the screened vegetables. These prevalence is lower compared to published reports from other developing countries such as Chile, where pesticide screening in 118 leafy vegetable samples found 72% of spinach samples to contain pesticide residues at higher concentrations than the current study (Elgueta, et al., 2017). In Tanzania, Kiwango et al., (2018) found 31% of sampled vegetables to contain detectable levels of OP residues including dimethoate, acephate, profenofos, dichlorvos and malathion at a mean of 8,560 µg/kg, 2,900 µg/kg, 8,440 µg/kg 20,800 and 5,470 µg/kg respectively. In Algeria, Mbedoua, et al., (2017) found OP pesticide residues in 58% of the 120 vegetable analyzed. Another study by Elgueta et al., (2019) reported a higher frequency of chlorpyrifos detection at 21% and a mean of 10 µg/kg in lettuce, while the detection frequency in spinach and chard was 13% and a mean of 130 µg/kg for both leafy vegetables. Furthermore, methamidophos was found in spinach, chard and lettuce with a frequency of 8% and a mean of 60 µg/kg. The levels of pesticide residues in vegetables in this study were higher than those reported in India (Bhanti and Taneja, 2007).
Profenofos and chlorpyrifos were the most frequently detected pesticide residues in vegetables followed by acephate, and its metabolite methamidophos. These results are in agreement with previous studies involving pesticide screening in vegetables in peri urban Nairobi that reported profenofos (Karanja et al., 2012) and chlorpyrifos (Kunyanga et al., 2018) as the most frequently detected pesticides among others. Although omethoate is restricted for use in fruits and vegetables, it was detected in 15% of the vegetable samples. This might be due to spray drifting from neighboring farmers’ fields, or cross contamination by different vectors since it is registered for use as insecticide for coffee and ornamental flowers (PCPB, 2019). Its presence could also be due to illegal use or its persistent nature (Xu et al., 2015). A previous study by Mutai et al. (2015) found kales and French beans in peri urban Nairobi to contain up to 100 and 700 µg/kg of chlorpyrifos and dimethoate residues, respectively. Furthermore, the pesticide levels were reported to be higher during the dry period than during the wet period in that study, though there was no significant difference. Seasonal variability in pesticide residues has been observed, a phenomenon that leads to inadequate assessment of total exposure to pesticides (Mtashobya, 2017). In the same study, significant pesticide residues were found in French beans as compared to kales, an observation that Mutai et al. (2015) related to the coarse nature and dense texture of French beans that slow down the rate of volatilization, a process by which pesticides dissipate in contrast to smooth texture of kales (Bedos et al., 2002). Other factors that could affect the occurrence of pesticides and their residues in different matrices include lipid content, rainfall, temperature, soil properties, and soil organisms (Bento et al., 2016).

Pesticide residues need to comply with maximum residue levels (MRLs) which are based on Good Agricultural Practice (GAP). Since GAP may differ in different countries, also MRLs can differ. Exceedance of local MRLs are an indication that local GAP is not well followed. There are no national MRLs in Kenya. Therefore, codex MRLs were used instead as benchmark. For
the five OPs found in the four crops in this study, Codex MRLs were available for only five OP/crops combinations, thus most vegetables in this study had no established codex MRL for comparison with the measured OP levels. Chlorpyrifos exceeded the codex MRL of 10 µg/kg in French beans. Profenofos and acephate were below codex MRLs in tomatoes. Similarly, methamidophos was below the codex MRL in French beans. In lack of Codex MRLs, findings were also compared to EU-MRLs. EU-MRLs were exceeded in 8-33% of the vegetable samples. Acephate/methamidophos and omethoate have no registration in the EU, and for their residues no import tolerances apply. Hence, an EU-MRL set at the default LOQ of 10 µg/kg applies and may obviously be exceeded when these pesticides are applied in the field. Several exceedances were observed for chlorpyrifos, banned in the EU since January 2020, but at the time of collecting and analyzing the samples it was still having MRLs above the 10 µg/kg default for certain crops (e.g. tomatoes). With a relatively high MRL for profenofos in tomatoes, no exceedances were observed for this OP pesticide although it was the most frequently detected pesticide in this study. In a previous study, Karanja et al. (2012) reported levels of profenofos, diazinon, cypermethrin and bitertanol above EU permissible limits in kales in peri urban Nairobi.
Table 2: Frequency and levels of organophosphate residues detected in/on various vegetables

<table>
<thead>
<tr>
<th>Pesticides</th>
<th>French beans n=19</th>
<th>Kales n=29</th>
<th>Spinach n=24</th>
<th>Tomatoes n=18</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>number detected</td>
<td>Min- max</td>
<td>EU-MRL</td>
<td>number detected</td>
</tr>
<tr>
<td></td>
<td>(%)</td>
<td>(μg/kg)</td>
<td></td>
<td>(%)</td>
</tr>
<tr>
<td>Profenofos</td>
<td>0</td>
<td>-</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Omethoate</td>
<td>0</td>
<td>-</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Chlorpyrifos</td>
<td>1(5.3)</td>
<td>117</td>
<td>10</td>
<td>2(6.9)</td>
</tr>
<tr>
<td>Acephate</td>
<td>4(21)</td>
<td>41-66</td>
<td>10</td>
<td>1(3.4)</td>
</tr>
<tr>
<td>Methamidophos</td>
<td>4(21)</td>
<td>20-25</td>
<td>10</td>
<td>1(3.4)</td>
</tr>
</tbody>
</table>
3.2 Risk characterisation of the detected pesticides

The HQs related to exposure via dietary intake of the investigated vegetables contaminated with OPs for children and adults are presented in Table 3. Table 4 shows acute reference dose and acceptable daily intake values used in this study. The consumption of spinach was found to imply an acute risk in children and adults with an aHQ of 3.3 and 2.2 for chlorpyrifos in children and adults, respectively. In all other cases, the aHQ and cHQ for the individual pesticides were below 1, implying no risk. Chlorpyrifos, methamidofos and omethoate contributed most to chronic HQs with 0.32, 0.13 and 0.04 in children, and 0.21, 0.09 and 0.03 in adults, respectively. The aHQs for the individual pesticides for children and adults varied from 0.05 to 3.27, and from 0.03 to 2.15, while the cHQ varied from 0.00 to 0.25 for children and 0.00 to 0.14 for adults at the UB, respectively. The HQ for each residue is higher for children than for adults, due to the fact that exposure per kilogram body weight is highest for children.

Due to extensive use of OPs to control pests in vegetable farming, one expects consumer exposure to insecticide mixtures. Indeed, a number of biomonitoring studies have reported the presence of several organophosphate metabolites in urine and inhibition of acetylcholinesterase in plasma of agricultural workers (Timchalk & Poet, 2008). Therefore, many studies begin to characterize the toxicological effects of exposures to concurrent or sequential OP pesticide mixtures (Timchalk & Poet, 2008; Reffstrup et al., 2010). In this study, some vegetables showed more than one type of pesticide residue. The presence of multiple residues could be a result of plant uptake of persistent pesticides (Zhang et al., 2015), spray drift (Coronado et al., 2011) and poor agricultural practices that involve mixing of more than one kind of pesticides during application based on the conception that as a mixture they will be more potent, as has been observed among Nepalese farmers (Bhandari et al., 2018). Indeed, the practice of using pesticide cocktails that sometimes include unapproved or banned pesticides is worrying but in practice among some farmers in Africa.
Exposure to two or more pesticides may result in additive and/or interactive effects (Reffstrup et al., 2010; Saha and Zaman 2012). We used the hazard index method proposed by the US EPA to assess risk posed by a group of pesticides that act by a common mechanism (i.e. AChE inhibition) or that are toxicologically similar, assuming additive effects (US EPA, 2000; Reffstrup et al., 2010). Chronic HIs for OPs in all vegetables sampled were < 1 in both children and adults, implying no health risks upon long-term combined exposure.
Table 3: HQs for detected pesticides in French beans, kales, spinach and tomatoes

<table>
<thead>
<tr>
<th>Pesticide</th>
<th>ARID</th>
<th>ESTI</th>
<th>aHQ</th>
<th>ESTI</th>
<th>aHQ</th>
<th>HR</th>
<th>ADI</th>
<th>Mean</th>
<th>EDI</th>
<th>cHQ</th>
<th>EDI</th>
<th>cHQ</th>
<th>HR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>F. beans</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methamidophos</td>
<td>3</td>
<td>0.03</td>
<td>0.01</td>
<td>0</td>
<td>0</td>
<td>no</td>
<td>1</td>
<td>LB</td>
<td>2.47</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Acephate</td>
<td>100</td>
<td>0.07</td>
<td>0</td>
<td>0.05</td>
<td>0</td>
<td>no</td>
<td>30</td>
<td>LB</td>
<td>11.84</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Chlorpyrifos</td>
<td>5</td>
<td>0.13</td>
<td>0.03</td>
<td>0.08</td>
<td>0.02</td>
<td>no</td>
<td>1</td>
<td>LB</td>
<td>8.32</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Kales</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acephate</td>
<td>100</td>
<td>0.12</td>
<td>0</td>
<td>0.08</td>
<td>0</td>
<td>no</td>
<td>30</td>
<td>LB</td>
<td>1.48</td>
<td>0.01</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Chlorpyrifos</td>
<td>5</td>
<td>3.83</td>
<td>0.77</td>
<td>2.52</td>
<td>0.5</td>
<td>no</td>
<td>1</td>
<td>LB</td>
<td>11.76</td>
<td>0.05</td>
<td>0.05</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td>Methamidophos</td>
<td>3</td>
<td>0.16</td>
<td>0.05</td>
<td>0.1</td>
<td>0.03</td>
<td>no</td>
<td>1</td>
<td>LB</td>
<td>0.45</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Spinach</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorpyrifos</td>
<td>5</td>
<td>16.35</td>
<td>3.27</td>
<td>10.74</td>
<td>2.15</td>
<td>yes</td>
<td>1</td>
<td>LB</td>
<td>56.96</td>
<td>0.12</td>
<td>0.12</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Tomatoes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acephate</td>
<td>100</td>
<td>4.98</td>
<td>0.05</td>
<td>3.27</td>
<td>0.03</td>
<td>no</td>
<td>30</td>
<td>LB</td>
<td>22.72</td>
<td>0.1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Chlorpyrifos</td>
<td>5</td>
<td>1.3</td>
<td>0.26</td>
<td>0.86</td>
<td>0.17</td>
<td>no</td>
<td>1</td>
<td>LB</td>
<td>5.94</td>
<td>0.03</td>
<td>0.03</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>Methamidophos</td>
<td>3</td>
<td>2.23</td>
<td>0.74</td>
<td>1.46</td>
<td>0.49</td>
<td>no</td>
<td>1</td>
<td>LB</td>
<td>10.17</td>
<td>0.09</td>
<td>0.09</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td>Omethoate</td>
<td>2</td>
<td>1.19</td>
<td>0.6</td>
<td>0.78</td>
<td>0.39</td>
<td>no</td>
<td>2</td>
<td>LB</td>
<td>9.67</td>
<td>0</td>
<td>0</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td>Profenofos</td>
<td>1000</td>
<td>11.66</td>
<td>0.01</td>
<td>7.66</td>
<td>0.01</td>
<td>no</td>
<td>30</td>
<td>LB</td>
<td>100.22</td>
<td>0.44</td>
<td>0.01</td>
<td>0.29</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Chapter 2

3.4 Uncertainties related to dietary exposure assessment

Scientific uncertainties affect dietary exposure assessments and therefore should be considered during interpretation of the results. Due to paucity of data on Kenyan large portion consumption of the vegetables for aHQ determination, the maximum consumption value was assumed to be 560 (g/day) for tomatoes, kales and spinach based on a study conducted in Tanzania (Kariathi et al., 2016). Though the dietary habits of the two countries are similar to a large extent, there is a possibility to under- or over-estimate the consumption and therefore in future a dietary recall questionnaire should be used to assess large portion consumption of vegetables in Kenya. In addition, processing factors such as washing, peeling and cooking were not considered during exposure assessment in this study. Generally, inclusion of processing factors could have led to lower estimated exposure. Finally, the high proportion of left-censored data may have introduced uncertainties in the overall estimate. The substitution method applied for non-detects as described in the EFSA scientific report (EFSA, 2010b) could lead to an over-estimation of the exposure (substitution of non detects with LOQ (10 µg/kg)) or under-estimation (substitution of non detects with zero). Nevertheless, given that all individual cHQs and His, even with the worst-case approach, were below 1, indicates no risk resulting from long term consumption of the vegetables.

Since the dietary pesticide intakes determined in the current study considered only exposures from the major vegetables, it did not cover the total dietary exposure to OP pesticides. Other
food products such as fish, meats, dairy, grains, and drinking water, and exposure due to occupational or residential sources may add to the overall exposure.

Table 4: Acute reference dose and acceptable daily intake values used in this study

<table>
<thead>
<tr>
<th>Pesticide</th>
<th>ARfD (mg/kg bw/day)</th>
<th>ADI (mg/kg bw/day)</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorpyrifos</td>
<td>0.005</td>
<td>0.001</td>
<td>EFSA 2014</td>
</tr>
<tr>
<td>Profenofos</td>
<td>1</td>
<td>0.03</td>
<td>JMPR 2007</td>
</tr>
<tr>
<td>Acephate</td>
<td>0.1</td>
<td>0.03</td>
<td>JMPR 2005</td>
</tr>
<tr>
<td>Omethoate</td>
<td>0.002</td>
<td>0.0003</td>
<td>EFSA 2013</td>
</tr>
<tr>
<td>Methamidofos</td>
<td>0.003</td>
<td>0.001</td>
<td>EFSA Dir 06/131</td>
</tr>
</tbody>
</table>

**Conclusion**

This study revealed the occurrence of several organophosphate pesticide residues in French beans, kales, spinach and tomatoes, sampled from peri-urban Nairobi. Chlorpyrifos, acephate, omethoate and methamidophos exceeded the Codex and/or EU MRLs. However, only the aHQ of chlorpyrifos in spinach revealed that a potential acute risk to both children and adult consumers could not be excluded. There were no indications for chronic risks, not for the individual OPs found, and also not for the combined chronic exposure assessed through the HI. Routine monitoring of OPs and carbamates in vegetables is recommended to minimize consumer’s health risks.

**Acknowledgements**

This work is supported by the Netherlands Universities Foundation for International Cooperation (Nuffic) via scholarship granted to Isaac Omwenga (NFP - PhD.17/0019). The authors would like to thank the county government of Nairobi for consenting to this study as well as the local farmers and traders for their cooperation and support during the sample collection.

**Conflict of interest statement**

The authors declare that there are no conflicts of interest.
REFERENCES


EC (European Commission), 2002. Establishing Community Methods of Sampling for the


EFSA, 2012. Guidance on selected default values to be used by the EFSA scientific committee, scientific panels and units in the absence of actual measured data. EFSA Journal 10 (3), 2579.


http://doi.org/10.1016/j.scitotenv.2015.07.150


http://dx.doi.org/10.1016/j.foodcont.2011.06.011


OPs and Carbamate pesticide residues and related risks in vegetables consumed in Kenya

Chem. Toxicol. 64, 238–248.


NIP (National Implication Plan for Stockholm convention on Persistent Organic Pollutants,
Chapter 2


Quijano, L., Yusà, V., Font, G., Pardo, O., 2016. Chronic cumulative risk assessment of the exposure to organophosphorus, carbamate and pyrethroid and pyrethrin pesticides through fruit and vegetables consumption in the region of Valencia (Spain). Food
Chem. Toxicol. 89:39–46


Zomer, P., & Mol, H.G.J., 2015. Simultaneous quantitative determination, identification and
## Supplementary Material 1.

Organophosphorus pesticides and carbamates included in the suspect screening after LC-hrMS analysis of the vegetable extracts.

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Compound Formula</th>
<th>Adduct used</th>
<th>Rt [min.]</th>
<th>Fragment Formula</th>
<th>Fragment Mass</th>
<th>tDI window</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acephate</td>
<td>C4H10NO3PS</td>
<td>[M+H]+</td>
<td>5.72</td>
<td>C2H8O3PS</td>
<td>142.09260</td>
<td>150</td>
</tr>
<tr>
<td>Aldicarb</td>
<td>C7H14N2O4S</td>
<td>[M+H]+</td>
<td>8.35</td>
<td>C4H9S</td>
<td>89.04190</td>
<td>150</td>
</tr>
<tr>
<td>Aldicarb-sulfone</td>
<td>C7H14N2O4S</td>
<td>[M+Na]+</td>
<td>8.60</td>
<td>C3H8O2N</td>
<td>76.03910</td>
<td>250</td>
</tr>
<tr>
<td>Aldicarb-sulfate</td>
<td>C7H14N2O4S</td>
<td>[M+Na]+</td>
<td>8.92</td>
<td>C4H9S</td>
<td>89.04190</td>
<td>250</td>
</tr>
<tr>
<td>Azinphos</td>
<td>C12H16NO3PS2</td>
<td>[M+Na]+</td>
<td>10.97</td>
<td>C8H8O6N</td>
<td>132.04439</td>
<td>350</td>
</tr>
<tr>
<td>Azinphos-ethyl</td>
<td>C12H16NO3PS2</td>
<td>[M+Na]+</td>
<td>10.10</td>
<td>C8H8O6N</td>
<td>132.04439</td>
<td>350</td>
</tr>
<tr>
<td>Bendiocarb</td>
<td>C11H15NO4</td>
<td>[M+H]+</td>
<td>8.85</td>
<td>C8H10O2</td>
<td>109.02840</td>
<td>250</td>
</tr>
<tr>
<td>Chlorpyrifos</td>
<td>C8H19O3PS2</td>
<td>[M+H]+</td>
<td>10.29</td>
<td>C8H19O3PS2</td>
<td>258.05077</td>
<td>250</td>
</tr>
<tr>
<td>Chlorpyrifos-methyl</td>
<td>C7H7Cl3NO2PS2</td>
<td>[M+H]+</td>
<td>11.91</td>
<td>C8H12OCl3PS2</td>
<td>289.09145</td>
<td>250</td>
</tr>
<tr>
<td>Chlorpyrifos-oxon</td>
<td>C8H19O3PS2</td>
<td>[M+H]+</td>
<td>11.91</td>
<td>C8H12OCl3PS2</td>
<td>289.09145</td>
<td>250</td>
</tr>
<tr>
<td>Chlorpyrifos-sulfone</td>
<td>C8H19O3PS2</td>
<td>[M+H]+</td>
<td>11.91</td>
<td>C8H12OCl3PS2</td>
<td>289.09145</td>
<td>250</td>
</tr>
<tr>
<td>Chlorpyrifos-sulfoxide</td>
<td>C8H19O3PS2</td>
<td>[M+H]+</td>
<td>11.91</td>
<td>C8H12OCl3PS2</td>
<td>289.09145</td>
<td>250</td>
</tr>
<tr>
<td>Pesticide Name</td>
<td>Molecular Formula</td>
<td>Retention Time</td>
<td>M+H/mol</td>
<td>M+Na/mol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
<td>----------------</td>
<td>-----------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenthion-sulfone</td>
<td>C₁₁H₁₇O₅PS₂</td>
<td>9.79</td>
<td>C₁₁H₁₅O₄S₂</td>
<td>265.0508</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>Fenthion</td>
<td>C₁₀H₁₅O₃PS₂</td>
<td>11.44</td>
<td>C₁₀H₁₂O₂PS₂</td>
<td>247.0018</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Fenthion-oxon</td>
<td>C₁₀H₁₅O₄PS</td>
<td>10.17</td>
<td>#</td>
<td>#</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>Fenthion-oxon-sulfone</td>
<td>C₁₀H₁₅O₆PS₂</td>
<td>11.21</td>
<td>C₇H₇</td>
<td>91.0543</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Fenthion-oxon-sulfoxide</td>
<td>C₁₀H₁₅O₅PS₂</td>
<td>7.34</td>
<td>C₇H₈</td>
<td>89.0543</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Fenthion-sulfone</td>
<td>C₁₀H₁₅O₅PS₂</td>
<td>9.15</td>
<td>C₇H₈O₂PS</td>
<td>111.0406</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Fenthion-sulfoxide</td>
<td>C₁₀H₁₅O₄PS₂</td>
<td>8.99</td>
<td>C₇H₇O₂</td>
<td>104.0620</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Heptamethrin</td>
<td>C₉H₁₅N₃O₄PS</td>
<td>9.95</td>
<td>C₃H₆NO</td>
<td>88.0215</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>Iprobenfos</td>
<td>C₁₃H₂₁O₃PS</td>
<td>11.53</td>
<td>C₇H₈O</td>
<td>109.0647</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>Isofomethion</td>
<td>C₁₅H₂₄N₄O₄PS</td>
<td>11.72</td>
<td>C₃H₆NO</td>
<td>72.0444</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Methylthion</td>
<td>C₈H₁₄O₃PS</td>
<td>6.54</td>
<td>C₃H₆NO</td>
<td>72.0444</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phenthoate</td>
<td>C₁₂H₁₇O₄PS₂</td>
<td>11.27</td>
<td>#</td>
<td>#</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>Phorate</td>
<td>C₇H₁₇O₂PS₃</td>
<td>11.75</td>
<td>#</td>
<td>#</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phorate-sulfone</td>
<td>C₁₀H₁₅O₄PS₂</td>
<td>9.64</td>
<td>H₄O₂PS</td>
<td>114.0613</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phorate-sulfoxide</td>
<td>C₁₀H₁₅O₃PS₂</td>
<td>9.54</td>
<td>H₄O₂PS</td>
<td>114.0613</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₂H₁₅N₂O₃PS</td>
<td>11.56</td>
<td>#</td>
<td>#</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim-oxon</td>
<td>C₁₁H₁₁N₂O₃PS</td>
<td>8.29</td>
<td>C₇H₈O</td>
<td>160.0393</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phosalone</td>
<td>C₁₂H₁₅ClNO₄PS₂</td>
<td>11.68</td>
<td>C₇H₅O₂C₄O₂P</td>
<td>186.9710</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phosmet</td>
<td>C₁₁H₁₂NO₄PS</td>
<td>10.14</td>
<td>C₇H₈O₂N</td>
<td>160.0393</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phosmet-oxon</td>
<td>C₁₁H₁₂NO₅PS</td>
<td>8.29</td>
<td>C₇H₈O₂N</td>
<td>160.0393</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phosphamidon</td>
<td>C₁₀H₁₉ClNO₅P</td>
<td>8.60</td>
<td>C₇H₁₃ON</td>
<td>174.0689</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₂H₁₅NO₃PS</td>
<td>11.56</td>
<td>#</td>
<td>#</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₂H₁₅NO₄</td>
<td>11.56</td>
<td>#</td>
<td>#</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₄N₃O₄P</td>
<td>8.34</td>
<td>C₇H₈NO</td>
<td>128.0439</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₂NO₃PS</td>
<td>11.78</td>
<td>C₇H₁₄N</td>
<td>164.1182</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₂NO₄PS</td>
<td>12.20</td>
<td>C₇H₈O₂N</td>
<td>160.0393</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₄N₃O₄P</td>
<td>10.50</td>
<td>C₇H₁₄N</td>
<td>164.1182</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₂NO₃PS</td>
<td>11.56</td>
<td>#</td>
<td>#</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₂H₁₅NO₄</td>
<td>11.56</td>
<td>#</td>
<td>#</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₄N₃O₄P</td>
<td>8.34</td>
<td>C₇H₈NO</td>
<td>128.0439</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₂NO₃PS</td>
<td>11.78</td>
<td>C₇H₁₄N</td>
<td>164.1182</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₂NO₄PS</td>
<td>12.20</td>
<td>C₇H₈O₂N</td>
<td>160.0393</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₄N₃O₄P</td>
<td>10.50</td>
<td>C₇H₁₄N</td>
<td>164.1182</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₂NO₃PS</td>
<td>11.56</td>
<td>#</td>
<td>#</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₂H₁₅NO₄</td>
<td>11.56</td>
<td>#</td>
<td>#</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₄N₃O₄P</td>
<td>8.34</td>
<td>C₇H₈NO</td>
<td>128.0439</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₂NO₃PS</td>
<td>11.78</td>
<td>C₇H₁₄N</td>
<td>164.1182</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₂NO₄PS</td>
<td>12.20</td>
<td>C₇H₈O₂N</td>
<td>160.0393</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Phoxim</td>
<td>C₁₁H₁₄N₃O₄P</td>
<td>10.50</td>
<td>C₇H₁₄N</td>
<td>164.1182</td>
<td>250</td>
<td></td>
</tr>
<tr>
<td>Compound</td>
<td>Formula</td>
<td>[M+H]^+</td>
<td>Prec. (m/z)</td>
<td>Retention Time (min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------</td>
<td>---------</td>
<td>------------</td>
<td>---------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetrachlorvinphos</td>
<td>C₁₀H₉Cl₄O₄P</td>
<td>11.30</td>
<td>127.01550</td>
<td>150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiodicarb</td>
<td>C₁₀H₁₈N₄O₄S₃</td>
<td>9.28</td>
<td>88.02155</td>
<td>150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiodicarb</td>
<td>C₁₀H₁₈N₄O₄S₃</td>
<td>9.28</td>
<td>88.02155</td>
<td>150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxotrophi-methyl</td>
<td>C₉H₁₄C₂D₃P₂S</td>
<td>11.67</td>
<td>174.97120</td>
<td>150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triazophos</td>
<td>C₁₂H₁₆N₃O₃PS</td>
<td>10.78</td>
<td>162.06674</td>
<td>150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trichlorfon</td>
<td>C₄H₈Cl₃O₄P</td>
<td>7.59</td>
<td>220.97534</td>
<td>250</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vamidothion</td>
<td>C₈H₁₈NO₄PS₂</td>
<td>7.34</td>
<td>146.06341</td>
<td>250</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#: no fragment used in screening

**Supplementary material 2**

**LC gradient**

<table>
<thead>
<tr>
<th>Time [min.]</th>
<th>% A</th>
<th>% B</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>2.5</td>
<td>55</td>
<td>45</td>
</tr>
<tr>
<td>8.5</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>11.5</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>12</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>14</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

**Supplementary material 3**

**Source parameters LC-MS/MS measurement**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capillary</td>
<td>3 kV</td>
</tr>
<tr>
<td>Source Offset</td>
<td>50 V</td>
</tr>
<tr>
<td>Source Temp.</td>
<td>150 °C</td>
</tr>
<tr>
<td>Desolvation Temp.</td>
<td>590 °C</td>
</tr>
<tr>
<td>Cone Gas Flow</td>
<td>150 L/Hr</td>
</tr>
<tr>
<td>Desolvation Gas Flow</td>
<td>1000 L/Hr</td>
</tr>
<tr>
<td>Nebuliser gas flow</td>
<td>7 bar</td>
</tr>
</tbody>
</table>
Supplementary material 4

Compound specific parameters LC-MS/MS measurement

<table>
<thead>
<tr>
<th>Name</th>
<th>Precursor ion</th>
<th>Product ion</th>
<th>Cone [V]</th>
<th>Coll. En [V]</th>
<th>Dwell [s]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methamidophos Qn</td>
<td>142.2</td>
<td>94</td>
<td>20</td>
<td>13</td>
<td>0.05</td>
</tr>
<tr>
<td>Methamidophos Ql</td>
<td>142.2</td>
<td>125</td>
<td>20</td>
<td>13</td>
<td>0.05</td>
</tr>
<tr>
<td>Acephate Ql</td>
<td>184</td>
<td>125</td>
<td>10</td>
<td>20</td>
<td>0.1</td>
</tr>
<tr>
<td>Acephate Qn</td>
<td>184</td>
<td>143</td>
<td>10</td>
<td>17</td>
<td>0.1</td>
</tr>
<tr>
<td>Omethoate Ql</td>
<td>214</td>
<td>155</td>
<td>22</td>
<td>17</td>
<td>0.05</td>
</tr>
<tr>
<td>Omethoate Qn</td>
<td>214</td>
<td>183</td>
<td>22</td>
<td>10</td>
<td>0.05</td>
</tr>
<tr>
<td>Fenthion Qn</td>
<td>279</td>
<td>169</td>
<td>30</td>
<td>18</td>
<td>0.01</td>
</tr>
<tr>
<td>Fenthion Ql</td>
<td>279</td>
<td>247</td>
<td>30</td>
<td>12</td>
<td>0.01</td>
</tr>
<tr>
<td>Pirimiphos-methyl Ql</td>
<td>306</td>
<td>108</td>
<td>30</td>
<td>25</td>
<td>0.01</td>
</tr>
<tr>
<td>Pirimiphos-methyl Qn</td>
<td>306</td>
<td>164</td>
<td>30</td>
<td>25</td>
<td>0.01</td>
</tr>
<tr>
<td>Triazophos Qn</td>
<td>314</td>
<td>119</td>
<td>25</td>
<td>35</td>
<td>0.01</td>
</tr>
<tr>
<td>Triazophos Ql</td>
<td>314</td>
<td>162</td>
<td>25</td>
<td>20</td>
<td>0.01</td>
</tr>
<tr>
<td>Azinphos-ethyl Qn</td>
<td>346</td>
<td>132</td>
<td>10</td>
<td>15</td>
<td>0.01</td>
</tr>
<tr>
<td>Azinphos-ethyl Ql</td>
<td>346</td>
<td>160</td>
<td>10</td>
<td>10</td>
<td>0.01</td>
</tr>
<tr>
<td>Chlorpyrifos Qn</td>
<td>350</td>
<td>198</td>
<td>20</td>
<td>17</td>
<td>0.01</td>
</tr>
<tr>
<td>Chlorpyrifos Ql</td>
<td>352</td>
<td>200</td>
<td>20</td>
<td>17</td>
<td>0.01</td>
</tr>
<tr>
<td>Profenofos Ql</td>
<td>373</td>
<td>97</td>
<td>30</td>
<td>33</td>
<td>0.01</td>
</tr>
<tr>
<td>Profenofos Qn</td>
<td>373</td>
<td>303</td>
<td>30</td>
<td>18</td>
<td>0.01</td>
</tr>
</tbody>
</table>
### Supplementary material 5

Levels of pesticides detected in vegetable samples from peri-urban Nairobi and the respective

<table>
<thead>
<tr>
<th>Sample No.</th>
<th>Matrix</th>
<th>Pesticide</th>
<th>EU-MRL ug/kg</th>
<th>Level found ug/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>F. beans</td>
<td>Metamidophos</td>
<td>10</td>
<td>22</td>
</tr>
<tr>
<td>22</td>
<td>F. beans</td>
<td>Acephate</td>
<td>10</td>
<td>41</td>
</tr>
<tr>
<td>29</td>
<td>F. beans</td>
<td>Acephate</td>
<td>10</td>
<td>60</td>
</tr>
<tr>
<td>29</td>
<td>F. beans</td>
<td>Chlorpyrifos</td>
<td>10</td>
<td>117</td>
</tr>
<tr>
<td>29</td>
<td>F. beans</td>
<td>Metamidophos</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>44</td>
<td>F. beans</td>
<td>Acephate</td>
<td>10</td>
<td>66</td>
</tr>
<tr>
<td>44</td>
<td>F. beans</td>
<td>Metamidophos</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>75</td>
<td>F. beans</td>
<td>Acephate</td>
<td>10</td>
<td>58</td>
</tr>
<tr>
<td>75</td>
<td>F. beans</td>
<td>Metamidophos</td>
<td>10</td>
<td>21</td>
</tr>
<tr>
<td>13</td>
<td>Kales</td>
<td>Acephate</td>
<td>10</td>
<td>43</td>
</tr>
<tr>
<td>13</td>
<td>Kales</td>
<td>Metamidophos</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>46</td>
<td>Kales</td>
<td>Chlorpyrifos</td>
<td>10</td>
<td>26</td>
</tr>
<tr>
<td>65</td>
<td>Kales</td>
<td>Chlorpyrifos</td>
<td>10</td>
<td>315</td>
</tr>
<tr>
<td>21</td>
<td>Spinach</td>
<td>Chlorpyrifos</td>
<td>10</td>
<td>1343</td>
</tr>
<tr>
<td>57</td>
<td>Spinach</td>
<td>Chlorpyrifos</td>
<td>10</td>
<td>24</td>
</tr>
<tr>
<td>11</td>
<td>Tomatoes</td>
<td>Acephate</td>
<td>10</td>
<td>409</td>
</tr>
<tr>
<td>11</td>
<td>Tomatoes</td>
<td>Metamidophos</td>
<td>10</td>
<td>182</td>
</tr>
<tr>
<td>11</td>
<td>Tomatoes</td>
<td>Omethoate</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>18</td>
<td>Tomatoes</td>
<td>Chlorpyrifos</td>
<td>100</td>
<td>78</td>
</tr>
<tr>
<td>19</td>
<td>Tomatoes</td>
<td>Profenofos</td>
<td>10000</td>
<td>64</td>
</tr>
<tr>
<td>20</td>
<td>Tomatoes</td>
<td>Chlorpyrifos</td>
<td>100</td>
<td>107</td>
</tr>
<tr>
<td>25</td>
<td>Tomatoes</td>
<td>Profenofos</td>
<td>10000</td>
<td>958</td>
</tr>
<tr>
<td>27</td>
<td>Tomatoes</td>
<td>Omethoate</td>
<td>10</td>
<td>98</td>
</tr>
<tr>
<td>27</td>
<td>Tomatoes</td>
<td>Profenofos</td>
<td>10000</td>
<td>52</td>
</tr>
<tr>
<td>28</td>
<td>Tomatoes</td>
<td>Profenofos</td>
<td>10000</td>
<td>504</td>
</tr>
<tr>
<td>41</td>
<td>Tomatoes</td>
<td>Profenofos</td>
<td>10000</td>
<td>22</td>
</tr>
<tr>
<td>68</td>
<td>Tomatoes</td>
<td>Profenofos</td>
<td>10000</td>
<td>26</td>
</tr>
<tr>
<td>69</td>
<td>Tomatoes</td>
<td>Profenofos</td>
<td>10000</td>
<td>168</td>
</tr>
<tr>
<td>70</td>
<td>Tomatoes</td>
<td>Omethoate</td>
<td>10</td>
<td>76</td>
</tr>
<tr>
<td>70</td>
<td>Tomatoes</td>
<td>Profenofos</td>
<td>10000</td>
<td>10</td>
</tr>
</tbody>
</table>

EU MRLs
### Supplementary material 6

**Acute reference dose and acceptable daily intake values used in this study**

<table>
<thead>
<tr>
<th>Pesticide</th>
<th>ARfD (mg/kg bw/day)</th>
<th>ADI (mg/kg bw/day)</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorpyrifos</td>
<td>0.005</td>
<td>0.001</td>
<td>EFSA 2014</td>
</tr>
<tr>
<td>Profenofos</td>
<td>1</td>
<td>0.03</td>
<td>JMPR 2007</td>
</tr>
<tr>
<td>Acephate</td>
<td>0.1</td>
<td>0.03</td>
<td>JMPR 2005</td>
</tr>
<tr>
<td>Omethoate</td>
<td>0.002</td>
<td>0.0003</td>
<td>EFSA 2013</td>
</tr>
<tr>
<td>Methamidofos</td>
<td>0.003</td>
<td>0.001</td>
<td>EFSA Dir 06/131</td>
</tr>
</tbody>
</table>

### Supplementary material 7

**Codex MRLs for the various vegetable matrices**

<table>
<thead>
<tr>
<th>OP pesticide</th>
<th>Codex MRL (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tomatoes</td>
</tr>
<tr>
<td>Profenofos</td>
<td>10</td>
</tr>
<tr>
<td>Omethoate</td>
<td>-</td>
</tr>
<tr>
<td>Chlorpyrifos</td>
<td>-</td>
</tr>
<tr>
<td>Acephate</td>
<td>1</td>
</tr>
<tr>
<td>Methamidophos</td>
<td>-</td>
</tr>
</tbody>
</table>

*a) Kales is a leafy brassica for which no codex MRLs are available. The MRL for head cabbage is listed here for information. Acephate - Beans, except broad bean and soya bean

* - MRL not available in the database
CHAPTER 3.

Prediction of dose-dependent in vivo acetylcholinesterase inhibition by profenofos in rats and humans using physiologically based kinetic (PBK) modeling-facilitated reverse dosimetry

Isaac Omwenga
Shensheng Zhao
Laetitia Kanja
Hans Mol
Ivonne M.C.M. Rietjens
Jochem Louisse

Published in: Archives of Toxicology (2021) 95: 1287–1301
Abstract

Organophosphate pesticides (OPs) are known to inhibit acetylcholine esterase (AChE), a critical effect used to establish health based guidance values. This study developed a combined in vitro-in silico approach to predict AChE inhibition by the OP profenofos in rats and humans. A physiologically based kinetic (PBK) model was developed for both species. Parameter values for profenofos conversion to 4-bromo-2-chlorophenol (BCP) were derived from in vitro incubations with liver microsomes, liver cytosol, and plasma from rats (catalytic efficiencies of 1.1, 2.8, and 0.19 ml/min/mg protein, respectively) and humans (catalytic efficiencies of 0.17, 0.79, and 0.063 ml/min/mg protein, respectively), whereas other chemical-related parameter values were derived using in silico calculations. The rat PBK model was evaluated against literature data on urinary excretion of conjugated BCP. Concentration-dependent inhibition of rat and human AChE was determined in vitro and these data were translated with the PBK models to predicted dose-dependent AChE inhibition in rats and humans in vivo. Comparing predicted dose-dependent AChE inhibition in rats to literature data on profenofos-induced AChE inhibition revealed an accurate prediction of in vivo effect levels. Comparison of rat predictions (BMDL10 of predicted dose-response data of 0.45 mg/kg bw) and human predictions (BMDL10 of predicted dose-response data of 0.01 mg/kg bw) suggests that humans are more sensitive than rats, being mainly due to differences in kinetics. Altogether, the results demonstrate that in vivo AChE inhibition upon acute exposure to profenofos was closely predicted in rats, indicating the potential of this novel approach method in chemical hazard assessment.
3.1 Introduction

Organophosphorus or organophosphate pesticides (OPs) have been extensively used for the control of agricultural and household pests globally (Kumari and John 2019). Exposure to these pesticides has been reported for various segments of the population, including agriculture workers and their families, household members during home application of pesticides, people that live in proximity to farms, or the general public via residues on food (Lu et al 2000; Bradman et al 2003; Quandt et al 2004). Consequently, OPs and their metabolites have been found in human blood, serum, urine, and breast milk (Hardt and Angerer 2000; Liu et al 2014; Zhang et al 2014; Naksen et al 2016). Since various OPs have shown to cause adverse effects to the environment and to human health, many OPs are currently not registered for use as pesticides, and some OPs have even been banned (Hertz-Picciotto et al 2018).

Epidemiological studies have linked chronic OP exposure to reproductive disorders, developmental toxicity, birth defects, cancer, Parkinson’s disease, Alzheimer’s disease, diabetes, chronic respiratory disease, cardiovascular diseases, chronic nephropathies and amyotrophic lateral sclerosis (ALS) (Mostafalou and Abdollahi 2013). The critical effects of OPs in animal studies are related to neurotoxicity, which has been reported to be related to, amongst others, inhibition of acetylcholinesterase (AChE), neuropathy target esterase (NTE) (Costa 2018), acylpeptide hydrolase (APH) (Richards et al 2000), fatty acid amide hydrolase (FAAH) (Quistad et al 2001; Buntyn et al 2017) muscarinic M2 receptors (Costa 2006), and a variety of lipases (Quistad et al 2006). Inhibition of AChE is one of the mechanisms by which OPs cause acute neurotoxicity (Jamal et al 2002; Farahat et al 2003), characterized by decreased hydrolysis of acetylcholine in both central and peripheral cholinergic synapses, resulting initially in overstimulation of nicotinic and muscarinic receptors, followed by receptor down-regulation on post-synaptic membranes (Costa 2006). Acute or repeated exposure to OPs can lead to organophosphate ester-induced delayed polyneuropathy (OPIDP), a neurodegenerative
disorder caused by inhibition and aging of at least 70% of the activity of the neuropathy target esterase (NTE) present in nerve tissues as well as other tissues (e.g., lymphocytes, testis) (Johnson and Glynn 1995; Johnson and Glynn 2001; Costa 2018). In the hazard and risk assessment of OPs, in vivo animal studies on OP-induced inhibition of AChE have been used to derive a point of departure (POD) to set safe exposure levels, such as an Acute Reference Dose (ARfD). ARfDs for chlorpyrifos, acephate, methamidofos, omethoate and profenofos as reported by organizations as the European Food Safety Authority (EFSA), United States Environmental Protection Authority (EPA), and the Joint FAO/WHO Meeting on Pesticide Residues (JMPR) have been derived from data on OP-induced AChE inhibition from animal studies (EPA 2006; JMPR 2007; EPA 2011; EPA 2016; EFSA 2019). Although these in vivo studies do not measure complex neurotoxicity endpoints, the information on OP-induced inhibition of AChE in vivo is considered an important piece of information in the hazard characterization. In these in vivo studies, AChE activity is usually measured in blood and sometimes also brain tissue after OP exposure. In the present study we aimed to assess whether in vivo dose-dependent OP-induced AChE inhibition can be predicted by an animal-free approach. In order to inhibit AChE in the in vivo situation, the OP needs to reach its target (AChE) at sufficiently high concentrations. The in vivo potency of an OP to inhibit AChE is thus dependent on its intrinsic ability (potency) to inhibit AChE and the amount of OP that reaches that target. The potency of an OP to inhibit AChE can be determined using in vitro approaches. To estimate the amount of OP that reaches the target, so-called physiologically based kinetic (PBK) models can be used. A PBK model permits the simulation of the chemical’s in vivo kinetics (ADME) and can relate external exposure to internal exposure at the target sites. When having PBK models for different exposure routes and/or different species, these models can be used for exposure route and/or species extrapolations. These models can also be used as a tool to estimate exposure applying reverse dosimetry of biomonitoring data (e.g.
chemical levels in blood or urine), as has been shown, for example, for chlorpyrifos in rats and humans (Timchalk et al 2002), and chlorpyrifos in children (Rigas et al 2001). Furthermore, these models can be used for reverse dosimetry of in vitro toxicity data, thereby translating in vitro effect concentrations to in vivo doses, enabling prediction of in vivo dose-dependent toxicity, as has been shown for the OP chlorpyrifos (Zhao et al 2019). Such PBK modeling-facilitated reverse dosimetry of in vitro toxicity data is considered crucial in the transition to non-animal based novel approach methods (NAMs) for the safety assessment of chemicals (Louisse et al 2017).

PBK models have been developed for various OPs including chlorpyrifos (Timchalk et al 2002; Bouchard et al 2005; Mosquin et al 2009; Lu et al 2010; Zhao et al 2019), malathion (Bouchard et al 2003; Bogen and Singhal 2017; Bouchard et al 2017), parathion (Sultatos 1990) and diazinon (Poet et al 2004). To date, no PBK model has been built for the OP profenofos, despite its widespread use in developing countries and reported cases of human accidental poisoning (Gotoh et al 2001; Eddleston et al 2009).

Profenofos (O-(4-bromo-2-chlorophenyl) O-ethyl S-propyl phosphorothioate) (Figure 1) is a thiophosphate OP pesticide (O=P-S-C) that was developed for pest strains resistant to chlorpyrifos and other OPs (Gotoh et al 2001). Profenofos has been classified as a moderately hazardous (Toxicity Class II) pesticide by the World Health Organization (WHO) with moderate level of acute toxicity (LD50 of 358 to 1178 mg/kg in rat) following oral administration (Reported in JMPR (2007)). Dietary intake of profenofos is the primary exposure route for humans (Greish et al 2011) and residue levels exceeding EU MRLs have been found in various vegetables in Kenya (Karanja et al 2012). Our recent study reported profenofos as one of the most frequently encountered pesticide residues in vegetables sampled in peri-urban Nairobi, Kenya (Omwenga et al 2020).
The present study aims to develop a PBK model for profenofos in rats and humans and apply the models to predict dose-dependent in vivo AChE inhibition using PBK modeling-facilitated reverse dosimetry of in vitro data on profenofos-induced AChE inhibition, allowing interspecies comparisons and providing a proof-of-principle that OP-induced AChE inhibition can be predicted for both rats and humans without the need for in vivo studies. To that end, profenofos PBK models were developed based on in silico- and in vitro-derived input parameter values. The rat PBK model was evaluated by comparing PBK model predictions with available in vivo kinetic data in rats. Subsequently, in vitro data on profenofos-induced AChE inhibition were translated to predicted in vivo dose-dependent AChE inhibition in rats and humans, and predictions on dose-dependent AChE inhibition in rats were evaluated by comparison with available in vivo data.

3.2 Materials and Methods

3.2.1 Materials

Profenofos, 4-bromo-2-chlorophenol (BCP), bovine serum albumin (BSA), reduced nicotinamide adenine dinucleotide phosphate (NADPH), 5,5-dithiobis (2-nitrobenzoic acid) (DTNB) and acetylthiocholine iodide (ATC) were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Magnesium chloride hexahydrate (MgCl₂*6H₂O), trifluoroacetic acid (TFA), dimethylsulfoxide (DMSO), and calcium chloride dihydrate (CaCl₂*2H₂O) were purchased from VWR International (Amsterdam, The Netherlands). Acetonitrile (ACN, UPLC/MS grade) was purchased from Biosolve (Valkenswaard, The Netherlands). Human liver microsomes and cytosol (pooled from 150 human donors, mixed gender), rat liver microsomes and rat liver cytosol (pooled from 20 male Sprague Dawley rats) were purchased from Corning (Amsterdam, The Netherlands). Recombinant human acetylcholinesterase was purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Rat
blood was purchased from BioIVT (Westbury, USA), human and rat plasma were purchased from Innovate (New York, USA).

3.2.2 PBK model development

2.2.1 Model structure and software

The PBK model structure applied (Figure 2) is based on a generic PBK model that has been developed for humans (Jones and Rowland-Yeo 2013). Physiological parameter values (tissue volumes and blood flows) for rats and humans were taken from Jones and Rowland-Yeo (2013) (Supplementary Table 1) as collected previously by Punt et al (2020). The generic model contains separate compartments for liver, the gastrointestinal tract (GI-tract), fat, muscle, skin, bone, brain, heart, kidney, lung, spleen, venous blood, arterial blood, and a rest-of-body compartment. The uptake of profenofos from the GI-tract was described as a first order process with an absorption rate constant of 1 hr⁻¹. All absorbed profenofos was assumed to be transferred directly to the liver compartment via the portal vein. Tissue: plasma partition coefficients were estimated based on the method of Berezhkovskiy (2004) using logKₑₑ, pKa and fraction unbound plasma (fup) as input parameters. logKₑₑ and pKa values were estimated using chemicalize (www.chemicalize.com) and fup was estimated (based on LogP and pKa) using the online simcyp tool (https://www.certara.com/software/pbk-modeling-and-simulation/).

The main metabolite of profenofos reported in vivo is 4-bromo-2-chlorophenol (BCP), which has been reported to be formed upon paraoxonase 1 (PON1)-mediated hydrolysis of profenofos (JMPR 2007; EPA 2016; Dadson et al 2013) (Figure 1). Profenofos hydrolysis (BCP formation) was quantified in the present study using rat and human liver microsomes, liver cytosol and plasma (section 2.2.2). Profenofos clearance was included in the blood and liver compartments of the PBK model. In in vitro studies, also CYP-mediated formation of other metabolites has
been reported (in the presence of inhibitors of hydrolysis enzymes) (Dadson et al 2013), but these are considered less relevant, since the hydrolysis reaction is more efficient than the CYP-mediated oxidations, as indicated in our in vitro metabolism studies with liver microsomes or cytosol in which practically all profenofos was converted into BCP. Because BCP was shown to not inhibit AChE (see Results section), only profenofos kinetics were considered relevant for the reverse dosimetry and included in the PBK model (Figure 2). The only in vivo data publicly available on profenofos kinetics in rats or humans, required for model evaluation, relate to the urinary excretion of conjugated BCP in rats. Therefore, to allow model evaluation, the rat PBK model was extended to include a sub-model on BCP and BCP-glucuronide formation (Supplementary Figure 1). Estimated tissue: plasma partition coefficients of BCP and BCP-glucuronide and fraction unbound plasma (fup) values used for these sub-models are presented in Supplementary Table 1.

Renal excretion is also included in the model which is described by a passive renal clearance (via glomerular filtration) of the unbound fraction in blood at the rate of 6.7 L hr⁻¹ in humans and 0.078 L hr⁻¹ in rats. The model equations were coded and numerically integrated in Berkeley Madonna 9.1.18 (UC Berkeley, CA, USA), using the Rosenbrock’s algorithm for stiff systems. The PBK models’ differential equations are provided in the Supplementary Materials.

3.2.3 In vitro incubations to derive kinetic parameter values for description of metabolic clearance in the PBK model

Incubations of profenofos with rat and human liver microsomes, liver cytosol and plasma were performed to quantify in vitro rates of BCP formation. Conditions were optimized to be linear for metabolite formation with regard to incubation time and microsomal, cytosolic and plasma protein concentration (data not shown). The final incubations were carried out in 100 mM Tris HCl (pH 7.4, 37°C) containing (final concentrations) 5 mM MgCl₂, 2 mM CaCl₂ (to stimulate
PON1 activity (Carr et al 2015), 2 mM NADPH (cofactor to also include CYP-mediated metabolism), enzyme preparation (final concentration 2 mg/ml for human liver microsomes and cytosol and 4.4 mg/ml for human plasma; 0.5 mg/ml for rat microsomes and cytosol and 1.65 mg/ml for rat plasma) and profenofos (at final concentrations ranging from 1 to 100 μM, added from 100 times concentrated stock solutions in DMSO). Control incubations were performed in the absence of microsomes, cytosol or plasma. After 2 min pre-incubation, the reaction was initiated by adding the substrate and mixtures were incubated for 2 min in a 37 °C water bath. The total volume of the incubation mixtures was 200 μl. The reaction was terminated by the addition of 50 μl ice cold ACN and samples were kept on ice. The mixture was centrifuged at 14,000 g for 20 min at 4°C and the supernatant was analyzed using UPLC-UV.

3.2.4 UPLC-UV analysis

All samples from incubations were analyzed using a Waters Acquity UPLC H class system that consisted of a quaternary solvent manager, a sample manager, and a photodiode array (PDA) detector, equipped with a Water Acquity UPLC® BEH C18 column (1.7 μm, 2.1 × 50 mm) and Waters Xbridge UPLC® BEH C18 pre-column (2.5 μM, 2.1 x 5 mm). The temperature of the column was kept at 40°C and the auto sampler at 10°C during the UPLC analysis. The mobile phases used for the analysis consisted of (A) 0.1% TFA in nanopure water and (B) 100% ACN. A gradient elution at a flow rate of 0.6 ml/min was applied for the analysis with the initial condition of 100% A: 0% B (v/v), changing in a linear way to 0% A: 100% B from 0 to 6 min, which was maintained for 30 s, and then changed back to the initial conditions in 30 s, which were maintained for 1 min. The injection volume for each sample was 3.5 μl.

Under these conditions, the retention times of profenofos and BCP were 4.76 and 3.37 min, respectively. The amounts of profenofos and BCP were quantified by integrating the peak areas at 237 nm using calibration curves that were prepared using commercially available standards.
3.2.5 In vitro metabolism data analysis and scaling in the PBK model

Kinetic parameters including the apparent maximum velocity ($V_{\text{max}}$) and the apparent Michaelis–Menten constant ($K_{\text{m}}$) for BCP formation were obtained by fitting the data for the substrate concentration-dependent rate of conversion (expressed in nmol/min/mg protein) using GraphPad Prism 5, version 5.04 (San Diego, California, USA) to the standard Michaelis–Menten equation:

$$V = \frac{V_{\text{max}} \times [S]}{K_{\text{m}} + [S]}$$

in which the $S$ represents the concentration of substrate, expressed in μM, $V$ and $V_{\text{max}}$ the velocity and the maximum velocity of the reaction, respectively, expressed in nmol/min/mg protein, and $K_{\text{m}}$ the apparent Michaelis–Menten constant, expressed in μM. The kinetic parameter values for conversion of profenofos to BCP in the liver microsomes, liver cytosol and plasma were determined. To determine the catalytic efficiency, $V_{\text{max}}$ was divided by the $K_{\text{m}}$.

The in vitro $V_{\text{max}}$ values were scaled in the PBK model code (Supplementary Materials) using the following scaling factors for rats and humans: 35 mg microsomal protein/g liver, 80.7 mg cytosolic protein/g liver and 550 mg plasma/g blood (Medinsky et al 1994; Cubitt et al 2011). The apparent $V_{\text{max}}$ values obtained from enzymatic incubations expressed in nmol/min/mg protein were converted into μmol/h/kg liver and plasma in the PBK model code. The in vivo $K_{\text{m}}$ values were assumed to be equal to those obtained in vitro (taking into account the differences in free fraction in vitro vs in vivo).

3.2.6. Model evaluation

Since the only in vivo data available on profenofos kinetics for model evaluation were on the urinary excretion of conjugated BCP in rats, the rat PBK model was extended to include a sub-
model on BCP and BCP-glucuronide (Supplementary Figure 1). Estimated partition
coefficients and fup values of BCP and BCP-glucuronide used for these sub-models are
presented in Supplementary Table 1 and conversion of BCP to BCP-glucuronide was assumed
to take place only in the liver having the same apparent Km and Vmax values as reported before
by Strikwold et al (2013) for phenol glucuronidation. The PBK model-predicted cumulative
urinary excretion of BCP-glucuronide were compared with reported in vivo data on conjugated
BCP excretion in profenofos-exposed rats (Cho et al 2002).
Furthermore, a sensitivity analysis was performed to estimate the impact of the chemical-
specific parameters on the model output (maximum free (unbound) blood concentrations of
profenofos in this study). Normalized sensitivity coefficients (SCs) were calculated using the
following equation:
\[
SC = \frac{(C' - C)}{(P' - P)} \times \frac{P}{C}
\]
in which P represents the parameter value in the PBK model and P’ the parameter value with a
5% increase (Evans and Andersen 2000). Likewise, C’ represents the model output obtained
with the 5% increase in P, while C is the model output using the initial model parameter value.
The sensitivity analysis was conducted for oral exposure to predicted effect doses obtained with
the reverse dosimetry analysis (BMDL\textsubscript{10} values). BMDL\textsubscript{10} values were selected since a
BMDL\textsubscript{10} value from a rat study on profenofos-induced AChE inhibition was recently used to
derive the POD to obtain an acute reference dose (ARfD) for profenofos by the United States
Environmental Protection Agency (US EPA) (EPA 2016).

3.2.7 Determination of in vitro AChE inhibition by profenofos and quantitative in vitro
to in vivo extrapolation using reverse dosimetry
To perform reverse dosimetry of in vitro AChE inhibition by profenofos, first the in vitro AChE
activity in the absence or presence of increasing concentrations of profenofos was determined.
For humans, commercially available recombinant AChE was used. For rats, no commercially available recombinant AChE was available, so rat AChE was obtained from rat blood as described below.

### 3.2.8 Derivation of a concentration-response curve for human recombinant AChE inhibition

AChE inhibition was determined following the protocol of Ellman et al (1961) as modified by Chambers and Chambers (1989). The concentration of acetylthiocholine and recombinant AChE were optimized to be linear for metabolite formation (data not shown). Human recombinant AChE was dissolved in 0.1 M sodium phosphate (pH 7.4) containing 1 mg/ml BSA (which was present to stabilize human recombinant AChE (Rosenfeld and Sultatos 2006)) to reach an enzyme concentration of 200 U/ml. Subsequently, the AChE enzyme solution was further diluted with 0.1 M sodium phosphate (pH 7.4) containing 1 mg/ml BSA to a working concentration of 1 U/ml. A range of concentrated stock solutions of profenofos were prepared in ethanol and 50 times diluted by adding 5 µl of stock solution to 245 µl of 0.1 M sodium phosphate (pH 7.4) (containing 0.1 mg/ml BSA). For the negative control, 5 µl of ethanol without profenofos was added to 245 µl of 0.1 M sodium phosphate (pH 7.4) (containing 0.1 mg/ml BSA). Subsequently, 5 µl of these working solutions were added into wells of a 96 well plate already containing 44 µl sodium phosphate (pH 7.4) (containing 0.1 mg/ml BSA). To start the reaction (in absence or presence of a range of profenofos concentrations), 1 µl enzyme solution was added, giving a total volume of 50 µl per reaction with an AChE concentration of 0.02 U/ml and an ethanol concentration of 0.2%, a level that had no effect on the activity of the enzyme. After 15 minutes incubation at 37°C, the reactions were stopped by adding 150 µl of a mixture of 5,5-dithiobis (2-nitrobenzoic acid) (DTNB) and acetylthiocholine (ATC) (final DTNB and ATC concentrations were 0.075 and 0.15 mM, respectively). Subsequently,
Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos

time-dependent increase in absorbance due to formation of chromophore (DTNB + thiocholine) was measured at 37 °C using a wavelength of 412 nm during a period of 10 minutes, using a spectrophotometer (SpectraMax, Molecular Devices, UK).

AChE activity was expressed as enzyme activity (percent of control). The concentration of profenofos that produced a 50% decrease in AChE activity (IC50) was determined from best-fit plots of the mean (±SD) percentages of inhibition vs. the 10log logarithm of profenofos concentrations using GraphPad Prism 5, version 5.04 (San Diego, California, USA) equation; 

\[ Y = \frac{100}{1 + 10^{(X-\log IC50)}} \]

3.2.9 Derivation of a concentration-response curve for rat erythrocyte AChE inhibition

3.2.9.1 Blood sample processing and enzyme extraction

Rat blood samples were processed according to a method reported by Larsen et al (2019) with a few modifications to isolate the extrinsic membrane bound AChE. Briefly, the blood sample (2 ml) was centrifuged at 3000g for 15 minutes in order to separate plasma and cells. Aliquots of 500 µl of the cells were resuspended in 4.5 ml lysis buffer (20 mM sodium phosphate; pH 7.4) and frozen at -80°C for 24 h. After that, the cell samples were thawed and centrifuged (4000 g) for 15 min at 4°C. The supernatant was poured off and the precipitate was suspended in 4.5 ml lysis buffer. This treatment was repeated another two times. The residue containing what is called erythrocyte ‘ghost’ membranes, was resuspended in 500 µl analysis buffer (100 mM sodium phosphate; pH 7.4), and stored at -80°C until analysis. Aliquots of erythrocyte ‘ghost’ membrane preparations were used for protein measurement using the Pierce™ BCA Protein Assay Kit (Thermofisher) with BSA as standard for quantification (Lowry et al 1951), and for AChE activity assessment.

3.2.9.2 Rat red blood cell (RBC) AChE activity

The effect of profenofos on rat AChE activity was assessed as described above for human recombinant AChE, with a few modifications. Briefly, a typical reaction mixture (200 µl) for
AChE activity contained 0.005 mg/ml erythrocyte ‘ghost’ membrane protein. The rest of the steps were as described above for measurement of human recombinant AChE activity.

3.2.10 Quantitative in vitro to in vivo extrapolation (QIVIVE) of AChE inhibition data with PBK modeling-facilitated reverse dosimetry

In the present study, it was assumed that in vivo dose-dependent AChE inhibition (in blood) depends on the maximum concentration (Cmax) of profenofos reached in the blood. For adequate PBK modeling-facilitated reverse dosimetry, the active (unbound) concentration of a test chemical in the in vitro test system should be linked to the in vivo freely available chemical at the target site. This is important since it is assumed that it is the fraction unbound that causes the effect (AChE inhibition). In the in vitro incubations, a very low concentration of BSA (0.1 mg/mL) is present. Heilmair et al (2008) reported that with such low BSA concentrations, the free concentration of chlorpyrifos oxon is not affected. Furthermore, Rosenfeld and Sultatos (2006) found no evidence of binding of paraoxon by BSA even at a higher concentration (1 mg/ml) during incubations. Based on these observations no significant effect on the free fraction of profenofos in the in vitro AChE inhibition studies is expected, which corroborated with estimations on profenofos binding in the in vitro incubations with help of the online simcyp tool (https://www.certara.com/software/pbpk-modeling-and-simulation/)). A description of the fraction unbound in blood is incorporated in the PBK model, hence the predicted in vivo unbound Cmax values in blood were related to the profenofos concentrations we applied in vitro.

By calculating with the PBK model the external dose required to reach (as unbound Cmax) the concentrations applied in the in vitro test, each in vitro concentration was translated into an in vivo dose. In this way the concentration-response curves for rat and human AChE inhibition
were converted into in vivo dose-response curves for profenofos-induced AChE inhibition in rats and humans, respectively.

3.2.11 Evaluation of predicted dose-response curves for rat and human AChE inhibition

To evaluate the performance of the PBK modeling-facilitated reverse dosimetry approach to predict in vivo AChE inhibition, the predicted dose-response curve for rat AChE inhibition upon exposure to profenofos was compared with available in vivo data on AChE inhibition in rats (JMPR 2007). Furthermore, the predicted dose-response data were used for BMD modeling, using EFSA PROAST version 69.0 (https://shiny-efsa.openanalytics.eu/app/bmd) using the model averaging approach in order to allow evaluation of the prediction by comparison of BMDL_{10} values obtained from the predicted dose-response data to points of departure derived by regulatory bodies (JMPR 2007; EPA 2016; EFSA 2019). To that end, the obtained BMDL_{10} values were compared with a reported BMDL_{10} value from a rat study on profenofos-induced RBC AChE inhibition, which was recently used to obtain an ARfD by the US EPA (EPA 2016), and a reported NOAEL value on profenofos-induced rat brain acetylcholinesterase inhibition, which has been used to obtain an ARfD by JMPR (2007).

3.3 Results

3.3.1 In vitro conversion of profenofos to BCP

The conversion of profenofos to BCP was measured in incubations with both rat and human liver microsomes, cytosol and plasma. UPLC analysis revealed that only one peak (BCP) appeared when analyzing the samples obtained from these incubations. In control incubations, small amounts (max 0.04% of the amount of profenofos added) of BCP were detected, indicating some spontaneous hydrolysis of profenofos in the aqueous environment, which has also been observed in previous studies (Aly and Badawy 1982). The BCP formation data for
microsomes, cytosol and plasma were therefore corrected for BCP levels detected in control incubations.

The concentration-dependent velocity of BCP formation following incubation of profenofos with both human and rat liver microsomes, liver cytosol and plasma is depicted in Figure 3A-3C. The kinetic parameters derived from these data (Km and Vmax) as well as the catalytic efficiencies, calculated as Vmax/Km, are presented in Table 1.

The results indicate differences in the catalytic efficiencies for conversion of profenofos to BCP by rats and humans (Table 1). The catalytic efficiency for microsomal biotransformation of profenofos to BCP was 6.5-fold lower in incubations with human liver microsomes than with rat liver microsomes, due to a 7.7-fold lower Vmax and a 1.2-fold lower Km (Table 1). Likewise, the catalytic efficiency for cytosolic biotransformation of profenofos to BCP was 3.8-fold lower for human liver cytosol, with a 1.1-fold higher Vmax, and a 4.1-fold higher Km for human liver cytosol as compared to rat liver cytosol. Largest differences were observed for plasma, indicated by the 32-fold lower catalytic efficiency of biotransformation of profenofos to BCP for human plasma than for rat plasma, due to a 1.5-fold higher Vmax and 44-fold higher Km for human plasma as compared to rat plasma.
Table 1. Kinetic parameter values (Km, Vmax) and catalytic efficiencies (Vmax/Km) for in vitro conversion of profenofos to BCP.

<table>
<thead>
<tr>
<th></th>
<th>Human</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liver microsomes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Km (μM)</td>
<td>6.9</td>
<td>8.1</td>
</tr>
<tr>
<td>Vmax (nmol/min/mg microsomal protein)</td>
<td>1.2</td>
<td>8.9</td>
</tr>
<tr>
<td>Catalytic efficiency (ml/min/mg protein)</td>
<td>0.17</td>
<td>1.1</td>
</tr>
<tr>
<td><strong>Liver cytosol</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Km (μM)</td>
<td>1.4</td>
<td>0.34</td>
</tr>
<tr>
<td>Vmax (nmol/min/mg cytosolic protein)</td>
<td>1.1</td>
<td>0.95</td>
</tr>
<tr>
<td>Catalytic efficiency (ml/min/mg protein)</td>
<td>0.79</td>
<td>2.8</td>
</tr>
<tr>
<td><strong>Plasma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Km (μM)</td>
<td>158</td>
<td>3.6</td>
</tr>
<tr>
<td>Vmax (nmol/min/mg plasma protein)</td>
<td>0.99</td>
<td>0.68</td>
</tr>
<tr>
<td>Catalytic efficiency (ml/min/mg protein)</td>
<td>0.0063</td>
<td>0.19</td>
</tr>
</tbody>
</table>
Figure 1. Metabolic pathways for metabolism of profenofos (A) based on data reported in previous studies (Gotoh et al. 2001; Dadson et al. 2013). Metabolites include desethylated profenofos (B), desthiopropylprofenofos / des-S-propylated profenofos (C), hydroxypropyl profenofos (D), 4-bromo-2-chlorophenyl dihydrogen phosphate (E), and 4-bromo-2-chlorophenyl (BCP) (F).
3.3.2 PBK model development and evaluation

Using the kinetic parameters thus defined and the input parameters obtained with in silico methods summarized in Supplementary Table 1, PBK models for profenofos in rat and human were made. Figure 4 presents the rat PBK model-based prediction of the urinary BCP excretion. In a subsequent step first the developed rat profenofos PBK model was evaluated against in vivo data on urinary excretion of conjugated BCP in rats from a study by Cho et al (2002). These results indicate that the predictions made by the newly developed PBK model for rat match the reported in vivo data well. Due to a lack of in vivo kinetic data for humans, evaluation of the performance of the PBK model for profenofos in humans could not be performed. However, the human model was considered to be adequate, since it is based on the same conceptual model and in vitro- and in silico-derived input parameters were defined in the same way as those for the rat model.

Further evaluation of the PBK models included a local sensitivity analysis in which the impact of each chemical-specific parameter on the predicted free (unbound) Cmax of profenofos in the rat and human PBK model was determined upon exposure to predicted effect doses (BMDL10 values derived from predicted dose-response data (see section 3.2.6)). Figure 5 presents the parameters for which the SCs are higher than 0.1 (absolute value). For both rat and human models, the prediction of the Cmax of profenofos appeared to be mainly affected by the kinetic parameters for conversion of profenofos to BCP by enzymes from especially plasma and liver cytosol, in addition to the absorption rate constant (ka) and the gut to plasma partition coefficient.

The obtained PBK models reveal differences in kinetics in rats and humans (Figure 6). Figure 7 shows the PBK model-predicted dose-dependent Cmax values (free concentration) in rats and humans, indicating that humans are expected to reach around twenty-fold higher blood
concentrations than rats at equal oral exposure levels, mainly due to the lower catalytic efficiency for metabolic clearance of profenofos in humans.

Figure 2. Schematic diagram of the PBK model for profenofos for rats and humans.
Figure 3. Concentration-dependent rate of profenofos conversion to BCP in incubations with human (triangles) and rat (dots) (A) liver microsomal proteins, (B) liver cytosolic proteins, and (C) plasma proteins. Results represent data from 3 independent experiments and are presented as mean ± SEM.
Figure 4. Comparison of PBK model-predicted (continuous line) and experimentally determined (symbols, Cho et al 2002) time-dependent cumulative urinary excretion of BCP-glucuronide in rats upon oral administration of 35.8 mg profenofos/kg bw.

3.3.3 Prediction of in vivo dose-dependent AChE inhibition by PBK modeling-facilitated reverse dosimetry of in vitro data and comparison with reported in vivo effect data

Concentration-dependent inhibition of rat RBC AChE (obtained from rat blood) and human (recombinant) AChE by profenofos were obtained in vitro (Figure 7). Profenofos inhibited human AChE with an IC50 value of 302 nM, which is very close to the IC50 value of 350 nM reported by Das and Kamil (2006) using freshly obtained human erythrocytes. Profenofos inhibited rat AChE with an IC50 of 312 nM, suggesting no species difference in profenofos-induced AChE inhibition, based on effect concentrations related to 50% AChE inhibition.

The concentration-dependent AChE inhibition curves obtained in this study were converted into in vivo dose-dependent AChE inhibition curves in rats and humans (Figure 8) using the PBK modeling-facilitated reverse dosimetry approach as described in the materials and methods section. Figure 8 also presents in vivo data for male and female rat profenofos-induced AChE inhibition in RBCs and in the brain available from literature (JMPR 2007). The results reveal that predicted in vivo dose-response curves for rat AChE inhibition are close to the
Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos

reported in vivo data for male and female rat AChE inhibition in RBCs and in the brain (JMPR 2007), indicating that with this combined in vitro-in silico approach, good predictions for rats were obtained. Predictions for humans indicate that humans are expected to be more sensitive than rats regarding profenofos-induced AChE inhibition (Figure 8), which is mainly due to the slower metabolic clearance of profenofos, resulting in higher Cmax values at the same dose levels (Figure 7). Toxicity data for humans for further evaluation of the predicted dose-response curves are not available.

BMD analysis was performed on predicted dose-response data for rats and human. Results of these analyses are presented in Supplementary Tables 2 and 3 and Supplementary Figures 2 and 3. BMDL10 values obtained for rats and humans upon model averaging were 0.45 and 0.01 mg/kg bw, respectively, predicting humans to be more sensitive than rats. In theory, BMD values obtained from predicted dose-response data may serve as PODs for setting safe exposure levels, i.e. an ARfD, and these BMD values were therefore compared with PODs that have been used by the US EPA, JMPR and EFSA in their assessments.

The US EPA considered erythrocyte (RBC) AChE inhibition to be more suitable to derive a POD for human safety assessments, since it is more sensitive than brain AChE inhibition in case of profenofos exposure (EPA 2016). A 10% RBC inhibition of AChE has been adopted by the US EPA to obtain a POD to define the ARfD for profenofos (EPA 2016). The US EPA reported a BMDL10 of 1.99 mg/kg bw for profenofos-induced RBC AChE inhibition in adult rats upon a single exposure to profenofos, being 4 times higher than the BMDL10 obtained from the predicted dose-response data for rats in our study (0.45 mg/kg bw).

JMPR used a NOAEL value of 100 mg/kg bw to derive an ARfD, based on a dataset on profenofos-induced inhibition of brain AChE in rats (upon a single exposure to profenofos). This NOAEL value is 50-fold higher than the BMDL10 value reported by the US EPA and 200-
fold higher than the BMDL$_{10}$ value obtained from our predicted dose-response data in rats (0.45 mg/kg bw), suggesting the NOAEL to result in a POD that may be too high.

In a recent report from EFSA (EFSA 2019), an ARfD for profenofos of 0.005 mg/kg bw was reported, based on a German evaluation in 2001 that defined an ARfD based on a NOAEL in a dog study using inhibition of brain cholinesterase activity as critical effect. Unfortunately, no further information (e.g. NOAEL) on that particular dog study is publicly available. If a safety factor of 100 was used to derive this ARfD, the NOAEL derived from the dog study would be close to the BMDL$_{10}$ value obtained from our predicted dose-response data in rats (0.45 mg/kg bw (~ 100-fold higher than the ARfD)).

Figure 5. Sensitivity analysis representing the influence of model parameters on the predicted blood Cmax of profenofos in humans and rats at predicted BMDL$_{10}$ values of 0.01 and 0.45 mg/kg bw, respectively. PGU= gut:plasma partition coefficient; fu= fraction unbound in plasma; fumic= fraction unbound in microsomal incubation; fucyt= fraction unbound in cytosolic incubation; fupla= fraction unbound in incubation with plasma; ka= absorption constant; Vmax, cytosol= maximum rate of conversion of profenofos to BCP by liver cytosol; Km, cytosol= Michaelis-Menten constant for conversion of profenofos to BCP by liver cytosol; Vmax, plasma= maximum rate of conversion of profenofos to BCP by plasma; Km, plasma= Michaelis-Menten constant for conversion of profenofos to BCP by plasma.
Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos

Figure 6. PBK model-predicted dose-dependent Cmax (free) in blood upon oral profenofos exposure in rats (dotted line) and humans (continuous line).

Figure 7. Acetylcholinesterase (AChE) activity in RBCs of Sprague–Dawley rats (closed symbols) and of human recombinant AChE (open symbols) with increasing concentrations of profenofos. AChE activity in the solvent control is set at 100%. Results represent data from 3 independent experiments and are presented as mean ± SEM.
3.4 Discussion

The aim of the current study was to develop a physiologically based kinetic (PBK) model in rats and humans solely based on in vitro and in silico input parameters to be applied for the prediction of in vivo AChE inhibition by the OP pesticide profenofos by reverse dosimetry of in vitro AChE inhibition data. To this end, profenofos PBK models were developed for rats and humans and used to predict dose-dependent internal profenofos concentrations, which were applied for reverse dosimetry to translate in vitro concentration-dependent data on profenofos-induced inhibition of AChE to in vivo dose-response curves for profenofos-induced inhibition of AChE in blood. The results indicate that profenofos-induced AChE inhibition in rats was closely predicted and that humans are predicted to be more sensitive to profenofos-induced AChE inhibition than rats upon acute exposure.

This study has shown marked interspecies differences in toxicokinetics of profenofos with predicted blood Cmax values for profenofos in humans being around 20-fold higher than in rats at equal levels of exposure (Figure 6). This is mainly due to higher catalytic efficiencies for microsomal, cytosolic and plasma biotransformation of profenofos to BCP in rats as compared to humans as observed in this study (Table 1). Profenofos, being an oxon, is mainly detoxified through hydrolysis by hepatic and plasma PON1 and CYP450-mediated detoxification, resulting in the production of BCP (JMPR 2007; EPA 2016; Dadson et al 2013). Interspecies differences in activities between human and rat PON1 have been reported, with human PON1 having lower catalytic activity as compared to rat PON1 (Kaliste-Korhonen et al 1996). Another possible reason for the differences in profenofos detoxification may be related to quantitative differences in B-esterases in rats and humans, which may affect the metabolism and disposition of ester compounds including OPs (Ecobichon and Comeau 1973; Maxwell et al 1987). B-esterases, such as carboxylesterase (CaE), butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE), detoxify oxons, but these enzymes are inhibited by the oxons as
Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos

a consequence (Chanda et al. 1997). It has been reported that rat plasma contains almost all types of esterases including CaE, PON1, BChE, and AChE (Satoh and Hosokawa 2006; Bahar et al. 2012), whereas humans are deficient of plasma CaE (Li et al. 2005; Berry et al. 2009; Williams et al. 2011) and plasma AChE (Ecobichon and Comeau 1973). The relevance of CaE in OP detoxification is indicated by a study that demonstrated that in vivo inhibition of CaEs by cresylbenzodioxaphosphorin oxide (CBDP) caused an increase in the toxicity of many OPs in rats, mice, rabbits and guinea pigs (Ecobichon and Comeau 1973; Maxwell et al. 1987). In the same study, the interspecies differences observed in the toxicity of OPs were lost in the group treated with the in vivo CaE inhibitor (CBDP) (Maxwell et al. 1987). The absence of CaE in human plasma in addition to low PON1 activity may therefore be responsible for lower profenofos clearance resulting in higher sensitivity of humans to profenofos as compared to rodents (Kaliste-Korhonen et al. 1996). In this way, B-esterases may play a protective role in rats but not humans.

Data on RBC AChE inhibition can be considered as an appropriate surrogate measure of potential organophosphate effects on the peripheral and central nervous systems in absence of brain AChE inhibition data (Das and Kamil 2006; Chen et al. 1999).

To predict profenofos dose levels that result in AChE inhibition in rats and humans, profenofos in vitro concentration-response curves for RBC AChE inhibition (Figure 7) were translated to in vivo dose-response curves for RBC AChE inhibition for both rats and humans (Figure 8). The predicted data thus obtained for the rat matched with the available in vivo rat data as reported by JMPR (2007) (Figure 8), and the BMDL_{10} obtained from the predicted dose-response data differed only 4-fold from the BMDL_{10} obtained from data from an in vivo rat study on profenofos-induced blood AChE inhibition used by the US EPA for determination of an ARfD for profenofos. This indicates that in vivo dose-dependent AChE inhibition was closely predicted based on our approach, giving confidence in the human predictions, which
could not be further evaluated because of the lack of human in vivo data on this endpoint. Our predictions suggest that humans are more sensitive than rats towards profenofos-induced AChE inhibition. The interspecies differences (45-fold difference in BMDL$_{10}$) were predicted to be mainly due to interspecies differences in toxicokinetics, as discussed above, and these would not be covered by the standard uncertainty factor of 10 to account for interspecies differences. Currently we work on the assessment of human interindividual differences in profenofos metabolic clearance (using plasma and liver fractions of different donors) to be incorporated in PBK models, providing insight into whether a combined uncertainty factor of 100 (10 for interspecies differences and 10 for intraspecies differences) applied to the rat AChE inhibition data is expected to be sufficiently protective for sensitive human individuals.

In the present study, the BMDL$_{10}$ calculated based on predicted rat data was 4 times lower than the BMDL$_{10}$ value used by EPA and 200-fold lower than the NOAEL used by JMPR to obtain an ARfD, implying that our prediction is more conservative as compared to the rat data used by the two agencies. In a possible future risk assessment paradigm that would be independent of animal data, BMDL$_{10}$ values obtained from the predicted human dose-response data may be applied. In the present study, we determined a BMDL$_{10}$ value for ‘an average human’ (0.01 mg/kg bw), not quantifying possible interindividual differences. To take interindividual differences into account an uncertainty factor may be applied, but it would be scientifically more sound to quantify interindividual differences in the human population in profenofos detoxification. This is especially of interest given the reported genetic polymorphisms of human PON1 (and BuChE) with related phenotypes of low and high activities (Geldmacher et al 1989; Schwarz et al 1995), which may play a role in the interindividual differences in PON1 activity (Darney et al 2020), suggesting possible large human interindividual differences in profenofos detoxification. As indicated above, we currently work on the determination of such
interindividual differences in profenofos detoxification in humans and integrate these data in the human PBK modeling-based predictions of profenofos toxicity.

Although the current models quantitatively predicted profenofos tissue dosimetry and the resulting AChE inhibition, possible limitations of the approach should be considered. In the current PBK model, gut absorption of profenofos was estimated to be 100% using a first order process with an absorption rate constant of 1 hr$^{-1}$. Although this resulted in the adequate prediction of time-dependent BCP-glucuronide in rat urine, it must be noted that that specific model output is not so sensitive to the $ka$ (data not shown), whereas the (unbound) Cmax is (Figure 6). It is noteworthy that the extent of absorption varies depending on the dosing method, dose formulation (solution) and variations in species, strain and gender (Kararli 1995). Furthermore, profenofos absorption as present in the food matrix may be different.

We used a static approach to determine the AChE inhibitory effect concentrations, using a single preincubation time point (15 minutes). When including more time points, information on the time-dependent inhibition kinetics can be obtained. However, a previous study with chlorpyrifos oxon showed that human recombinant acetylcholinesterase active sites were 100% inhibited after a pre-incubation period of 11 minutes (Kaushik et al 2007). One would expect that effect concentrations would decrease with longer incubation times until 100% of the binding sites is inhibited, as shown before by Aurbek et al (2006) and Krstić et al (2008). With a relatively long pre-incubation time of 15 minutes as we have used in the present study, similar to incubation times previously applied by other research groups (e.g. Aurbek et al 2006; Kasteel et al 2020), we aimed to obtain a relevant and conservative estimation of the effect concentrations, as also indicated by the small difference between the BMDL$_{10}$ value obtained with our predicted rat dose-response data and the BMDL$_{10}$ value from a reported in vivo study in rats.
It must also be noted that the approach used in this study may be suitable to estimate AChE inhibition upon a single exposure, while not predicting effects upon repeated exposure, since upon longer exposures, one must take the time-dependent de novo AChE production into account to adequately estimate the AChE activity upon a second and further exposure. In that regard a phenomenon referred to as steady state AChE inhibition is of interest, which is the situation when the degree of AChE inhibition reaches equilibrium with the production of new enzyme at which AChE inhibition remains constant at a specified dose over the exposure period (EPA 2016). Adequate prediction of these processes based on only in vitro data, as applied in the present study, seems at this stage not possible. Furthermore, one must consider that OPs inhibit detoxifying enzymes, such as CaE and BuChe, which may result in a decrease in metabolic clearance, and related higher internal concentrations and increased sensitivity upon repeated dosing.

Another limitation of the approach is that the prediction of OP toxicity was only based on AChE inhibition as the endpoint. It should, however, be noted that OPs may affect a number of additional targets (such as Neuropathy target esterase (NTE) (Costa 2018), muscarinic M2 receptors (Costa 2006), acylpeptide hydrolase (APH) (Richards et al 2000), fatty acid amide hydrolase (FAAH) (Quistad et al 2001; Buntyn et al 2017) and a variety of lipases (Quistad et al 2006)) that lead to OP toxicity, including neuroinflammation, autoimmunity and axonal transport deficits (Naughton and Terry 2018). On the other hand, AChE inhibition has been used as an endpoint to set a POD for the risk assessment (EPA 2016; EFSA 2019), indicating its relevance. The QIVIVE approach could be extended in the future to also predict dose-dependent effects related to other OP targets, allowing a more extensive hazard assessment based on NAMs.

In conclusion, the predicted dose-dependent profenofos-induced AChE inhibition in rats are close to reported data on dose-dependent in vivo AChE inhibition in rats upon single dosing,
Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos

providing also confidence in the predictions obtained for humans. Results from this study suggest that humans may be more sensitive to AChE inhibition upon profenofos exposure than rats, which is mainly due to differences in profenofos detoxification. Altogether, the results demonstrate the ability to predict in vivo AChE inhibition by profenofos, providing another proof-of-principle that with NAMs in vivo effects of chemicals can be predicted without the use of in vivo studies.

Acknowledgements

This work is supported by the Netherlands Universities Foundation for International Cooperation (Nuffic) (scholarship granted to Isaac Omwenga (PhD.17/0019)), the China Scholarship Council (scholarship (No. 201707720063) granted to Shensheng Zhao), and the Dutch Ministry of Agriculture, Nature and Food Quality (project KB-23-002-021).

Conflict of interest statement

The authors declare that they have no conflicts of interest.
References


Chanda SM, Mortensen SR, Moser VC, Padilla S (1997) Tissue-specific effects of
Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos


EFSA (European Food Safety Authority) (2019). Scientific Report on scientific support for
preparing an EU position in the 51st Session of the Codex Committee on Pesticide Residues (CCPR). EFSA Journal 17:5797.


Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos


Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos


inhibition by the organophosphate paraoxon. Toxicol Sci 90:460–469.


Supplementary Table 1. Physiological and chemical-specific parameters used for the PBK models.

<table>
<thead>
<tr>
<th>Model parameter</th>
<th>Human</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physiological parameters</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight</td>
<td>70</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>Fractional tissue volumes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fat</td>
<td>0.213</td>
<td>0.07</td>
</tr>
<tr>
<td>Bone</td>
<td>0.0856</td>
<td>0.0659</td>
</tr>
<tr>
<td>Brain</td>
<td>0.02</td>
<td>0.0052</td>
</tr>
<tr>
<td>Gut</td>
<td>0.0171</td>
<td>0.026</td>
</tr>
<tr>
<td>Heart</td>
<td>0.0057</td>
<td>0.0044</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.0044</td>
<td>0.0092</td>
</tr>
<tr>
<td>Liver</td>
<td>0.021</td>
<td>0.036</td>
</tr>
<tr>
<td>Lung</td>
<td>0.0076</td>
<td>0.0052</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.4</td>
<td>0.488</td>
</tr>
<tr>
<td>Skin</td>
<td>0.0371</td>
<td>0.1656</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.0026</td>
<td>0.0024</td>
</tr>
<tr>
<td>Venous blood</td>
<td>0.0514</td>
<td>0.0429</td>
</tr>
<tr>
<td>Arterial blood</td>
<td>0.0257</td>
<td>0.0215</td>
</tr>
<tr>
<td>Rest of body</td>
<td>0.1098</td>
<td>0.0577</td>
</tr>
<tr>
<td>Cardiac output (mL/s)</td>
<td>108.33</td>
<td>1.33</td>
</tr>
<tr>
<td><strong>Fractional tissue blood flows</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fat</td>
<td>0.05</td>
<td>0.059</td>
</tr>
<tr>
<td>Bone</td>
<td>0.05</td>
<td>0.10</td>
</tr>
<tr>
<td>Brain</td>
<td>0.12</td>
<td>0.014</td>
</tr>
<tr>
<td>Tissue</td>
<td>Value 1</td>
<td>Value 2</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Gut</td>
<td>0.1465</td>
<td>0.0101</td>
</tr>
<tr>
<td>Heart</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.19</td>
<td>0.145</td>
</tr>
<tr>
<td>Liver (Venous side)</td>
<td>0.2154</td>
<td>0.242</td>
</tr>
<tr>
<td>Lung</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.17</td>
<td>0.237</td>
</tr>
<tr>
<td>Skin</td>
<td>0.05</td>
<td>0.051</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.0172</td>
<td>0.011</td>
</tr>
<tr>
<td>Rest of body</td>
<td>0.02119</td>
<td>0.112</td>
</tr>
<tr>
<td>Renal clearance (L/hr)</td>
<td>6.7</td>
<td>0.078</td>
</tr>
</tbody>
</table>

**Chemical specific parameters profenofos**

- Molecular weight: 373.63
- LogP: 4.88
- pKa: NA
- LogD*(olive oil: water): 4.09

**Binding data**

- Fu blood: 0.034

- Fraction unbound microsomes: $0.07^a$, $0.232^b$
- Fraction unbound cytosol: $0.07^c$, $0.232^d$
- Fraction unbound plasma (in vitro incubations): $0.83^e$, $0.93^f$

**Tissue to plasma partition coefficients**

- Fat: 96.3, 147
- Bone: 15.4, 11.9
Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Absorption Ka (/hr)</th>
<th>Fraction absorbed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>14.1</td>
<td>23.3</td>
</tr>
<tr>
<td>Gut</td>
<td>11.1</td>
<td>14.1</td>
</tr>
<tr>
<td>Heart</td>
<td>3.47</td>
<td>7.47</td>
</tr>
<tr>
<td>Kidney</td>
<td>5.35</td>
<td>8.84</td>
</tr>
<tr>
<td>Liver</td>
<td>8.82</td>
<td>9.70</td>
</tr>
<tr>
<td>Lung</td>
<td>1.24</td>
<td>11.1</td>
</tr>
<tr>
<td>Muscle</td>
<td>5.43</td>
<td>5.44</td>
</tr>
<tr>
<td>Skin</td>
<td>6.62</td>
<td>12.4</td>
</tr>
<tr>
<td>Spleen</td>
<td>5.45</td>
<td>5.05</td>
</tr>
<tr>
<td>Rest of body</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Absorption Ka (/hr)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Fraction absorbed</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
**Chemical specific parameters: BCP**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LogP</td>
<td>3.04</td>
</tr>
<tr>
<td>pKa</td>
<td>7.54</td>
</tr>
<tr>
<td>LogD*(olive oil: water)</td>
<td>1.80</td>
</tr>
</tbody>
</table>

**Tissue plasma partition coefficients**

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fat</td>
<td>5.62</td>
</tr>
<tr>
<td>Bone</td>
<td>2.90</td>
</tr>
<tr>
<td>Brain</td>
<td>5.65</td>
</tr>
<tr>
<td>Gut</td>
<td>3.54</td>
</tr>
<tr>
<td>Heart</td>
<td>2.05</td>
</tr>
<tr>
<td>Kidney</td>
<td>2.36</td>
</tr>
<tr>
<td>Liver</td>
<td>2.52</td>
</tr>
<tr>
<td>Lung</td>
<td>2.87</td>
</tr>
<tr>
<td>Muscle</td>
<td>1.58</td>
</tr>
<tr>
<td>Skin</td>
<td>3.11</td>
</tr>
<tr>
<td>Spleen</td>
<td>1.49</td>
</tr>
<tr>
<td>Rest of body</td>
<td>1</td>
</tr>
</tbody>
</table>

**Binding data**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fu blood</td>
<td>0.113</td>
</tr>
<tr>
<td>Fraction unbound microsomes</td>
<td>0.761g</td>
</tr>
</tbody>
</table>

**Chemical specific parameters: BCP glucuronide**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LogP</td>
<td>1.06</td>
</tr>
<tr>
<td>pKa</td>
<td>2.72</td>
</tr>
</tbody>
</table>
Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos

<table>
<thead>
<tr>
<th>Tissue to plasma partition coefficients</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fat</td>
<td>0.13</td>
</tr>
<tr>
<td>Bone</td>
<td>0.79</td>
</tr>
<tr>
<td>Brain</td>
<td>1.49</td>
</tr>
<tr>
<td>Gut</td>
<td>1.16</td>
</tr>
<tr>
<td>Heart</td>
<td>1.00</td>
</tr>
<tr>
<td>Kidney</td>
<td>1.05</td>
</tr>
<tr>
<td>Liver</td>
<td>1.01</td>
</tr>
<tr>
<td>Lung</td>
<td>1.12</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.93</td>
</tr>
<tr>
<td>Skin</td>
<td>1.05</td>
</tr>
<tr>
<td>Spleen</td>
<td>1.02</td>
</tr>
<tr>
<td>Rest of body</td>
<td>1</td>
</tr>
</tbody>
</table>

**Binding data**

| Fu blood | 0.226 |

**Scaling factors**

<table>
<thead>
<tr>
<th>Microsomal protein (mg) per g liver</th>
<th>32</th>
<th>35</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytosolic protein (mg) per g liver</td>
<td>80.7</td>
<td>80.7</td>
</tr>
<tr>
<td>Plasma (mg) per g blood</td>
<td>550</td>
<td>550</td>
</tr>
</tbody>
</table>
a) fraction unbound profenofos in human microsome incubation (with 2 mg/mL)

b) fraction unbound profenofos in rat microsome incubation (with 0.5 mg/mL)

c) fraction unbound profenofos in human cytosol incubation (with 2 mg/mL)

d) fraction unbound profenofos in rat cytosol incubation (with 0.5 mg/mL)

e) fraction unbound profenofos in human plasma incubation (estimated with help of simcyp (via Kd: 13 µM); 4.4 mg plasma/mL (0.20 g albumin/L))

f) fraction unbound profenofos in rat plasma incubation (estimated with help of simcyp (via Kd: 13 µM); 1.65 mg plasma/mL (0.074 g albumin/L))

g) fraction unbound BCP in rat microsome incubation (with 1 mg/mL)
Inter-species differences in red blood cell acetylcholinesterase inhibition of profenofos

Supplementary figure 1. Schematic diagram of the PBK model for profenofos for rat consisting of three sub-models including one for profenofos (left), 4-bromo-2-chlorophenol (BCP) (center) and for BCP glucuronide (right). BCP formation is also described in the blood compartments in the PBK model, but for the sake of clarity of the figure, this is not depicted in the schematic diagram.

Abbreviation: GI tract: gastrointestinal tract.
**Supplementary Table 2.** Results of BMD modelling of predicted human dose-response data, applying model averaging

**Fitted Models**

<table>
<thead>
<tr>
<th>model</th>
<th>converged</th>
<th>loglik</th>
<th>npar</th>
<th>AIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>full model</td>
<td>Yes</td>
<td>17.79</td>
<td>13</td>
<td>-9.58</td>
</tr>
<tr>
<td>null model</td>
<td>Yes</td>
<td>-57.88</td>
<td>2</td>
<td>119.76</td>
</tr>
<tr>
<td>Expon. m3-</td>
<td>Yes</td>
<td>-1.13</td>
<td>4</td>
<td>10.26</td>
</tr>
<tr>
<td>Expon. m5-</td>
<td>Yes</td>
<td>12.71</td>
<td>5</td>
<td>-15.42</td>
</tr>
<tr>
<td>Hill m3-</td>
<td>Yes</td>
<td>-0.61</td>
<td>4</td>
<td>9.22</td>
</tr>
<tr>
<td>Hill m5-</td>
<td>Yes</td>
<td>13.53</td>
<td>5</td>
<td>-17.06</td>
</tr>
<tr>
<td>Inv.Expon. m3-</td>
<td>Yes</td>
<td>4.78</td>
<td>4</td>
<td>-1.56</td>
</tr>
<tr>
<td>Inv.Expon. m5-</td>
<td>Yes</td>
<td>13.13</td>
<td>5</td>
<td>-16.26</td>
</tr>
<tr>
<td>LN m3-</td>
<td>Yes</td>
<td>2.16</td>
<td>4</td>
<td>3.68</td>
</tr>
<tr>
<td>LN m5-</td>
<td>Yes</td>
<td>13.47</td>
<td>5</td>
<td>-16.94</td>
</tr>
</tbody>
</table>

**Weights for Model Averaging**

<table>
<thead>
<tr>
<th>EXP</th>
<th>HILL</th>
<th>INVEXP</th>
<th>LOGN</th>
<th>EXP</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.14</td>
<td>0.33</td>
<td>0.22</td>
<td>0.31</td>
<td>0.14</td>
</tr>
</tbody>
</table>

**Final BMD Values**

<table>
<thead>
<tr>
<th>endpoint</th>
<th>subgroup</th>
<th>BMDL</th>
<th>BMDU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response</td>
<td>All</td>
<td>0.01</td>
<td>0.81</td>
</tr>
</tbody>
</table>
Supplementary Figure 2

**bootstrap curves based on model averaging**

Bootstrap curves based on model averaging for predicted human AChE inhibition.
**Supplementary Figure 3**

Supplementary Table 3. Results of BMD modelling of predicted rat dose-response data, applying model averaging.

Fitted Models

<table>
<thead>
<tr>
<th>model</th>
<th>converged</th>
<th>loglik</th>
<th>npar</th>
<th>AIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>full model</td>
<td>yes</td>
<td>-10.87</td>
<td>13</td>
<td>47.74</td>
</tr>
<tr>
<td>null model</td>
<td>yes</td>
<td>-44.71</td>
<td>2</td>
<td>93.42</td>
</tr>
<tr>
<td>Expon. m3-</td>
<td>yes</td>
<td>-15.31</td>
<td>4</td>
<td>38.62</td>
</tr>
<tr>
<td>Expon. m5-</td>
<td>yes</td>
<td>-12.87</td>
<td>5</td>
<td>35.74</td>
</tr>
<tr>
<td>Hill m3-</td>
<td>yes</td>
<td>-15.25</td>
<td>4</td>
<td>38.50</td>
</tr>
<tr>
<td>Hill m5-</td>
<td>yes</td>
<td>-13.15</td>
<td>5</td>
<td>36.30</td>
</tr>
<tr>
<td>Inv.Expon. m3-</td>
<td>yes</td>
<td>-14.61</td>
<td>4</td>
<td>37.22</td>
</tr>
<tr>
<td>Inv.Expon. m5-</td>
<td>yes</td>
<td>-13.70</td>
<td>5</td>
<td>37.40</td>
</tr>
<tr>
<td>LN m3-</td>
<td>yes</td>
<td>-14.87</td>
<td>4</td>
<td>37.74</td>
</tr>
<tr>
<td>LN m5-</td>
<td>yes</td>
<td>-13.38</td>
<td>5</td>
<td>36.76</td>
</tr>
</tbody>
</table>

Weights for Model Averaging

<table>
<thead>
<tr>
<th>EXP</th>
<th>HILL</th>
<th>INVEXP</th>
<th>LOGN</th>
<th>EXP</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.35</td>
<td>0.27</td>
<td>0.17</td>
<td>0.21</td>
<td>0.35</td>
</tr>
</tbody>
</table>

Final BMD Values

<table>
<thead>
<tr>
<th>endpoint</th>
<th>subgroup</th>
<th>BMDL</th>
<th>BMDU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response</td>
<td>all</td>
<td>0.45</td>
<td>190</td>
</tr>
</tbody>
</table>
Supplementary Figure 4

Bootstrap curves based on model averaging for predicted rat AChE inhibition.
Supplementary Figure 5

CHAPTER 4.

Prediction of in vivo acetylcholinesterase inhibition upon acute combined exposure to profenofos and chlorpyrifos by using a combined in vitro and in silico approach

Isaac Omwenga
Shensheng Zhao
Hans Mol
Ivonne M.C.M. Rietjens
Jochem Louise

In Preparation
Abstract
Residues of organophosphates (OPs) such as profenofos (PFF) and chlorpyrifos (CPF) have been detected together in various fruits and vegetables. Consequently, consumers can be concurrently exposed to these OPs and knowledge on adverse effects upon combined exposure is desirable. The present study aims to provide insight into the combination effects of two selected OPs (PFF and CPF), by studying the combined effects of PFF and CPF’s toxic metabolite CPF oxon (CPO) on acetylcholinesterase (AChE) inhibition in vitro, as well as the effects of CPF and CPO on PFF biotransformation (detoxification) by human liver microsomes, cytosol, and human plasma. AChE inhibition was shown to be 199-fold more potent by CPO than by PFF, and combined exposure to CPO and PFF resulted in effects that are in line with the principles of dose addition. CPF and CPO appeared to affect PFF detoxification to its main metabolite (BCP) in a non-competitive manner at high concentrations, with Ki values of 120, 256 and 473 μM for CPF, and 80, 63 and 326 μM for CPO, for liver microsomes, liver cytosol and plasma, respectively, concentrations far higher than considered relevant in vivo. Using the parameters thus defined, our recently published physiologically based kinetic (PBK) model of PFF was extended to include the description of CPF kinetics, using also in vitro kinetic data from the literature and in silico calculations. PFF concentrations in the model were expressed as CPO-equivalents allowing prediction of total internal CPO-equivalents upon combined exposure to PFF and CPF. By comparing PBK model-predicted internal CPO-equivalents to in vitro data on CPO-induced AChE inhibition, combined exposure to PFF and CPF at their ARfD (0.005 mg/kg bw) was predicted to not affect AChE activity. Altogether, this study reveals that AChE inhibition upon combined exposure to these OPs follows the concept of dose addition, and that at estimated exposure levels, no toxicokinetic interactions of CPF on PFF detoxification are expected.
4.1 Introduction

Organophosphate pesticides (OPs) are among the most widely used pesticides in agriculture. OP usage has been on the rise in the field of agriculture from the 1960’s to such an extent that at present the majority of all the pesticides used in the world belong to this category (Thunga et al., 2010; Kaushal et al., 2021). In developing countries, where the economy depends on the agricultural produce, OPs have become an indispensable part of the agricultural process where they are necessary for pest control (Omwenga et al., 2016; Omwenga et al., 2021a; Kaushal et al., 2021). In contrast, the use of OPs is on the decline in western countries such as the USA and the EU member countries (U.S. EPA, 2002, 2004; Sudakin and Power, 2007). Human exposure to these pesticides has been reported through inhalation, dermal absorption or ingestion via residues on food (Bradman et al., 2003; Suratman et al., 2015; EFSA, 2019a). Since a variety of pesticides is being used, environmental, occupational and dietary exposures are primarily to pesticide mixtures. Consequently, there is lifelong combined exposure to various pesticides from, for example, one food item containing multiple compounds or combinations of food items, each containing different residues (Boobis et al., 2008). If these pesticides have a similar mechanism of action and toxic end point, assessing the dietary risk of exposure for each pesticide separately may lead to underestimation of the health risk (Boon et al., 2008). Therefore, current approaches in pesticide risk assessment include cumulative and probabilistic approaches in order to include the amount and variety of pesticide residues likely to be present in the vegetable sample (Jensen et al., 2015; Boon et al., 2015; Elgueta et al., 2019; Omwenga et al., 2021a). The first step in assessing effects on combined exposure to pesticide mixtures is to identify substances with a similar mechanism of toxicity (Gallagher et al., 2015; EFSA, 2019b). For example, acetylcholinesterase (AChE) inhibitors, such as OPs and carbamates have been assigned to the same cumulative assessment group (CAG) by the United States Environmental Protection Agency (US EPA) as well as by the European Food Safety
Authority (EFSA) (USEPA, 2007, 2011; EFSA, 2019b). AChE inhibition occurs through phosphorylation of the serine residue at the active site of the AChE enzyme, leading to diminished ability to hydrolyse the neurotransmitter, acetylcholine. For chemicals in the same CAG, the current scientific and regulatory recommendations for the risk assessment of mixtures follows a test strategy based on a component-based assessment, a concept with dose addition as the default model (Kortenkamp et al., 2009; EFSA, 2014a; Bopp et al., 2015; EFSA, 2019c).

We recently reported profenofos (PFF) and chlorpyrifos (CPF) (Figure 1) as the most frequently detected pesticide residues in commonly consumed vegetables in Kenya (Omwenga et al., 2021a). In the same study, co-occurrence of PFF and CPF was reported in some of these vegetables including tomatoes (Omwenga et al., 2021a). PFF and CPF are both OP pesticides assigned to the CAG related to brain and/or erythrocyte AChE inhibition (EFSA, 2019b). Therefore, risks of combined exposure to these (and other) OPs is suggested to be based on a component-based assessment with dose addition as the default model. Although dose addition is plausible, it would be of help to have experimental data supporting the concept of dose addition for these chemicals. Approaches that combine in vitro studies and in silico modelling are promising tools to obtain such insights. One must consider combination effects at both the toxicodynamic and toxicokinetic level. At the dynamic level, combined effects may show concentration addition, but possibly also less than addition or more than additive effects. At the kinetic level, chemicals may affect (increase in case of enzyme induction, or inhibit) each other’s biotransformation. In case of enzyme induction they may increase (in case of bioactivation) or decrease (in case of detoxification) each other’s toxicity. In contrast, in case of enzyme inhibition they may increase (in case of detoxification) or decrease (in case of bioactivation) each other’s toxicity. With in vitro studies, combined effects related to the toxicodynamics (AChE inhibition) and possible toxicokinetics can be studied in isolation and
integrated in physiologically based kinetic/dynamic (PBK/D) models to predict responses upon combined exposure scenarios.

In the present study, we assessed the combination effects of PFF and CPO, the toxic metabolite of CPF, on human recombinant AChE activity in vitro. To that end, PFF and CPO were tested alone and in an equipotent mixture. The data were assessed using PROAST software, using an approach as developed in the Euromix project to assess whether combination effects follow the concept of dose addition (Fischer et al., 2020). Regarding toxicokinetic interactions, we assessed whether CPF and/or CPO affect the detoxification of PFF. Possible inhibition of PFF detoxification may result in increased internal exposure of PFF upon combined exposure, possibly causing a potentiation of PFF toxicity by CPF. We used our recently developed human PBK model for PFF, which was developed to predict dose-dependent AChE inhibition in humans upon acute (single) oral exposure (Omwenga et al., 2021b) and extended it to also include a description of the kinetics of CPF and CPO, as well as possible kinetic interactions of CPF and/or CPO with the kinetics of PFF, allowing prediction of AChE inhibition by both PFF and CPO upon combined oral exposure to these pesticides.
Figure 1. A) Metabolic pathways for CPF and its metabolites CPO, DETP, DEP and TCPy based on data reported in previous studies (Timchalk et al., 2008). B) Metabolic pathway for profenofos (PFF) as described in the PBK model (conversion of PFF to BCP).
4.2. Materials and methods

4.2.1 Materials and chemicals

Profenofos (PFF), 4-bromo-2-chlorophenol (BCP), chlorpyrifos (CPF), recombinant human acetylcholinesterase (AChE) enzyme, bovine serum albumin (BSA), and reduced nicotinamide adenine dinucleotide phosphate (NADPH) were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Chlorpyrifos-oxon (CPO) was purchased from TRC-Canada (Toronto, Ontario, Canada). Magnesium chloride hexahydrate (MgCl$_2$*6H$_2$O), dimethylsulfoxide (DMSO), trifluoroacetic acid (TFA) and calcium chloride dihydrate (CaCl$_2$*2H$_2$O) were purchased from VWR International (Amsterdam, The Netherlands). Acetonitrile (ACN, UPLC/MS grade) was purchased from Biosolve (Valkenswaard, The Netherlands). Human liver microsomes (pooled from 150 human donors, mixed gender Lot No. 38271) were purchased from Corning (Amsterdam, The Netherlands). Pooled human plasma was from Innovative research inc (Novi, USA). For the human plasma further information on number of individuals used to create the samples or on gender was not provided by the company. Pooled mixed-gender human liver cytosol (pool of 10) was purchased from Xenotech (Kansas City, USA).

4.2.2 Human recombinant AChE inhibition by PFF, CPO and PFF/CPO mixtures

AChE inhibition by single compounds and mixtures was determined following the protocol of Ellman et al. (1961) as modified by Chambers and Chambers (1989). A range of concentrated stock solutions of PFF, CPO and an equipotent mixture prepared in this study based on their estimated relative potencies, were prepared in ethanol and 50 times diluted by adding 5 µl of stock solution to 245 µl of 0.1 M sodium phosphate (pH 7.4) containing 0.1 mg/ml BSA, which was present to stabilize the human recombinant AChE. For the negative control, 5 µl of ethanol without the test compounds was added to 245 µl of 0.1 M sodium phosphate (pH 7.4)
(containing 0.1 mg/ml BSA). Subsequently, 5 µl of these working solutions were added into wells of a 96 well plate already containing 44 µl sodium phosphate (pH 7.4) (containing 0.1 mg/ml BSA). To start the reaction, 1 µl enzyme solution containing 1 U/ml AChE and 1 mg/ml BSA (present to stabilize human recombinant AChE (Rosenfeld and Saltatos, 2006)) were added, giving a total volume of 50 µl per reaction with an AChE concentration of 0.02 U/ml and an ethanol concentration of 0.2%, a level that has no effect on the activity of the enzyme. After 15 minutes incubation at 37°C, 150 µl of a mixture of 5,5-dithiobis (2-nitrobenzoic acid) (DTNB) and acetylthiocholine (ATC) were added (final DTNB and ATC concentrations were 0.075 and 0.15 mM, respectively). Subsequently, the time-dependent increase in absorbance due to formation of chromophore (DTNB + thiocholine) was measured at 37°C using a wavelength of 412 nm during a period of 10 minutes, using a spectrophotometer (SpectraMax, Molecular Devices, UK). AChE activity was expressed as percentage enzyme activity compared to the solvent control.

4.2.2.1 Analysis of mixture effects and relative potencies

To obtain insight into relative potencies between PFF and CPO, AChE inhibition studies for PFF and CPO were first conducted separately. The BMD approach was then applied to determine the BMC50 for AChE inhibition and these values were used to estimate potency differences of CPO and PFF. BMD analysis was performed using PROAST (version 70.1, https://proastweb.rivm.nl, RIVM, Bilthoven, The Netherlands) as described by previous studies and in the PROAST manual instructions (Slob, 2002; Kienhuis et al., 2015; EFSA., 2017; Lichtenstein et al., 2020). Data expressed as percentage of the solvent control were loaded to PROAST as continuous, summary data in tab-delimited text files containing mean AChE activity (as percentage of control), standard deviation and sample size. Concentration-response data are analyzed by fitting the following 4-parameter exponential and hill models;
Red blood cell acetylcholinesterase inhibition by combined exposure to profenofos and chlorpyrifos

Exponential model: \( y = a \cdot c - (c - 1) \cdot \exp(-bx^d) \)

Hill model: \( y = a \cdot \frac{1 + (c - 1)x^d}{bd - x^d} \)

Previously, these models have been reported to adequately describe a wide range of toxicological dose-response data (Slob and Setzer, 2014).

Based on the obtained information on relative potencies of PFF and CPO, equipotent mixtures were prepared for the mixture studies. To obtain a relative potency factor (RPF) and to assess whether combination effects follow the concept of concentration addition, the approach as described by Lichtenstein et al. (2020) was used. To that end AChE inhibition were performed for PFF, CPO and the equipotent mixture of PPF and CPO. As described by Lichtenstein et al. (2020), first data are analysed of the single compounds and initial RPF values were derived. RPFs were calculated for a benchmark response of 50\% (BMC50, as well as with confidence limits BMCL-BMCU), including the corresponding two-sided 90\% RPF confidence interval given by the RPFL (lower bound of the RPF confidence interval) and the RPFU (upper bound of the RPF confidence interval). Then BMD analysis was performed including in the analysis besides the data of the individual OPs also the data for the equipotent mixture. In that analysis, RPF values are calculated by PROAST taking into account the data of the single chemicals as well as the mixture data in such a way that all three datasets are best described by the fitted concentration-response curve. As explained in the study of Lichtenstein et al. (2020), the RPFs from both analyses (with and without inclusion of mixture data) were compared by calculating a ratio of overlap of the confidence intervals of the RPF values obtained by both analyses. Thereby, the highest RPFL is divided by the other RPFU and the obtained ratio(s) of overlap can be used to conclude whether dose addition applies. Ratios above 1 indicate a high degree of deviation of dose addition (i.e. dose addition does not apply) as the RPF derived when including data of the mixture experiment significantly differs from the RPF in the single compound analysis. Ratios below 1 indicate that dose addition can be assumed. Thus, the ratio
of overlap in principle describes numerically what one can already see graphically in the PROAST plots: in case of dose addition, dose-response curves of single compounds and their related mixture, all expressed in reference compound equivalents, appear close together and can be adequately described by one concentration-response curve. We considered the RPF value obtained from the analysis including the mixture data the most relevant, since it is based on both the data on the single chemicals as well as the mixture data.

4.2.3 In vitro incubations to assess kinetic interactions of CPF and CPO on PFF detoxification

Human liver microsomal, cytosolic and plasma incubations were conducted as described before by Omwenga et al. (2021b). Briefly, the incubations of PFF with human liver microsomes, liver cytosol and plasma were conducted to quantify in vitro rates of detoxication of PFF to BCP. The final incubations were carried out in 100 mM Tris HCl (pH 7.4, 37°C) containing (final concentrations) 5 mM MgCl₂, 2 mM CaCl₂ (to stimulate PON1 activity (Carr et al., 2015)), 2 mM NADPH (cofactor to also include CYP-mediated metabolism), enzyme preparation (final concentration 2 mg/ml for liver microsomes and cytosol and 4.4 mg/ml for plasma) at final concentrations ranging from 5 to 100 μM, added from 200 times concentrated stock solutions in DMSO. Control incubations were performed in the absence of microsomes, cytosol or plasma. After 2 min pre-incubation, the reaction was initiated by adding the substrate and mixtures were incubated for 2 min in a 37 °C water bath. The total volume of the incubation mixtures was 200 μl. The reaction was terminated by the addition of 50 μl ice cold ACN and samples were kept on ice. The mixture was centrifuged at 14,000 g for 20 min at 4°C and the supernatant was analyzed using UPLC-UV.

For the interaction studies, incubations were performed with PFF in the presence of CPF or CPO. First, a concentration range-finding study was performed to choose an inhibitor concentration inhibiting PFF conversion by around 50% using a PFF substrate concentration of
100 µM (providing a velocity of PFF conversion close to Vmax). From these studies (data not shown) a concentration of 100 µM was chosen for both CPF and CPO for all incubations (microsomes, cytosol, plasma) and used in inhibition studies in which PFF conversion to BCP was determined at different PFF concentrations (5, 10, 25, 50, 100 µM, added from 200 times concentrated stock solutions in DMSO).

4.2.3.1 UPLC-UV analysis
Following incubation, the samples were analyzed using a Waters Acquity UPLC H class system with a sample manager, a quaternary solvent manager and a photodiode array (PDA) detector, equipped with a Water Acquity UPLC® BEH C18 column (1.7 μm, 2.1 × 50 mm) and Waters Xbridge UPLC® BEH C18 pre-column (2.5 μM, 2.1 x 5 mm). The column temperature was kept at 40°C and the auto sampler at 10°C during the UPLC analysis. The mobile phases used for the analysis consisted of 0.1% TFA in nanopure water (A) and 100% ACN (B). A gradient elution at a flow rate of 0.6 ml/min was applied for the analysis with the starting condition of 100% A: 0% B (v/v), changing linearly to 0% A: 100% B from 0 to 6 min, which was maintained for 30 s, and then changed back to the initial starting conditions in 30 s, which were maintained for 1 min. The injection volume for each sample was 3.5 µl.
Under these conditions, the retention times of PFF and BCP were 4.76 and 3.37 min, respectively. The amount of BCP was quantified by integrating the peak areas at 237 nm using calibration curves that were prepared using the commercially available standards.

4.2.3.2 Kinetic data analysis
Kinetic parameters, including the apparent maximum velocity (Vmax) and the apparent Michaelis–Menten constant (Km) for BCP formation were obtained by fitting the data for the substrate concentration-dependent rate of conversion (expressed in nmol/min/mg protein) using
GraphPad Prism 5, version 5.04 (San Diego, California, USA) to the standard Michaelis–Menten equation:

$$V = \frac{V_{\text{max}} \cdot [S]}{(K_m + [S])}$$

in which the $S$ represents the concentration of substrate, expressed in μM, $V$ and $V_{\text{max}}$ the velocity and the maximum velocity of the reaction, respectively, expressed in nmol/min/mg protein, and $K_m$ the apparent Michaelis–Menten constant, expressed in μM. The kinetic parameter values for conversion of PFF to BCP in the incubations with liver microsomes, liver cytosol or plasma were determined in the present study and are summarised in Table 1 and discussed in some more detail in the Results section. To determine the catalytic efficiency, $V_{\text{max}}$ was divided by the $K_m$.

$K_m$ and $V_{\text{max}}$ values obtained with the PFF biotransformation data in the presence of 100 μM CPF or 100 μM CPO were compared to $K_m$ and $V_{\text{max}}$ values obtained with the PFF biotransformation data in the absence of CPF or CPO, in order to get insight into the type of inhibition. In case of a decrease in the apparent $V_{\text{max}}$ but no change in the $K_m$ value as compared to the values of the uninhibited reaction (without CPF and CPO), a non-competitive type of inhibition is assumed (Delaune and Alsayouri, 2020). In this type of inhibition, the inhibitor binds at the allosteric site which is independent of substrate binding, modulating the enzyme activity in the process. The inhibitor shares the same affinity for both enzyme and enzyme-substrate complex in this type of inhibition (Delaune and Alsayouri, 2020). There is a relative decrease in the apparent $V_{\text{max}}$ but not $K_m$ and thus the $K_i$ value can be calculated by fitting the kinetic parameters to the related equation, e.g. using GraphPad Prism (GraphPad Prism 5, version 5.04 (San Diego, California, USA)):

$$V'_{\text{max inh}} = \frac{V_{\text{max}}}{1 + ([I]/K_i)}$$
in which the \( V'_{\text{maxinh}} \) represents the maximum velocity of the inhibited reaction, \([I]\) represents the concentration of the inhibitor (CPF or CPO), expressed in \( \mu \text{M} \), and \( V_{\text{max}} \) the maximum velocity of the uninhibited reaction (in the absence of CPF or CPO).

### 4.2.4 Human PBK model describing kinetics of PFF, CPF and CPO (and other CPF metabolites)

Our human PFF PBK model previously developed (Omwenga et al., 2021b) was extended to include a description of the kinetics of CPF and CPF metabolites (CPO, TCPy, DEP, DETP and TCPy-conjugates) (Figure 1). The model includes separate compartments for the gastrointestinal tract (GI-tract), the liver, fat, skin, muscle, bone, brain, lung, heart, kidney, spleen, venous blood, arterial blood, and a rest-of-body compartment. Intestinal uptake rate constants for PFF and CPF were estimated based on the approach described in Punt et al. (2020) based on the topological surface areas, which were obtained from Pubchem. Fraction binding to plasma, tissue: plasma partition coefficients and binding to tissue fractions were estimated based on the LogP and pKa of the chemicals and metabolites (which were estimated with Chemicalize) using the method of Lobell and Sivarajah (2003), and Berezhkovskiy (2004), respectively. Data on PFF conversion obtained in the present study were included in the model and scaled as described in Omwenga et al. (2021b). Data on the metabolism of CPF were obtained from the literature (CPF to CPO and CPF to TCPy in liver from Zhao et al. (2019), and CPF to TCPy and CPO to TCPy in blood from Furlong et al. (1989) and Ned Smith et al. (2011)). TCPy conjugation was also described in the model, and the kinetic parameters for this conjugation were fitted in order to best describe plasma concentrations and total urine levels of TCPy as reported from human studies in the literature. Model predictions for CPF were evaluated against human in vivo data as reported in the literature (Drevenkar et al., 1993; Brzak, 2000; Timchalk et al., 2002).
Chapter 4

PFF and CPF share a similar mechanism of toxicity, hence belong to the same CAG related to brain and/or erythrocyte AChE inhibition (EFSA, 2019b). Therefore, to determine the combined effect of PFF and CPF at the target site, the free effective blood maximum concentration of PFF and the active metabolite of CPF (CPO) was expressed in CPO equivalents using a relative potency factor (RPF) (see Eq. below):

Total free CPO equivalents = \([PFF] \times fuPFF \text{ in vivo} \times RPFPFF + [CPO] \times fuCPO \text{ in vivo} \times \text{RPFCPO},\)

in which the ‘Total free CPO equivalents’ represents the free blood concentration of CPO and PFF expressed in CPO equivalents, \([PFF]\) and \([CPO]\) represent the blood concentrations of PFF and CPO, \(fuPFF \text{ in vivo}\) and \(fuCPO \text{ in vivo}\) represent the unbound fraction in blood in vivo, and \(RPFPFF\) and \(RPFCPO\) represent the RPF values for PFF and CPO (the RPF for the latter set at 1). The RPF was calculated from the BMD analysis as described in section 2.2.1. The PBK model code was numerically integrated in Berkeley Madonna 9.1.18 (UC Berkeley, CA, USA), using the Rosenbrock’s algorithm for stiff systems. The PBK models’ differential equations are provided in the Supplementary Materials.

4.3. Results

4.3.1 Human AChE inhibition by PFF, CPO and the equipotent mixture

A first study was performed to estimate the potency differences of CPO and PFF based on the BMC50 values for AChE inhibition obtained using BMD analysis (data not shown). Based on these results, an equivalent mixture was prepared, which was applied in the mixture experiment, in which also full concentration-response curves of CPO and PFF as single compounds were included. We assessed the data thus obtained for dose-addition applying the approach described previously by Lichtenstein et al., (2020). Data on concentration-dependent inhibition of human
(recombinant) AChE by PFF, CPO and the binary mixture are presented in Figure 2, expressed in PFF equivalents. The data were analysed using RIVM PROAST software as described in the materials and methods section, analysing first the data of PFF and CPO separately, obtaining a BMC50 of 783 µM for PFF (with confidence limits BMCL-BMCU of 733-836) and an RPF of 155 for CPO (with RPFL-RPFU of 143-175) (Figure 2A). In the second analysis, data were analysed again using the PROAST software, also including the data on the combined exposure. From that analysis, the RPF of CPO was estimated to amount to 199 (with RPFL-RPFU of 163-242) and the BMC50 for PFF was 724 µM (with confidence limits BMCL-BMCU of 615-852). These analyses indicate that the confidence intervals of the estimated RPF in both analyses overlap (highest RPFL (163) divided by the other RPFU (175) amounts to 0.93), from which can be concluded that in vitro AChE inhibition by combined exposure to PFF and CPO follow dose addition principles (Lichtenstein et al., 2020). Figure 2B shows the visual plot of the second BMD analysis, indicating that the mixture data (red asterisks) are scattered around the curve fit with no deviation from the overall concentration-response fit, also corroborating that dose addition can be assumed (Figure 2B) (Slob, 2002; Slob et al., 2014; Kienhuis et al., 2015; Lichtenstein et al., 2020). We used the RPF of 199 for further analyses, as this value is considered most relevant, since obtained from analysing both data on single and combined exposures.
Figure 2. PROAST-based concentration-response modeling of AChE inhibition data of PFF (red asterixes in Fig A; green diamonds in Fig B), CPO (black triangles) and binary mixture (PFF and CPO, red asterixis in Fig B) of the datasets without inclusion of the mixture data (A) and with inclusion of the mixture data (B). Concentrations are all expressed in PFF equivalents (nM). The curves represent the four-parameter exponential and hill models.
4.3.2 In vitro inhibition of PFF metabolism by CPF and CPO

The kinetics of PFF conversion to BCP in the absence and presence of CPF or CPO were investigated for human liver microsomes, cytosol and plasma. Incubations were conducted in the absence and presence of 100 µM CPF or CPO with human liver microsomes, cytosol and plasma. The PFF concentration-dependent BCP formation in presence and absence of CPF or CPO in incubations with liver microsomes, cytosol and plasma is depicted in Figure 3. The related kinetic parameters (apparent Vmax and Km values) for the detoxication of PFF to BCP in the presence and absence of CPF and CPO are shown in Table 1. Generally, there was a decrease in the apparent Km and Vmax values of the reactions in the presence of CPF or CPO as compared to those of the uninhibited reaction (without CPF or CPO). However, confidence intervals of apparent Km and Vmax values overlap for the apparent Km values (Table 1). For most conditions, apparent Vmax values were significantly lowered by the inhibitors, especially by CPO, as indicated by the non-overlapping confidence intervals. The inhibition was therefore considered to be a non-competitive type of inhibition (Delaune and Alsayouri, 2020), and Ki values were estimated by fitting the data to the formula for non-competitive inhibition (GraphPad Prism 5, version 5.04 (San Diego, California, USA)).

Unlike non-competitive inhibition, competitive inhibition is characterised by an increase in Km while Vmax remains unchanged. On the other hand, uncompetitive inhibition is characterised by a decrease in Km because of increased binding efficiency and decrease in Vmax due to interference with substrate binding, resulting from hampered catalysis in the enzyme substrate complex. As indicated above, results obtained indicate that both CPF and CPO inhibited PFF metabolism to its main metabolite (BCP) in a non-competitive manner, with estimated Ki values amounting to 119 (90% confidence intervals of 69-169), 251 (90% confidence intervals of 126-375) and 456 (90% confidence intervals of 73-839) µM, respectively, for CPF, and 80 (90% confidence intervals of 52-107), 62 (90% confidence intervals of 38-84) and 314 (90%
confidence intervals of 111-516) μM, respectively, for CPO (Table 1). Based on the in vitro results of this study, effects of CPF or CPO on the detoxification of PFF are expected to take place only at high internal CPF and CPO concentrations given these high Ki values, indicating that occurrence of interaction effects are considered to be unlikely (see for further information next section).

Table 1: Kinetic parameters for formation of BCP by pooled human liver microsomes, cytosol and plasma in the absence or presence of 100 μM CPO or CPF. Data represent estimated Vmax, Km and Ki values including 95% confidence intervals between brackets. Ki values were obtained by fitting the data to the equations as present in GraphPad Prism 5 on noncompetitive inhibition.

<table>
<thead>
<tr>
<th></th>
<th>Vmax (nmol/min/mg protein)</th>
<th>Km (µM)</th>
<th>Ki (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microsomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No inhibitor</td>
<td>1.4 (1.1-1.8)</td>
<td>21 (7.2-35)</td>
<td>NA</td>
</tr>
<tr>
<td>With CPF</td>
<td>0.80 (0.50-1.1)</td>
<td>23 (0-46)</td>
<td>119 (69-169)</td>
</tr>
<tr>
<td>With CPO</td>
<td>0.57 (0.44-0.69)</td>
<td>14 (4.1-24)</td>
<td>80 (52-107)</td>
</tr>
<tr>
<td>Cytosol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No inhibitor</td>
<td>1.1 (0.87-1.3)</td>
<td>23 (11-35)</td>
<td>NA</td>
</tr>
<tr>
<td>With CPF</td>
<td>0.69 (0.52-0.87)</td>
<td>16 (3.6-29)</td>
<td>251 (126-375)</td>
</tr>
<tr>
<td>With CPO</td>
<td>0.34 (0.20-0.49)</td>
<td>12 (0-29)</td>
<td>62 (38-84)</td>
</tr>
<tr>
<td>Plasma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No inhibitor</td>
<td>0.44 (0.34-0.53)</td>
<td>17 (6.0-29)</td>
<td>NA</td>
</tr>
<tr>
<td>With CPF</td>
<td>0.31 (0.25-0.37)</td>
<td>9.5 (2.7-16)</td>
<td>456 (73-839)</td>
</tr>
<tr>
<td>With CPO</td>
<td>0.26 (0.22-0.31)</td>
<td>6.5 (1.8-11)</td>
<td>314 (111-516)</td>
</tr>
</tbody>
</table>

NA: not applicable
Figure 3. Concentration-dependent rate of PFF conversion to BCP in absence of CPF and CPO (dots) and in the presence of 100 µM CPF (triangles) or 100 µM CPO (squares) in incubations with (A) human liver microsomal proteins, (B) human liver cytosolic proteins, or (C) human plasma proteins. Results represent data from 3 independent experiments and are presented as mean ± SEM.
4.3.3 PBK model development and evaluation

Our previously published PBK model for PFF (Omwenga et al., 2021b) was extended to include CPF kinetics, based on in silico estimations of parameters related to uptake, plasma protein binding, plasma: tissue partitioning and in vitro data on kinetic conversions from the literature. The model was developed to describe the dose-dependent internal concentrations of PFF and CPO, and to describe the combined internal concentrations of the two expressed in CPO-equivalents, applying the RPF of 0.005 for PFF (1/199). The model also describes the kinetics of CPO and other CPF metabolites being DETP, DEP and TCPy, used for model evaluation. In addition, the model describes the blood concentrations of the dialkyl phosphate (DAP) metabolites in a similar manner as reported for in vivo studies in the literature, being the sum of DEP and DETP.

The CPF sub model included in the developed PBK model was evaluated against in vivo data on CPF and DAP in blood in a hospitalized person with CPF poisoning (Figure 4A and 4B (Drevenkar et al., 1993)) and TCPy concentrations in blood as well as TCPy in urine from human volunteers (Figure 4C and 4D (Timchalk et al., 2002)). These results indicate that the predictions made by the newly developed binary PBK model match the reported in vivo data quite well. The obtained Ki values related to CPF- and CPO-induced inhibition of PFF conversion were in the high μM range and the PBK model predicts that these concentrations of CPF and CPO cannot be reached in vivo, due to rapid conversion of both CPF and CPO (Figure 5).
Red blood cell acetylcholinesterase inhibition by combined exposure to profenofos and chlorpyrifos

A

![Graph of CPF concentration in blood vs. time](image)

B

![Graph of DAP concentration in blood vs. time](image)

C

![Graph of TCPy concentration in blood vs. time](image)

- Predicted TCPy 0.5mg/kg in blood
- Predicted TCPy 1mg/kg in blood
- Predicted TCPy 2mg/kg in blood
- 0.5mg/kg Timchalk et al., 2002
- 1mg/kg Timchalk et al. 2002
- 2mg/kg Timchalk et al. 2002
Figure 4. A) Comparison of PBK model-based predicted CPF concentrations in blood (continuous line) and reported CPF blood concentrations of a hospitalized person with CPF poisoning (~150 mg/kg) (Drevenkar et al., 1993); B) Comparison of PBK model-based predicted DAP concentrations in blood (continuous line) and reported DAP blood concentrations of a hospitalized person with CPF poisoning (~150 mg/kg) (Drevenkar et al., 1993); C) Comparison of PBK model-based predicted TCPy concentrations in blood (lines) and reported blood concentrations in human volunteers upon exposure to 0.5, 1 or 2 mg/kg bw CPF (Timchalk et al., 2002); and D) Comparison of PBK model-predicted and experimentally determined time-dependent cumulative urinary excretion of TCPy (lines) and reported urinary excretion in human volunteers upon exposure to 0.5, 1 or 2 mg/kg CPF (Brzak, 2000).
Figure 5. Predicted CPF (solid continuous line) and CPO (dashed line) maximum blood concentrations upon oral exposure to CPF up to a dose of 150 mg/kg bw. Considering the high Ki values obtained in the in vitro kinetic studies (high µM range), the dose dependent Cmax values predicted reveal that occurrence of interaction effects are considered to be unlikely in the in vivo situation.

4.3.4 PBK model-based predictions of ACHE inhibition upon single and combined acute exposure to PFF and CPF

After PBK model evaluation, the model was used to describe the dose-dependent internal (in blood) maximal free CPO and PFF concentrations, expressed in CPO-equivalents at two combined exposure scenarios (Figure 6A and 6B). Figure 6A shows the dose-dependent maximal blood concentrations in CPO-equivalents upon exposure to 0.005 mg/kg bw CPF (ARfD CPF, (EFSA, 2014b) black continuous curve) or 0.005 mg/kg bw PFF (ARfD PFF reported by a German evaluation as reported by EFSA (2019d), black dotted curve), indicating
that upon equal oral exposure levels, PFF is expected to be a bit more potent in AChE inhibition than CPF. The prediction of in vivo AChE inhibition was evaluated using the data for the hospitalized patient (Drevenker et al., 1993), from which the in vivo kinetic data were also used for PBK model evaluation (Figure 4 A and B). At the reported dose of 150 mg/kg bw the Cmax of free CPO in blood was predicted to amount to 57 nM. When interpolating this concentration into the concentration-response curve of CPO-induced AChE inhibition (Figure 6C) an inhibition of 60% would be predicted. AChE inhibition for the hospitalized patient was reported to amount to 50%, indicating that quite an accurate prediction was obtained. The model was then used to estimate internal CPO-equivalents at defined exposure scenarios, including combined exposure to the ARfD of PFF and CPF (0.005 mg/kg bw each) (EFSA, 2014b; EFSA, 2019d) as well as the estimated acute exposure upon intake of tomatoes contaminated with PFF and CPF residues as we measured before (Omwenga et al., 2021a), using a maximum daily consumption rate of 560 g/day for tomatoes and a residue concentration of 958 and 107 μg/kg for PFF and CPF respectively, amounting to an estimated intake of 0.0077 and 0.00086 mg/kg bw, respectively, using a bw of 70 kg. Obtained internal free maximal CPO-equivalent concentrations in blood were then compared to the in vitro concentration-response data on AChE inhibition by CPO (Figure 6C) to estimate whether AChE inhibition is expected with these exposure scenarios. The predicted Cmax values expressed in free CPO-equivalents in these exposure scenarios amount to 0.8 pM (combined exposure ARfDs) and 1 pM (consumption of tomatoes with both residues), being 1500 and 1200-fold lower than the BMC10 of CPO-induced human AChE inhibition of 1270 pM suggesting that at these exposure scenarios no effects on AChE activity are expected.
Red blood cell acetylcholinesterase inhibition by combined exposure to profenofos and chlorpyrifos

A

B
Figure 6. PBK model predicted CPO-equivalents in blood (free concentration) upon A) oral exposure to an equal acute reference dose of PFF and/or CPF (0.005 mg/kg bw) and B) acute exposure to estimated intake of tomatoes contaminated with PFF and CPF residues (Omwenga et al., 2021a), upon a maximum daily consumption rate of 560 g/day of tomatoes, resulting in an estimated intake of 0.008 mg/kg bw and 0.0009 mg/kg bw, respectively. Straight grey line: CPO-equivalents from combined CPF and PFF exposure. Straight black line: CPO-equivalents from CPF exposure; dotted line: CPO-equivalents from PFF exposure; and C) PROAST-based concentration-response modeling of AChE inhibition data of CPO (black triangles), resulting in a BMDL10 of 1.27nM.

4.4. Discussion

The present study was conducted to develop a combined in vitro-in silico approach to predict the effects of combined exposure to CPF and PFF on AChE activity in humans. To that end, our previously published PBK model of PFF was extended to also include the description of CPF kinetics, allowing to describe internal concentrations of PFF and CPO as chemical entities.
responsible for AChE inhibition at defined exposure scenarios based on CPO equivalents. In vitro combination studies showed that combined exposure to PFF and CPO follows the concept of concentration addition, with PFF shown to be 199-fold less potent than CPO. PFF concentrations in the PBK model were therefore expressed as CPO-equivalents, allowing the description of total AChE inhibiting entities in CPO-equivalents at combined exposure to both pesticides. In vitro kinetic studies on possible interaction effects showed that inhibition of PFF detoxification (BCP formation) by CPF or CPO takes place only at very high concentrations that are not reached at relevant exposure scenarios and even not at high CPF exposures that have been reported to be encountered in CPF poisoning cases (Figure 5). Therefore, interaction effects of CPF on PFF are considered unlikely at the kinetic (biotransformation) level, and the data from the present study support the assumption of dose addition related to AChE inhibition upon combined exposure to these pesticides.

Although PFF and CPO share a common detoxification pathway and a common mode of toxicological action, they quantitatively differ in their potential for AChE inhibition as shown in the in vitro AChE inhibition studies (Figure 2). Combining the in vitro toxicity data with PBK modelling shows that, in spite of the 199-fold lower AChE inhibitory potency of PFF than CPO, the internal maximal concentrations expressed in CPO-equivalents are estimated to be higher for PFF than for CPF at similar oral dose levels (Figure 6A). This is due to the fact that PFF exposure occurs from the parent compound while CPO has to be formed from CPF as a metabolite. Furthermore, it should be noted that the toxic potency of OPs is dependent upon a balance between bioactivation versus detoxification of OP dose delivered to the target site (Calabrese, 1991; Poet et al., 2003), hence the significance of PFF during combined exposure given the toxicity in its original form as well as slower clearance. By enabling description of Cmax values in terms of CPO equivalents the PBK model appears able to provide a way to quantitatively integrate data on individual compounds to obtain insight in the consequences of
combined exposures. This indicates the clear added value of the application of PBK modelling for the translation of in vitro toxicity data to the in vivo situation.

This study shows that in vitro toxicodynamic effects on AChE activity upon combined exposure to PFF and CPO follow the concept of dose addition. Furthermore, comparison of the PBK model-based predictions of plasma levels of CPF and CPO to the kinetic parameters for inhibitory interactions at the level of biotransformation enzymes, suggests that at realistic dose levels no toxicokinetic interactions for binary exposure are expected, suggesting that the overall in vivo effect on AChE activity upon combined exposure is expected to also follow the concept of dose addition. Dose additivity for OPs has also been reported by Richardson et al. (2001) who observed that in vitro combined effects of CPO and azinophosmethyl-oxon on brain AChE activity were best characterized using a dose-additive model. Another study by Timchalk and Poet (2008) evaluated AChE effects upon combined exposure to CPF and diazinon in rats using in vitro methods and a binary PBK model. Their results suggested that AChE inhibition by a binary mixture of CPF and diazinon was also best described by a dose additive model. These findings therefore support the current scientific and regulatory recommendation that promote the application of the dose addition model as a default model for risk assessment of OP pesticides within the same CAG.

The model simulations performed in this study were consistent with the published in vivo data on CPF and DAP concentrations in blood in a hospitalized person with CPF poisoning (Figure 4A and 4B (Drevenkar et al., 1993)) and TCPy concentrations in blood as well as TCPy excretion in urine from human volunteer studies in the Caucasian population (Figure 4C and 4D (Brzak et al., 2000; Timchalk et al., 2002)). These results indicate that the predictions made by the newly developed binary PBK model match the reported in vivo kinetic data well. Furthermore, combining the PBK model-predicted free Cmax of CPO with the in vitro concentration-response curve of CPO-induced AChE inhibition, shows that AChE inhibition of
Red blood cell acetylcholinesterase inhibition by combined exposure to profenofos and chlorpyrifos

A person exposed to 150 mg/kg bw CPF was estimated to amount to 50% inhibition, being close to the reported AChE inhibition of 60% reported for a hospitalized patient that was exposed to this high dose of CPF. This finding further re-enforces the concept that PBK modeling together with focused in vitro experimentation can be utilized to estimate in vivo oral equivalent doses of related in vitro bioactivity data that can be used in the hazard assessment of chemicals. For chemicals that follow the concept of concentration addition in vitro, the RPF approach as used in the current study for CPO and PFF in the PBK model could be extended in the future to also include other OPs and carbamates, allowing a more extensive assessment of the combined exposure to OPs and carbamates based on novel approach methods (NAMs) as applied in the present study. Such an approach to include data for more than one chemical has recently been used by our group to predict in vivo human and rat RBC (AChE) inhibition upon acute exposure to diazinon and its active metabolite, diazinon oxon (Zhao et al., 2021).

Although the current NAM-based approach combining in vitro toxicity data and PBK modelling is promising in evaluating combined effects of chemicals that follow the principles of dose addition, it cannot be applied as such when combined effects of chemicals do not follow the concept of dose addition, like when other combination effects, such as synergism or antagonism apply. Possible synergistic or antagonist effects can be identified using in vitro studies (Cedergreen 2014). However, extrapolating such findings for specific applied exposure conditions to other (non-tested) combination exposures is more difficult than when combination effects follow the concept of dose addition. Consequently, predicting effects of mixtures would be more complex in case of less than dose addition or more than dose addition. It should, however, be noted that deviations from predicted additivity are considered to be rare (Kortenkamp et al., 2009; Cedergreen, 2014).

In conclusion, this study showed that effects of CPF or CPO on the detoxification of PFF are expected to take place only at unrealistic high concentrations, indicating that interaction effects
are considered to be unlikely, and that the OP-induced AChE inhibition upon combined exposure to PFF and CPF follows the concept of dose addition, supporting the use of a relative potency factor (RPF)-coded PBK model approach for assessing effects on AChE activity upon combined exposure to these OPs.

Acknowledgements

This work is supported by the Netherlands Universities Foundation for International Cooperation (Nuffic) (scholarship granted to Isaac Omwenga (PhD.17/0019)), and the Dutch Ministry of Agriculture, Nature and Food Quality (project KB-23-002-021).

Conflict of interest statement

The authors declare that they have no conflicts of interest.
Red blood cell acetylcholinesterase inhibition by combined exposure to profenofos and chlorpyrifos

References


Dadson, O. A., Ellison, C. A., Singleton, S. T., Chi, L. H., Mcgarrigle, B. P., Lein, P. J., 
Farahat, F. M., Farahat, T. & Olson, J. R. 2013. Metabolism of profenofos to 4-bromo-

[Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.
https://www.ncbi.nlm.nih.gov/books/NBK545242/

metabolites in serum and urine of poisoned persons. *Chem Biol Interact*. 87(1-3):315-
22.

EFSA (European Food Safety Authority) Panel on Plant Protection Products and their 
Residues (PPR), 2014a. Scientific Opinion on the identification of pesticides to be 
included in cumulative assessment groups on the basis of their toxicological profile 

EFSA (European Food Safety Authority), 2014b. Conclusion on the peer review of the 
pesticide human health risk assessment of the active substance chlorpyrifos. EFSA J. 
12, 3640.

EFSA (European Food Safety Authority), Scientific Committee, Hardy, A., Benford, D., 
Halldorsson, T., Jeger, M.J., Knutsen, K.H., More, S., Mortensen, A., Naegeli, H., 
Noteborn, H., Ockleford, C., Ricci, A., Rychen, G., Silano, V., Solecki, R., Turck, D., 
Aerts, M., Bodin, L., Davis, A., Edler, L., Gundert-Remy, U., Sand, S., Slob, W., 
Guidance on the use of the benchmark dose approach in risk assessment. EFSA 

EFSA (European Food Safety Authority), 2019a. Scientific report on the 2017 European 
https://doi.org/10.2903/j.efsa.2019.5743

EFSA (European Food Safety Authority), Crivellente, F., Hart, A., Hernandez-Jerez, A.F., 
Hougaard Bennekou, S., Pedersen, R., Terron, A., Wolterink, G., Mohimont, L.,


Red blood cell acetylcholinesterase inhibition by combined exposure to profenofos and chlorpyrifos

http://www.epa.gov/pesticides/cumulative/rria-op/.


Red blood cell acetylcholinesterase inhibition by combined exposure to profenofos and chlorpyrifos


## Supplementary material 1

Data format for single compound analysis

<table>
<thead>
<tr>
<th>PPF</th>
<th>CPO</th>
<th>Admin.comp</th>
<th>AChE activity</th>
<th>SD</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>0</td>
<td>PPF</td>
<td>94.99953</td>
<td>1.533608</td>
<td>3</td>
</tr>
<tr>
<td>10</td>
<td>0</td>
<td>PPF</td>
<td>99.23282</td>
<td>3.662433</td>
<td>3</td>
</tr>
<tr>
<td>25</td>
<td>0</td>
<td>PPF</td>
<td>96.30271</td>
<td>1.85084</td>
<td>3</td>
</tr>
<tr>
<td>50</td>
<td>0</td>
<td>PPF</td>
<td>95.75581</td>
<td>1.48049</td>
<td>3</td>
</tr>
<tr>
<td>100</td>
<td>0</td>
<td>PPF</td>
<td>90.17884</td>
<td>0.222605</td>
<td>3</td>
</tr>
<tr>
<td>250</td>
<td>0</td>
<td>PPF</td>
<td>89.79521</td>
<td>0.928884</td>
<td>3</td>
</tr>
<tr>
<td>500</td>
<td>0</td>
<td>PPF</td>
<td>66.17205</td>
<td>1.921244</td>
<td>3</td>
</tr>
<tr>
<td>1000</td>
<td>0</td>
<td>PPF</td>
<td>36.21096</td>
<td>1.504951</td>
<td>3</td>
</tr>
<tr>
<td>2500</td>
<td>0</td>
<td>PPF</td>
<td>19.59966</td>
<td>0.936861</td>
<td>3</td>
</tr>
<tr>
<td>5000</td>
<td>0</td>
<td>PPF</td>
<td>12.75182</td>
<td>0.540977</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>0.05</td>
<td>CPO</td>
<td>100.3569</td>
<td>0.432987</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>0.1</td>
<td>CPO</td>
<td>99.96475</td>
<td>1.241101</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>0.2</td>
<td>CPO</td>
<td>100.0426</td>
<td>1.658234</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>0.5</td>
<td>CPO</td>
<td>98.41019</td>
<td>2.49912</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>CPO</td>
<td>94.20221</td>
<td>1.860128</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>2.5</td>
<td>CPO</td>
<td>80.16323</td>
<td>3.552664</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>5</td>
<td>CPO</td>
<td>52.92886</td>
<td>2.181251</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>10</td>
<td>CPO</td>
<td>18.55614</td>
<td>1.861837</td>
<td>3</td>
</tr>
</tbody>
</table>
### Supplementary material 2

Data format for mixture analysis

<table>
<thead>
<tr>
<th>PF</th>
<th>CPO</th>
<th>Admin.comp</th>
<th>AChE activity</th>
<th>SD</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>0</td>
<td>PPF</td>
<td>94.99953</td>
<td>1.533608</td>
<td>3</td>
</tr>
<tr>
<td>10</td>
<td>0</td>
<td>PPF</td>
<td>99.23282</td>
<td>3.662433</td>
<td>3</td>
</tr>
<tr>
<td>25</td>
<td>0</td>
<td>PPF</td>
<td>96.30271</td>
<td>1.85084</td>
<td>3</td>
</tr>
<tr>
<td>50</td>
<td>0</td>
<td>PPF</td>
<td>95.75581</td>
<td>1.48049</td>
<td>3</td>
</tr>
<tr>
<td>100</td>
<td>0</td>
<td>PPF</td>
<td>90.17884</td>
<td>0.222605</td>
<td>3</td>
</tr>
<tr>
<td>250</td>
<td>0</td>
<td>PPF</td>
<td>89.79521</td>
<td>0.928884</td>
<td>3</td>
</tr>
<tr>
<td>500</td>
<td>0</td>
<td>PPF</td>
<td>66.17205</td>
<td>1.921244</td>
<td>3</td>
</tr>
<tr>
<td>1000</td>
<td>0</td>
<td>PPF</td>
<td>36.21096</td>
<td>1.504951</td>
<td>3</td>
</tr>
<tr>
<td>2500</td>
<td>0</td>
<td>PPF</td>
<td>19.59666</td>
<td>0.936861</td>
<td>3</td>
</tr>
<tr>
<td>5000</td>
<td>0</td>
<td>PPF</td>
<td>12.75182</td>
<td>0.540977</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>0.05</td>
<td>CPO</td>
<td>100.3569</td>
<td>0.432987</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>0.1</td>
<td>CPO</td>
<td>99.96475</td>
<td>1.241101</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>0.2</td>
<td>CPO</td>
<td>100.0426</td>
<td>1.658234</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>0.5</td>
<td>CPO</td>
<td>98.41019</td>
<td>2.49912</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>1</td>
<td>CPO</td>
<td>94.20221</td>
<td>1.860128</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>2.5</td>
<td>CPO</td>
<td>80.16323</td>
<td>3.552664</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>5</td>
<td>CPO</td>
<td>52.92886</td>
<td>2.181251</td>
<td>3</td>
</tr>
<tr>
<td>0</td>
<td>10</td>
<td>CPO</td>
<td>18.55614</td>
<td>1.861837</td>
<td>3</td>
</tr>
<tr>
<td>0.603042</td>
<td>0.003655</td>
<td>ZZ-tern</td>
<td>99.48359</td>
<td>4.175577</td>
<td>3</td>
</tr>
<tr>
<td>1.206084</td>
<td>0.00731</td>
<td>ZZ-tern</td>
<td>99.66572</td>
<td>3.631524</td>
<td>3</td>
</tr>
<tr>
<td>2.412168</td>
<td>0.014619</td>
<td>ZZ-tern</td>
<td>99.95854</td>
<td>1.201876</td>
<td>3</td>
</tr>
<tr>
<td>4.824336</td>
<td>0.029238</td>
<td>ZZ-tern</td>
<td>99.47792</td>
<td>4.965794</td>
<td>3</td>
</tr>
<tr>
<td>9.648671</td>
<td>0.058477</td>
<td>ZZ-tern</td>
<td>98.21343</td>
<td>5.179981</td>
<td>3</td>
</tr>
</tbody>
</table>
CHAPTER 5.

Predicting interindividual differences in profenofos detoxification based on in vitro kinetic data and a physiologically based kinetic (PBK) and Monte Carlo modelling approach

Isaac Omwenga
Hans Mol
Ivonne M.C.M. Rietjens
Jochem Louisse

In Preparation
Abstract

The aim of the present study was to predict human interindividual differences in profenofos (PFF) detoxification based on a combined in vitro-in silico approach. To that end, PFF conversion to 4-bromo-2-chlorophenol (BCP) was studied in in vitro incubations with liver S9 fractions of 25 different Caucasian donors and plasma samples of 25 different Caucasian donors. The obtained information on the variation in the in vitro kinetic constants Vmax and Km was applied in our previously published physiologically based kinetic (PBK) model using a Monte Carlo simulation modelling approach. Analysis of the predicted internal maximum concentrations of the simulated population indicated a 1.4- and 1.5-fold difference between the geometric mean (GM) and the 90th and 99th percentile, respectively, of the simulated population, being smaller than the default uncertainty factor accounting for human variability in toxicokinetics of 3.16. Concentration-response curves for inhibition of human AChE determined in vitro were translated with the PBK model to predicted dose-dependent AChE inhibition in humans in vivo. In line with the differences in Cmax values, the 99th percentile of the population was predicted to be 1.5-fold more sensitive to PFF-induced AChE inhibition than the GM of the population based on the BMDL10 values derived from predicted dose-response data for the virtual population. This predicted BMDL10 of 0.0057 mg/kg bw (99th percentile of population) is comparable to the ARfD adopted by EFSA (0.005 mg/kg bw) and EPA (0.002 mg/kg bw), but much lower than the ARfD adopted by JMPR (1 mg/kg bw). Altogether, the results obtained demonstrate that integrating PBK modelling with Monte Carlo simulations using human in vitro data provides a powerful strategy to quantify human interindividual variation in kinetics, which can be used to refine the hazard characterization of organophosphate pesticides.
5.1 Introduction

Organophosphates (OPs) are chemicals extensively used for the control of agricultural and household pests (van der Veen and de Boer, 2012). The OPs have played a key role in controlling pests and increasing agricultural production since the 1970s (Zhao and Yu, 2013). Despite their role in pest control, about three million OP pesticide poisoning cases are annually reported on the global scale, with an estimated 220,000–250,000 deaths, of which up to 99% have occurred in low-income or developing countries (Robb and Baker, 2000; Roberts and Aaron, 2007; Chiari et al., 2017). Consequently, some countries have taken measures to reduce the use of OPs, with many OPs currently deregistered for use as pesticides, while some have been banned (Hertz-Picciotto et al. 2018; Pesticide Action Network International, 2020).

Unlike many other OPs, PFF is a direct acting phosphorothioate OP pesticide with the capability of inhibiting β-esterases such as butyrylcholinesterase, acetylcholinesterase, and carboxylesterase without requiring activation (Dadson et al., 2013). It has been reported to be mainly detoxified through paraoxonase 1 (PON1)-mediated hydrolysis in the liver and plasma as well as CYP450-mediated detoxification, resulting in the production of 4-bromo-2-chlorophenol (BCP) (FAO, 2012; Dadson et al., 2013; EPA, 2016) (Figure 1).

Recently, we developed a physiologically based kinetic (PBK) model for PFF detoxification in rats and humans based on in vitro and in silico input data (Omwenga et al., 2021). We used this model to predict in vivo AChE inhibition, translating in vitro concentration-response data on PFF-induced AChE inhibition to in vivo dose-response data using a reverse dosimetry approach. We showed that with this approach in vivo AChE inhibition in rats was adequately predicted, and that humans were predicted to be 45-fold more sensitive than rats, due to a less efficient PON1- and CYP-mediated PFF detoxification by humans than by rats as well as interspecies differences in B-esterases, with rat plasma containing almost all types of esterases including CaE, PON1, BChE, and AChE (Satoh and Hosokawa, 2006; Bahar et al., 2012),
whereas humans are deficient of plasma CaE (Berry et al., 2009; Li et al., 2005; Williams et al., 2011) and plasma AChE (Ecobichon and Comeau, 1973). We used the predicted dose-response data to derive points-of-departure (BMDL10 values) for AChE inhibition, which can be used as a starting point in the hazard assessment (Omwenga et al., 2021). Since we used pooled human liver fractions and plasma for the in vitro kinetic studies we were able to make predictions for ‘an average human’, but we could not take interindividual differences into account, which may occur as a result of differences in kinetic processes between individuals. In general, a default uncertainty factor of 3.16 is applied to account for human variation in toxicokinetics (IPCS 2005). However, having more detailed insights in possible interindividual variation might provide risk assessors a more science-based approach to derive factors accounting for intraspecies and interspecies differences in toxicokinetics, which may be applied to define chemical specific adjustment factors (CSAFs) for chemicals.

In the present study we aimed to predict interindividual differences in PFF detoxification by determining PFF detoxification in in vitro incubations with liver S9 fractions of 25 different Caucasian donors and with plasma samples of 25 different Caucasian donors. The obtained information on the variation in the in vitro kinetic constants Vmax and Km was applied in our previously published PBK model using a Monte Carlo simulation modelling approach, providing insights into human interindividual differences in PFF detoxification in a simulated adult human population, allowing estimation of expected differences between internal exposure for the geometric mean (GM) of the population compared to that of sensitive individuals (90-99th percentile).
PBK and MCM simulation to study interindividual differences in profenofos detoxification

Figure 1. Metabolic pathways for metabolism of profenofos (A) based on data reported in previous studies (Gotoh et al., 2001; Dadson et al., 2013). Metabolites include desethylated profenofos (B), desthiopropylprofenofos / des-S-propylated profenofos (C), hydroxypropyl profenofos (D), 4-bromo-2-chlorophenyl dihydrogen phosphate (E), and 4-bromo-2-chlorophenyl (BCP) (F).
5.2. Materials and Methods

5.2.1 Materials

PFF, 4-bromo-2-chlorophenol (BCP), bovine serum albumin (BSA), reduced nicotinamide adenine dinucleotide phosphate (NADPH), 5,5-dithiobis (2-nitrobenzoic acid) (DTNB) and acetylthiocholine iodide (ATC) were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Magnesium chloride hexahydrate (MgCl2·6H2O), trifluoroacetic acid (TFA), dimethylsulfoxide (DMSO), and calcium chloride dihydrate (CaCl2·2H2O) were purchased from VWR International (Amsterdam, The Netherlands). Acetonitrile (ACN, UPLC/MS grade) was purchased from Biosolve (Valkenswaard, The Netherlands). S9 liver fractions of 25 different Caucasian donors and plasma samples of 25 different Caucasian donors were obtained from SEKISUI XenoTech (Kansas City, USA) and BIOIVT (West Sussex, UK), respectively.

5.2.2.1 General outline of PBK modelling approach with Monte Carlo simulation to study interindividual differences in PFF detoxification

To predict and simulate human interindividual differences in the detoxification of PFF, the present study follows the steps as described below.

1) The conversion of PFF to BCP in the liver was studied using liver S9 fractions of 25 Caucasian individuals and the conversion of PFF to BCP in plasma was studied using plasma samples of 25 Caucasian individuals. From these studies, kinetic parameters (Km, Vmax and kcat) were derived.

2) The in vitro kinetic data were applied in the PBK model using two approaches. In the first approach 625 PBK models were prepared combining each S9 dataset to each plasma dataset (25·25). For the second approach the interindividual variation in the Caucasian population in the kinetic constants Vmax and Km of PFF conversion to BCP were included in the PBK model in connection with Monte Carlo simulations to predict interindividual variation of PFF.
clearance by the liver and in the plasma. For results obtained with both approaches, differences between the Cmax values for the geometric mean (GM) of the simulated population compared to the Cmax values for the 90th, 95th and 99th percentile in the population were determined and were compared with the default uncertainty factor applied for interindividual variation in toxicokinetics (3.16; IPCS, 2005).

3) Finally, we performed reverse dosimetry of in vitro data on PFF-induced AChE inhibition from our previous study (Omwenga et al., 2021) to estimate BMDL10 values for PFF-induced AChE inhibition in humans for the GM of the simulated human population as well as for the more sensitive individuals with slower PFF clearance. We used these data to estimate whether at different reported ARfD values for PFF, effects on AChE activity are to be expected in the simulated human population based on our predictions.

5.2.2.2 Step 1: In vitro incubations to derive individual human liver S9 and plasma kinetic parameter values for description of metabolic clearance of PFF in the PBK model

Incubations of PFF with human individual liver S9 and plasma to quantify in vitro rates of BCP formation were performed as described before by Omwenga et al. (2021) for incubations with pooled samples. Briefly, the final incubations were carried out in 100 mM Tris HCl (pH 7.4, 37°C) containing (final concentrations) 5 mM MgCl₂, 2 mM CaCl₂ (to stimulate PON1 activity (Carr et al., 2015)), 2 mM NADPH (cofactor to also include CYP-mediated metabolism), enzyme preparation (final concentration 2 mg S9 protein/ml for human liver S9 and 7.7 mg plasma protein/ml for individual human plasma) and PFF (at final concentrations ranging from 1 to 100 μM, added from 200 times concentrated stock solutions in DMSO). Control incubations were performed in the absence of individual human liver S9 or plasma. After 2 min pre-incubation, the reaction was initiated by adding the substrate and mixtures were incubated for 2 min in a 37 °C water bath. The total volume of the incubation mixtures was 200 μl. The
reaction was terminated by the addition of 50 μl ice cold ACN and samples were kept on ice. The mixture was centrifuged at 14,000 g for 20 min at 4°C and the supernatant was analyzed using UPLC-UV.

5.2.2.2.1 UPLC-UV analysis

All samples from incubations were analyzed using a Waters Acquity UPLC H class system that consisted of a quaternary solvent manager, a sample manager, and a photodiode array (PDA) detector, equipped with a Water Acquity UPLC® BEH C18 column (1.7 μm, 2.1 × 50 mm) and Waters Xbridge UPLC® BEH C18 pre-column (2.5 μM, 2.1 x 5 mm). The temperature of the column was kept at 40°C and the auto sampler at 10°C during the UPLC analysis. The mobile phases used for the analysis consisted of (A) 0.1% TFA in nanopure water and (B) 100% ACN. A gradient elution at a flow rate of 0.6 ml/min was applied for the analysis with the initial condition of 100% A: 0% B (v/v), changing in a linear way to 0% A: 100% B from 0 to 6 min, which was maintained for 30 s, and then changed back to the initial conditions in 30 s, which were maintained for 1 min. The injection volume for each sample was 3.5 μl. Under these conditions, the retention times of PFF and BCP were 4.76 and 3.37 min, respectively. The amounts of PFF and BCP were quantified by integrating the peak areas at 237 nm using calibration curves that were prepared using commercially available standards.

5.2.2.3 Step 2: Inclusion of interindividual variation in the kinetic constants of PFF detoxification in the PBK model in connection with Monte Carlo simulations to predict interindividual variation in internal PFF exposure

5.2.2.3.1 In vitro metabolism data analysis and scaling in the PBK model

Kinetic parameters including the apparent maximum velocity (Vmax) and the apparent Michaelis–Menten constant (Km) for BCP formation were obtained by fitting the data for the
substrate concentration-dependent rate of conversion (expressed in nmol/min/mg protein) using
GraphPad Prism 5, version 5.04 (San Diego, California, USA) to the standard Michaelis–Menten equation:
\[ V = \frac{V_{\text{max}} \cdot [S]}{K_m + [S]} \]
in which \([S]\) represents the concentration of substrate, expressed in μM, \(V\) and \(V_{\text{max}}\) the velocity and the maximum velocity of the reaction, respectively, expressed in nmol/min/mg protein, and \(K_m\) the apparent Michaelis–Menten constant, expressed in μM. The kinetic parameter values for conversion of PFF to BCP by the individual human liver S9 and plasma samples were determined. To determine the catalytic efficiency, \(V_{\text{max}}\) was divided by the \(K_m\).

The in vitro \(V_{\text{max}}\) values were scaled in the PBK model code (Supplementary Materials) using the following scaling factors for humans: 121 mg S9 protein/g liver and 550 mg plasma protein/g blood (Houston and Galetin, 2008; Nishimuta et al., 2014; Cubitt et al., 2011). The apparent \(V_{\text{max}}\) values obtained from enzymatic incubations expressed in nmol/min/mg protein were converted into μmol/h/kg liver and plasma in the PBK model code. The in vivo \(K_m\) values were assumed to be equal to those obtained in vitro (taking into account the differences in free fraction in vitro vs in vivo).

5.2.2.3.2 PBK model structure and software
The PBK model previously developed for PFF in adult Caucasians was used in the present study to evaluate the human interindividual variation in PFF detoxification and related PFF-induced AChE inhibition resulting from differences in the detoxification of PFF in the liver and plasma. Our human PFF PBK model previously developed was modified to include equations for Monte Carlo simulations (Omwenga et al., 2021).

The main metabolite of PFF reported in vivo is BCP, which has been reported to be formed upon PON1-mediated hydrolysis of PFF (JMPR 2007; EPA 2016; Dadson et al 2013). CYP-
mediated formation of other metabolites has been reported (Dadson et al., 2013), but these are considered less relevant, since the hydrolysis reaction is more efficient than the CYP-mediated oxidations, as indicated in our in vitro metabolism studies with liver microsomes or cytosol in which practically all PFF was converted into BCP. PFF hydrolysis (BCP formation) was quantified in the present study using human liver S9 and plasma and was included in the blood and liver compartments of the PBK model.

The model equations were coded and numerically integrated in Berkeley Madonna 9.1.18 (UC Berkeley, CA, USA), using the Rosenbrock’s algorithm for stiff systems. The PBK models’ differential equations are provided in the Supplementary Materials.

5.2.2.3.3 Integration of in vitro kinetic data of individual samples in PBK modelling approach

In the present study, we were able to derive in vitro data on interindividual differences in PFF detoxification in the liver and in plasma. These data were applied in the PBK model to obtain insight into internal PFF concentrations in humans using two different approaches. In the first approach, 625 different PBK models were made based on the scaled datasets for metabolism, combining each human liver S9 dataset with each plasma dataset, resulting in 25*25=625 combinations. At 0.01mg/kg bw internal exposures (Cmax unbound PFF concentration) were determined with each PBK model and from these data the GM, the 90th, 95th and 99th percentile of this ‘population’ was determined. For the second approach obtained information on the variation in biotransformation kinetics was applied in our PFF PBK model using Monte Carlo simulations, using a similar approach as applied by Punt et al. (2016), Strikwold et al. (2017) and Ning et al. (2019). For the Monte Carlo analysis, a total of 10,000 simulations were performed, where in each simulation, the Vmax and Km of PFF detoxification in the liver and of PFF detoxification in plasma were randomly taken from a log-normal distribution. The
distributions were truncated at ± 3SD by excluding individuals with kinetic constants that were three times higher or lower than the GM values from the Monte Carlo simulation (Punt et al., 2016; Strikwold et al., 2017, Ning et al., 2019). The kinetic constants for the PFF detoxification in the liver and plasma were assumed to vary independently. The mean (μw) and standard deviation (σw) describing the log-normal distribution of Vmax and Km values were derived using the following equation (Zhang et al. 2007):

$$μw = \ln\left(\frac{μx}{\sqrt{1 + CVx^2}}\right)$$ and $$σw = \ln (1 + CVx^2)$$

where μx is the mean of Vmax or Km and CVx is the coefficient of variation for each parameter.

Monte Carlo simulations were performed to obtain insight into the variation in human PFF Cmax values in blood (unbound) upon exposure to 0.01 mg/kg bw per day, being the predicted BMDL10 for PFF-induced AChE inhibition in humans from our earlier study (Omwenga et al., 2021).

The output of the Monte Carlo simulations was further analyzed with GraphPad (GraphPad Prism software version 5.04, San Diego California USA) to obtain the different percentiles, i.e. GM, 90th, 95th and 99th percentile of the PFF Cmax in blood (unbound) in the simulated population. The difference between the GM and the 90th, 95th and 99th percentile were obtained by dividing the 90th, 95th or 99th percentile of BCP formation by the GM (IPCS, 2005).

**5.2.2.4 Step 3: Reverse dosimetry of in vitro AChE inhibition data**

In our previous study (Omwenga et al., 2021), the in vitro concentration-response data for PFF-induced inhibition of human (recombinant) AChE were translated to in vivo dose-response data using PBK modelling-based reverse dosimetry. This quantitative in vitro to in vivo extrapolation (QIVIVE) was performed based on the Cmax (the unbound maximum concentration in blood). For the QIVIVE, each concentration of PFF in the in vitro studies, was
set equal to the free Cmax of PFF in blood in the PBK model to calculate the oral dose that results in this concentration (Omwenga et al., 2021). In the present study, a similar approach was applied to define the dose-response curve for the average population (GM), while the dose-response curves of the sensitive individuals (90th, 95th and 99th percentile) in the human population, were derived by applying the obtained values on the differences between these high percentiles and the GM of the population (see section 5.2.2.3). BMD modelling was applied on these dose-response datasets using PROAST software as described before in Omwenga et al. (2021) to obtain a BMDL10 for the average human (Caucasian), as well as for the more sensitive individuals. The obtained predicted dose-response data were applied to estimate whether at defined PFF exposure scenarios (different PFF ARfD values reported (0.005 mg/kg (EFSA, 2014), 0.002 mg/kg (EPA, 2016) and 1 mg/kg (JMPR, 2007)) effects of PFF in the simulated human population is to be expected.

5.3. Results

5.3.1 In vitro conversion of PFF to BCP by liver S9 and plasma of different human donors

Tables 1, 2 and 3 show the kinetic constants Vmax and Km, and the catalytic efficiencies for conversion of PFF to BCP by 25 Caucasian individuals, derived from experiments with liver S9 and plasma incubations, respectively. It also presents for these kinetic constants the mean (μw), the standard deviation (σw) and the % coefficient of variation (%CV). The difference between the highest and the lowest catalytic efficiencies for Caucasian liver S9 amounted to 5.8-fold with a mean (μw) of 143 μl/min/mg and a CV of 41%. This relatively high CV is mainly caused by individuals 098H0533 and 098H0447 which have relatively high Vmax and low Km values resulting in catalytic efficiencies that are 1.8- and 1.6-fold higher respectively than the mean (μw) catalytic efficiency (Table 2). The difference between the highest and the lowest catalytic efficiencies for Caucasian plasma was 6.4-fold with a mean (μw) of 15
μl/min/mg and a CV of 62%. Individuals HMN431414 and HMN431432 have relatively high V\text{max} and low Km values resulting in catalytic efficiencies that are both 2.7-fold higher than the mean (\(\mu\text{w}\)) catalytic efficiency of human plasma (Table 3).

Table 1. In vitro kinetic constants \(V\text{max}\) and Km and catalytic efficiencies for the conversion of PFF to BCP by 25 Caucasian individual liver S9 fractions.

<table>
<thead>
<tr>
<th>Code</th>
<th>(V\text{max}^a) (µM)</th>
<th>(K\text{m}^b) (µM)</th>
<th>Catalytic efficiency$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td>098H0025</td>
<td>1.7</td>
<td>9.1</td>
<td>190</td>
</tr>
<tr>
<td>098H0026</td>
<td>1.4</td>
<td>19</td>
<td>74</td>
</tr>
<tr>
<td>098H0033</td>
<td>1</td>
<td>9.3</td>
<td>108</td>
</tr>
<tr>
<td>098H0041</td>
<td>0.96</td>
<td>12</td>
<td>78</td>
</tr>
<tr>
<td>098H0057</td>
<td>1.4</td>
<td>11</td>
<td>127</td>
</tr>
<tr>
<td>098H0062</td>
<td>1.6</td>
<td>34</td>
<td>46</td>
</tr>
<tr>
<td>098H0068</td>
<td>1.7</td>
<td>20</td>
<td>87</td>
</tr>
<tr>
<td>098H0164</td>
<td>1.8</td>
<td>9.2</td>
<td>193</td>
</tr>
<tr>
<td>098H0177</td>
<td>0.89</td>
<td>3.9</td>
<td>230</td>
</tr>
<tr>
<td>098H0208</td>
<td>1.3</td>
<td>6.3</td>
<td>204</td>
</tr>
<tr>
<td>098H0217</td>
<td>2.1</td>
<td>19</td>
<td>113</td>
</tr>
<tr>
<td>098H0220</td>
<td>1.4</td>
<td>5.9</td>
<td>232</td>
</tr>
<tr>
<td>098H0236</td>
<td>1.5</td>
<td>7.7</td>
<td>200</td>
</tr>
<tr>
<td>098H0246</td>
<td>0.97</td>
<td>8.6</td>
<td>111</td>
</tr>
<tr>
<td>098H0291</td>
<td>2.1</td>
<td>19</td>
<td>111</td>
</tr>
<tr>
<td>098H0311</td>
<td>1.9</td>
<td>14</td>
<td>137</td>
</tr>
<tr>
<td>098H0397</td>
<td>1.8</td>
<td>12</td>
<td>151</td>
</tr>
<tr>
<td>098H0420</td>
<td>1.5</td>
<td>18</td>
<td>84</td>
</tr>
<tr>
<td>098H0428</td>
<td>1.6</td>
<td>12</td>
<td>136</td>
</tr>
<tr>
<td>098H0430</td>
<td>1.5</td>
<td>12</td>
<td>124</td>
</tr>
<tr>
<td>098H0447</td>
<td>1.7</td>
<td>7.4</td>
<td>233</td>
</tr>
<tr>
<td>098H0463</td>
<td>1.8</td>
<td>29</td>
<td>64</td>
</tr>
<tr>
<td>098H0487</td>
<td>2.4</td>
<td>17</td>
<td>141</td>
</tr>
<tr>
<td>098H0533</td>
<td>2.1</td>
<td>8</td>
<td>261</td>
</tr>
<tr>
<td>098H0751</td>
<td>1.8</td>
<td>12</td>
<td>152</td>
</tr>
<tr>
<td>Mean$^c$ ((\mu\text{x}))</td>
<td>1.6</td>
<td>13</td>
<td>143</td>
</tr>
<tr>
<td>SD$^d$</td>
<td>0.38</td>
<td>6.9</td>
<td>58.5</td>
</tr>
<tr>
<td>CV%,$^e$</td>
<td>23.7</td>
<td>52.2</td>
<td>40.9</td>
</tr>
<tr>
<td>(\mu\text{w}$^f$</td>
<td>-2.7</td>
<td>-1.36</td>
<td>-2</td>
</tr>
<tr>
<td>(\Sigma\text{w}$^g$</td>
<td>2.5</td>
<td>2.81</td>
<td>3.15</td>
</tr>
<tr>
<td>3-fold SD high=(\text{EXP}(\mu\text{w}+\sigma\text{w}*3))</td>
<td>0.73</td>
<td>3.76</td>
<td>31.5</td>
</tr>
<tr>
<td>3-fold SD low=(\text{EXP}(\mu\text{w}-\sigma\text{w}*3))</td>
<td>0.006</td>
<td>0.018</td>
<td>1.95052E-07</td>
</tr>
</tbody>
</table>
a nmol/min/mg liver S9 and plasma protein for PFF conversion to BCP

b μl/min/mg liver S9 and plasma protein for PFF conversion to BCP

c Mean of kinetic constants Vmax and Km, and catalytic efficiency for PFF conversion to BCP for 25 Caucasian individuals

d Standard deviation of kinetic constants Vmax and Km, and catalytic efficiency for PFF conversion to BCP for the 25 Caucasian individuals

e Coefficient variation % = SD/mean ($\mu x$) × 100%

f The mean for describing the log-normal distribution $\mu W = \ln \left( \frac{\mu x}{\sqrt{1+CV^2}} \right)$

g The standard deviation for describing the log-normal distribution ($\sigma W = \ln(1 + CV^2)$)
Table 2. In vitro kinetic constants $V_{max}$ and $K_m$ and catalytic efficiencies for the conversion of PFF to BCP by 25 Caucasian individual plasma fractions.

<table>
<thead>
<tr>
<th>Code</th>
<th>$V_{max}^a$ (nmol/min/mg liver S9 and plasma protein)</th>
<th>$K_m$ (µM)</th>
<th>Catalytic efficiency$^b$ (µl/min/mg liver S9 and plasma protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HMN431413</td>
<td>0.7036</td>
<td>38.91</td>
<td>18.08</td>
</tr>
<tr>
<td>HMN431414</td>
<td>0.9395</td>
<td>22.77</td>
<td>41.26</td>
</tr>
<tr>
<td>HMN431415</td>
<td>1.076</td>
<td>81.1</td>
<td>13.27</td>
</tr>
<tr>
<td>HMN431416</td>
<td>1.446</td>
<td>125.2</td>
<td>11.55</td>
</tr>
<tr>
<td>HMN431417</td>
<td>0.8388</td>
<td>27.85</td>
<td>30.12</td>
</tr>
<tr>
<td>HMN431418</td>
<td>0.8348</td>
<td>62.77</td>
<td>13.3</td>
</tr>
<tr>
<td>HMN431419</td>
<td>1.488</td>
<td>157.8</td>
<td>9.43</td>
</tr>
<tr>
<td>HMN431420</td>
<td>1.693</td>
<td>101.4</td>
<td>16.7</td>
</tr>
<tr>
<td>HMN431421</td>
<td>2.412</td>
<td>277.9</td>
<td>8.68</td>
</tr>
<tr>
<td>HMN431422</td>
<td>1.177</td>
<td>93.25</td>
<td>12.62</td>
</tr>
<tr>
<td>HMN431423</td>
<td>2.061</td>
<td>165.1</td>
<td>12.48</td>
</tr>
<tr>
<td>HMN431424</td>
<td>0.3436</td>
<td>49.28</td>
<td>6.97</td>
</tr>
<tr>
<td>HMN431425</td>
<td>0.7404</td>
<td>74.27</td>
<td>9.97</td>
</tr>
<tr>
<td>HMN431426</td>
<td>0.8455</td>
<td>56.5</td>
<td>14.96</td>
</tr>
<tr>
<td>HMN431427</td>
<td>0.6893</td>
<td>25.57</td>
<td>26.96</td>
</tr>
<tr>
<td>HMN431428</td>
<td>1.399</td>
<td>217.7</td>
<td>6.43</td>
</tr>
<tr>
<td>HMN431429</td>
<td>3.131</td>
<td>347.5</td>
<td>9.01</td>
</tr>
<tr>
<td>HMN431430</td>
<td>1.088</td>
<td>130.4</td>
<td>8.34</td>
</tr>
<tr>
<td>HMN431431</td>
<td>1.655</td>
<td>195</td>
<td>8.49</td>
</tr>
<tr>
<td>HMN431432</td>
<td>2.969</td>
<td>72.51</td>
<td>40.95</td>
</tr>
<tr>
<td>HMN431433</td>
<td>2.594</td>
<td>253.2</td>
<td>10.24</td>
</tr>
<tr>
<td>HMN431434</td>
<td>4.014</td>
<td>314.7</td>
<td>12.76</td>
</tr>
<tr>
<td>HMN431435</td>
<td>1.783</td>
<td>116.5</td>
<td>15.3</td>
</tr>
<tr>
<td>HMN431436</td>
<td>2.21</td>
<td>199.2</td>
<td>11.09</td>
</tr>
<tr>
<td>HMN431437</td>
<td>1.869</td>
<td>190.6</td>
<td>9.81</td>
</tr>
<tr>
<td>Mean$^c$</td>
<td>1.6</td>
<td>135.88</td>
<td>15.15</td>
</tr>
<tr>
<td>SD$^d$</td>
<td>0.88</td>
<td>91.38</td>
<td>9.39</td>
</tr>
<tr>
<td>CV,$^%e$</td>
<td>54.9</td>
<td>67.2</td>
<td>61.98</td>
</tr>
<tr>
<td>$\mu w^f$</td>
<td>-3.54</td>
<td>0.7</td>
<td>-1.41</td>
</tr>
<tr>
<td>$\sigma w^f$</td>
<td>2.83</td>
<td>2.9</td>
<td>2.87</td>
</tr>
<tr>
<td>3-fold SD high=$\exp(\mu w+\sigma w*3)$</td>
<td>0.43</td>
<td>32.19</td>
<td>1339.43</td>
</tr>
<tr>
<td>3-fold SD low=$\exp(\mu w-\sigma w*3)$</td>
<td>0.002</td>
<td>0.13</td>
<td>4.4501E-05</td>
</tr>
</tbody>
</table>

$^a$ nmol/min/mg liver S9 and plasma protein for PFF conversion to BCP

$^b$ µl/min/mg liver S9 and plasma protein for PFF conversion to BCP

$^c$ Mean of kinetic constants $V_{max}$ and $K_m$, and catalytic efficiency for PFF conversion to BCP for 25 Caucasian individuals
d Standard deviation of kinetic constants Vmax and Km, and catalytic efficiency for PFF conversion to BCP for the 25 Caucasian individuals

c Coefficient variation % = SD/mean (μx) × 100%

f The mean for describing the log-normal distribution \( \mu_w = \ln \left( \frac{\mu_x}{\sqrt{1 + CV_x^2}} \right) \)

\( \mu \) The standard deviation for describing the log-normal distribution (\( \sigma_w = \ln(1 + CV_x^2) \))

Table 3. Geometric mean (GM), CV (%) and the fold difference between the minimum and maximum Cmax of PFF upon exposure to an oral dose of 0.01 mg PFF/kg bw predicted by 625 individual PBK models and by PBK modelling linked to Monte Carlo (MC) simulation.

<table>
<thead>
<tr>
<th></th>
<th>Cmax of PFF of 625 individual PBK models</th>
<th>Cmax of PFF of PBK model with MC simulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>GM (pM)</td>
<td>0.1827</td>
<td>0.1572</td>
</tr>
<tr>
<td>CV (%)</td>
<td>11.1%</td>
<td>27.1%</td>
</tr>
<tr>
<td>Fold-difference min-max</td>
<td>0.69(^a)</td>
<td>9.3(^b)</td>
</tr>
</tbody>
</table>

\(^a\) Fold-difference between the predicted minimum and maximum Cmax of PFF by individual PBK models

\(^b\) Fold-difference between the predicted minimum and maximum Cmax of PFF by PBK models coupled with Monte Carlo simulation
5.3.2 Individual PBK models and Monte Carlo simulation

The impact of the interindividual differences in PFF metabolism in liver and plasma on the Cmax in plasma (free concentration) were evaluated by two methods. Firstly, the variation in Cmax of PFF was determined using the kinetic data derived from in vitro incubations of PFF using one set of 25 Caucasian liver S9 fractions and one set of 25 individual plasma samples (Tables 1 and 2). The individual kinetic parameters, i.e. Vmax and Km, present in these data sets were combined to result in 625 individual PBK models. Figure 2 shows the box and whisker plot for the predicted Cmax of PFF obtained with these 625 individual PBK models at an oral dose equivalent to a BMDL10 of 0.01mg/kg bw derived from the predicted dose-response data on PFF-induced AChE inhibition from our previous study (Omwenga et al., 2021). Table 3 presents the GM, CV (%) and fold-variation between the minimum and maximum of the predictions thus obtained.

In the second approach, a Monte Carlo simulation was performed at an oral predicted BMDL10 of 0.01 mg/kg bw (Omwenga et al., 2021) and the highest reported ARfD of PFF of 1 mg/kg bw (JMPR, 2007) to evaluate the interindividual variation in PFF metabolism that could occur in a larger population. The Monte Carlo simulation was performed in order to take the combination of the variability in liver S9 and plasma kinetics into account. In the Monte Carlo simulation 10,000 individuals were considered. The box and whisker plot for the predicted PFF Cmax obtained from the Monte Carlo simulations is also shown in Figure 2. The frequency distributions for the predicted Cmax obtained from the simulated population for both doses are presented in Figures 3A and 3B. The GM, CV (%) and the fold variations of the simulated population are presented in Table 3. The GM for the Cmax of PFF obtained from the Monte Carlo simulation (at a dose level of 0.01 mg/kg bw) appeared to be comparable (1.2-fold higher) to the GM obtained from the 625 individual PBK models.
Figure 4 shows the PBK model-based predictions for the time-dependent blood concentration of PFF at an oral dose of 0.01 mg/kg bw for the average, and the most and least active of the 625 Caucasian individuals. The difference between the predicted Cmax of PFF in blood for the individual with the highest and the lowest efficiency in PFF depletion is 1.7-fold for the 625 individuals.

Applying a Monte Carlo simulation, the difference between the GM and the 90th, 95th and the 99th percentile values was 1.4, 1.4 and 1.5 for the 90th, 95th and the 99th percentiles at 0.01 mg/kg bw. At an ARfD of 1 mg/kg bw as reported by JMPR, (2007), the difference between the GM and the 90th, 95th and the 99th percentile values were the same.

Figure 2. Box and whisker plot representing the distribution of the PFF maximum blood concentration (Cmax, unbound) at an oral dose of 0.01 mg/kg bw, referring to the predicted BMDL10 of PFF from our previous study (Omwenga et al., 2021), predicted with the 625 individual PBK models from a combination of kinetic data obtained with 25 individual human liver S9 fractions and 25 individual human plasma samples (lower part figure). Also, the distribution in Cmax predicted with the PBK model linked with a Monte Carlo (MC) simulation for 10,000 individuals including the variation in Vmax and Km for PFF detoxification in the liver and human plasma metabolism is presented (upper part figure). The whiskers represent the 1st and 99th percentile of the Cmax of the virtual populations. The vertical lines of the box represent the 25th percentile, GM and the 75th percentile.
5.3.3 Predicted dose–response curve for the PFF-induced AChE inhibition

Figure 5 shows the predicted in vivo dose–response curves for AChE inhibition by PFF for the average and the most sensitive individuals of the simulated Caucasian population (GM, 95th and 99th percentile of the population). The dose-response curves of the sensitive individuals (95th and 99th percentile, were derived by applying the obtained values on the differences between these high percentiles and the GM of the population. Considering that a factor of 1.4 and 1.5 were used to derive the dose response curves for the 95th and the 99th percentile population, it was expected that the obtained BMDL10 related to PFF-induced AChE inhibition will be 1.4- and 1.5- fold lower in individuals within the 95th and 99th percentile in the virtual population than ‘an average Caucasian’. Indeed, the obtained BMDL10 values were 0.0085 mg/kg bw for the GM of the population (close to the BMDL10 of 0.010 mg/kg bw we predicted before for ‘an average Caucasian’ (Omwenga et al., 2021)), and 0.0060 mg/kg bw and 0.0057 mg/kg bw for the 95th and 99th percentiles respectively.

Comparing the predicted BMDL10 of 0.0057mg/kg bw for the 99th percentile with that of the regulatory bodies reveals a close similarity to the ARfD adopted by EFSA (2019) of 0.005 mg/kg bw (based on a German evaluation in 2001 that defined an ARfD based on a NOAEL in a dog study using inhibition of brain cholinesterase activity as critical effect) and is slightly higher than that of EPA (2016) of 0.002 mg/kg bw (based on RBC AChE inhibition with a BMDL10 of 1.99mg/kg/day, (EPA, 2016)). It is however 200-fold lower than the ARfD of 1mg/kg bw adopted by JMPR (2007) (based on RBC AChE inhibition, with a NOAEL of 100mg/kg/day (JMPR, 2007)).
Figure 3. Frequency distribution for the maximum predicted unbound plasma concentration (Cmax) of PFF in 10000 individuals after Monte Carlo simulation including variation in Vmax and Km in PFF metabolism as measured with human liver S9 and plasma integrated in the PFF PBK model at A) our previously predicted BMDL10 of AChE inhibition of 0.01 mg/kg bw upon single exposure (Omwenga et al., 2021) and B) the ARfD of 1 mg/kg bw reported by JMPR (2007). The GM, P95, and P99 represent the geometric mean, the 95th and the 99th percentile of the distribution corresponding to 0.216, 0.2215, and 0.2283 pM for a dose of 0.01 mg/kg bw and 0.02207, 0.02275 and 0.0235 uM for a dose of 1 mg/kg bw.
Figure 4. PBK model-predicted time-dependent unbound blood concentration of PFF at an oral PFF dose of 0.01 mg/kg bw in the virtual Caucasian population. The dashed line represents individuals in the population within the 99th percentile (lowest efficiencies in PPF detoxification) while the dotted line represents individuals in the 1st percentile (highest efficiencies in PPF detoxification). The average population is represented by the solid line (average detoxification).
Chapter 5

Figure 5. Predicted dose-response curves for PFF-induced decrease of AChE activity for the GM of the virtual human population (dashed line) and the sensitive individuals of that population (99th percentile population; continuous line). The dotted line represents the dose-response curve for PFF-induced AChE inhibition for the average human previously reported by our group (Omwenga et al., 2021). Acute reference doses (ARfDs) of 0.005mg/kg bw (EFSA, 2014), 0.002mg/kg bw (EPA, 2016) and 1mg/kg bw (JMPR, 2007) are included (vertical line, dashed line and dotted line respectively). The predicted BMDL10 of the 99th percentile (0.0057 mg/kg bw) is indicated by an arrow, being close to EFSA’s ARfD.

5.4. Discussion

This study was conducted to investigate the effect of the inter-individual human kinetic variation in PFF detoxification in a virtual Caucasian population by integrating in vitro kinetic data with PBK modelling and Monte Carlo simulations. The obtained differences in PFF Cmax values between the GM and the 90th, 95th and 99th percentile of this virtual population amounted
PBK and MCM simulation to study interindividual differences in profenofos detoxification

to 1.4-, 1.4- and 1.5-fold, respectively, indicating that expected differences between adult individuals are minor and well covered by the default uncertainty factor for human interindividual differences in kinetics (3.16). Translation of in vitro concentration-response data on PFF-induced AChE inhibition provided a BMDL10 value of 0.0085 and 0.0057 mg/kg bw for the GM and the 99th percentile of this virtual population, the former being close to the BMDL10 of 0.010 mg/kg bw obtained in our previous study for ‘an average Caucasian’ (Omwenga et al., 2021).

PFF, being an oxon, is mainly detoxified through hydrolysis by hepatic and plasma PON1 and CYP450-mediated detoxification, resulting in the production of BCP (FAO, 2012; EPA, 2016; Dadson et al., 2013). In addition, previous studies have reported the involvement of CYP in the formation of other PFF metabolites (Dadson et al., 2013), that are eventually also converted to BCP. In our previous study we assessed the liver biotransformation kinetics by assessing conversion by both microsomes and cytosol. Since both liver fractions showed conversion, we used liver S9 fractions in the present study, consisting of both microsomal and cytosolic proteins. Paraoxonase-1 (PON1) is an esterase synthesized by the liver and found in the plasma associated with high-density lipoproteins (Camps et al., 2009; Pyati et al., 2015). The enzyme (PON1) causes hydroxylation of oxygen analogues of OPs, aromatic esters and carbamate insecticides (Costa et al., 2005), and has been regarded as a good predictor of individual susceptibility to OP toxicity (Costa et al., 2013; Alejo-González et al., 2018; Dardiotis et al., 2019). Unlike CYP-mediated metabolism that occurs predominantly in the liver, PON1-mediated detoxification occurs to an important extent in the plasma due to PON-1 excretion from liver to blood (Pyati et al. 2015). Up to 200 single-nucleotide polymorphisms (SNPs) have been identified in PON1 in different regions (Harel et al. 2004; Darney et al., 2020) and polymorphisms in the PON1 gene have been reported to influence the expression levels and enzyme activity of PON1 (Jarvik et al., 2000; Li et al., 2000). Although the current study
indicates minor differences in PFF conversion in the different human samples, it must be taken into account that individuals may exist that show more distinct differences in PFF conversion, due to SNPs in PON1 that may result in different catalytic efficiencies.

The SNPs of the coding region at positions 192 (glutamine (Q) / arginine (R) substitution at codon 192) have been reported to result in different hydrolytic activities towards various substrates, including OPs such as PFF (Humbert et al., 1993). Moreover, the arginine (Arg, R)/glutamine (Gln, Q) substitution has been reported to affect PON1 substrate specificity (10-fold decrease in paraoxon hydrolyzing activity), a phenomenon hypothetically attributed to differences in docking sites on the enzyme (Darney et al., 2020). On the other hand, the leucine (Leu, L)/methionine (Met, M) substitution of the L55M SNP has been reported to affect the stability and enzymatic activity of PON1. Furthermore, variant alleles have been found to have a lower frequency than the wild-type allele for the Caucasian population (Ginsberg, 2013). For example, the 192R allele is present in 20–30% of subjects in the Caucasian population, and in similar percentages in the Turkish, Asian Indian, and Canadian Inuit populations (Ginsberg, 2013). Moreover, the *55M allele has been found to have a lower frequency than *55L in all populations for which there are data, with the allele frequency ranging from 3–9% in Asians to 26–38% in Caucasians (Ginsberg, 2013). In addition, the variability in the metabolic activity of PON1 may also be introduced by age and lifestyle in addition to polymorphisms (Ginsberg et al., 2009; Nalcakan et al., 2016). For example, previous studies showed that PON 1 activity is 24% lower in pre-term babies as compared to babies at term (Ecobichon and Stephens, 1973) and that the activity increases steadily until it reaches a plateau phase at about 6 months to a few years post-partum (Huen et al., 2010; Smith et al., 2011).

Comparing the differences obtained between the GM and the 99th percentile for the conversion of PFF to BCP obtained from the Monte Carlo simulations to the default uncertainty factor of 3.16 for inter-individual kinetic variation reveals that the default uncertainty factor may be
adequately protective for PFF-induced AChE inhibition in the adult Caucasian population now studied. However, it should be noted that it remains to be established whether this holds equally well for specific potentially sensitive groups of the population such as children or pregnant women. Such studies should also consider inclusion of other endpoints potentially relevant for specific sensitive subgroups, such as neurodevelopmental effects in the unborn child upon exposure of pregnant women, for which more complex and sensitive in vitro assays for reverse dosimetry may be required.

Our previous findings reported humans to be 40-fold more sensitive to PFF-induced AChE inhibition as compared to rats, mainly due to differences in kinetics. Recently, we demonstrated limited interspecies differences (rats vs humans) in PFF-induced AChE inhibition in vitro (Omwenga et al., 2021). Furthermore, Kasteel et al. (2020) reported limited interindividual differences in OP-induced AChE inhibition (Kasteel et al., 2020). Combining our previously determined interspecies factor of 40, to account for differences between rats and ‘an average human’, with the factor of 1.5 determined in the present study, accounting for differences between ‘an average human’ and sensitive adult individuals’, results in a factor of 60. Although this may suggest that applying the default uncertainty factor of 100 for differences between the experimental animal and sensitive human individuals to be protective when setting a point of departure from a rat study on PFF-induced AChE inhibition, it should be noted that sensitive populations including infants, children, youths, and women of childbearing age have not yet been considered. As indicated before, one should take into account that more sensitive individuals could exist than modelled in the present studies, when having SNPs in PON1 leading to decrease in function, which may lead to limited biotransformation and detoxification of PFF, resulting in relatively high internal exposure. Furthermore, it should be noted that in the current approach, only toxicokinetic variability in PFF detoxification was considered. Other kinetic factors may play a role in interindividual susceptibility to OP toxicity such as differences
in oral uptake rate, plasma protein binding and/or plasma: tissue partitioning. Also, one must take into account that for specific endpoints in sensitive subgroups, such as neurodevelopmental toxicity in the unborn child upon exposure of pregnant women, more complex and sensitive in vitro assays are required to adequately predict toxicity dose levels based on reverse dosimetry.

In conclusion, the present study shows that linking Monte Carlo simulations with PBK modelling can be used to predict the effect of inter-individual human kinetic variation in PFF-induced AChE inhibition. Such information may be applied in the risk evaluation of chemicals, e.g. to provide supporting data for the derivation of CSAF values. Comparing the predicted BMDL10 of 0.0057 mg/kg bw for the 99th percentile with established health based guidance values reveals a close similarity to the ARfD adopted by EFSA (2019) of 0.005 mg/kg bw and by EPA (2016) of 0.002 mg/kg bw. Overall, the present study shows that integrating PBK modelling with Monte Carlo simulations is a powerful strategy to quantify interindividual variation in kinetics, which can be used to refine human risk assessment of OPs based on only human in vitro and in silico data.

**Acknowledgements**

This work is supported by the Netherlands Universities Foundation for International Cooperation (Nuffic) (scholarship granted to Isaac Omwenga (PhD.17/0019)) and the Dutch Ministry of Agriculture, Nature and Food Quality (project KB-23-002-021).

**Conflict of interest statement**

The authors declare that they have no conflicts of interest.
PBK and MCM simulation to study interindividual differences in profenofos detoxification

REFERENCES


Dardiotis, E., Aloizou, A.-M., Siokas, V., Tsouris, Z., Rikos, D., Marogiani, C., Aschner, M.,


PBK and MCM simulation to study interindividual differences in profenofos detoxification


Rahmioglu, N., Heaton, J., Clement, G., Gill, R., Surdulescu, G., Zlobeka, K., Hodgkiss, D.,
PBK and MCM simulation to study interindividual differences in profenofos detoxification


CHAPTER 6.
General Discussion and Future Perspectives
GENERAL DISCUSSION AND FUTURE PERSPECTIVES

6.1 Overview and discussion of the results

Pesticides are chemical substances that are primarily used to prevent, kill or control the growth of pests including insects, rodents and certain kind of animals that can damage crops as well as unwanted plant growth and fungi that can eventually damage the crops (Kaushal et al., 2021). The present thesis focussed on organophosphate pesticides (OPs). Epidemiological studies have linked chronic OP exposure to reproductive disorders, developmental toxicity, birth defects, cancer, Parkinson’s disease, Alzheimer’s disease, diabetes, chronic respiratory disease, cardiovascular diseases, chronic nephropathies and amyotrophic lateral sclerosis (ALS) (Mostafalou & Abdollahi, 2013). Due to the extensive use for agricultural produce, OPs have found their way in the ground water and rivers through run off agricultural water and run off from the surface of the plants that have been sprayed with these pesticides. Human exposure to OPs is mainly through diet (González-Alzaga et al., 2014; Costa, 2018). To date, the acute reference dose (ARfD) values of OPs have mainly been derived from data obtained for the inhibition of red blood cell (RBC) AChE activity as the surrogate for brain AChE activity, and are based on points of departure (PODs) like a benchmark dose (BMD), its lower confidence limit (BMDL) or a no observed adverse effect level (NOAEL) for this adverse effect. RBC AChE is more sensitive and easier to sample compared with AChE in other target organs like the spinal cord, brain and the peripheral nervous system (EPA, 2011). The current thesis aimed at developing non-animal approaches in OP risk assessment and application of these novel methods to predict the potential of the OPs to inhibit AChE in vivo upon acute exposure, also taking combined exposure into account. Furthermore, this thesis aimed to obtain data on the occurrence of OPs on commonly consumed vegetables in Kenya, as such data, and related estimations of human exposure, are lacking.
The use of chemical pesticides is indispensable in Kenya due to the hot and humid tropical environmental conditions that are conducive to the development of pests, weeds, and disease vectors (Omwenga et al., 2016). Chemical use is on the rise, especially use of fertilizers, veterinary chemicals and pesticides, in an attempt to increase agricultural produce to feed the rapidly increasing population, provide raw materials for the food related industries as well as earn foreign exchange (NIP, 2006). Vegetables provide vitamins, minerals and active compounds known to reduce the effect of cardiovascular diseases (Ivey et al., 2015). According to the WHO, vegetables and fruits constitute on average 30% of food consumption (WHO, 2003). In Kenya, it is estimated that fresh fruits and vegetables constitute 25% and >80% of the diets in the urban and the rural areas, respectively (Mungai et al., 2000; Kunyanga et al., 2018).

Among them, kales (Brassica oleracea var acephala), spinach (Spinacia oleracea), tomatoes (Solanum lycopersicum) and to a lesser extent French beans (Phaseolus vulgaris) are the most common vegetables used in various dishes (Karanja et al., 2012; Okello et al., 2012; Mutai et al., 2015: RSA, 2015; Njuguna et al., 2019). Like most countries, vegetable production in Kenya relies on extensive use of pesticides to control insect pests. Monitoring pesticide residues in vegetables is therefore key in determining and mitigating possible risks to human health from daily dietary pesticide exposure of consumers (Curl et al., 2003). Developed countries such as the USA, Canada and the EU have implemented pesticide monitoring programs. However, little effort has been focused on monitoring of pesticides exposure of the agricultural workers and local consumers in developing countries, leading to paucity of data on pesticide residue levels and the resulting adverse effects (Ecobichon, 2001). Many studies have reported on the levels of pesticide residues in various food products, including milk products (Golge et al., 2018), poultry and sheep fat (EFSA, 2019a), cereal (Lozowicka et al., 2014; EFSA, 2019a), olive oils (Razzaghi et al., 2018), fish (Sapozhnikova, 2014), and fruit and vegetables from various countries including Korea (Lee and Lee, 2012), Chile (Elgueta et al., 2019), Indonesia
Chapter 6

(Bhandari et al., 2019), China (Wang et al., 2019; Jiang et al., 2021), EU countries (EFSA 2019a), Turkey (Hepsağ and Kizildeniz, 2021), Canada (Wang et al., 2019) and the USA (Baker et al., 2002; Hu et al., 2016; Chiu et al., 2018). However, few data are available on the presence and levels of pesticide residues in vegetables consumed in Kenya (Ngatia and Kabaara, 1976; Karembu, 1991; Karanja et al., 2012; Mutai et al., 2015; Kunyangga et al., 2018). This thesis therefore assessed OP and carbamate pesticide residues in tomatoes, kales, spinach and French beans and the associated dietary exposure and potential health risks to children and adults in Kenya upon acute and chronic exposure (Chapter 2). A total of 90 samples, collected in peri-urban Nairobi, Kenya, were analysed by liquid chromatography/high resolution tandem mass spectrometry. Residues of acephate, chlorpyrifos (CPF), methamidophos, omethoate and profenofos (PFF) were found in 22% of the samples, at levels ranging from 10 to 1343 μg/kg. The EU MRL for these OPs was exceeded in 21%, 10%, 8% and 22% of the samples of French beans, kales, spinach, and tomatoes, respectively. CPF in spinach had an acute Health Quotient (HQ) of 3.3 and 2.2 for children and adults, respectively, implying that potential health risks with respect to acute dietary exposure cannot be excluded. For chronic dietary exposure, all chronic HQs were below 1. The Health Index (HI) for the pesticides, i.e. the sum of the chronic HQs, was 0.54 and 0.34 for children and adults, respectively. The risk assessments corroborate the need to continue routine monitoring of OPs and carbamates in vegetables to minimize consumer’s health risks, considering the high vegetable consumption among the Kenyan population and the fact that pesticide use is indispensable in Kenya due to the hot and humid tropical environmental conditions that are conducive to the development of pests, weeds, and disease vectors (Omwenga et al., 2016).

In the hazard and risk assessment of OPs, in vivo animal studies on OP-induced inhibition of AChE have been used to derive a point of departure (POD) to set safe exposure levels, such as an Acute Reference Dose (ARfD). ARfDs for CPF, acephate, methamidofos, omethoate and
PFF as reported by organizations as EFSA, EPA and the JMPR have been derived from data on OP-induced AChE inhibition from animal studies (JMPR, 2007; EPA, 2006; EPA 2011; EPA, 2016; EFSA, 2019b). However, the reliance on approaches based on animal experimentation has its drawbacks in terms of economical, ethical and scientific limitations. Therefore, an important aim of the present thesis was to assess whether in vivo dose-dependent OP-induced AChE inhibition can be predicted by an animal-free approach (Chapter 3, 4 and 5). In order to inhibit AChE in the in vivo situation, the OP needs to reach its target (AChE) at sufficiently high concentrations. The in vivo potency of an OP to inhibit AChE is thus dependent on its intrinsic ability (potency) to inhibit AChE and the amount of OP that reaches that target. To estimate the amount of OP that reaches the target, so-called physiologically based kinetic (PBK) models can be used. PBK modelling-based reverse dosimetry can support the prediction of toxic dose levels based on in vitro toxicity data by enabling quantitative in vitro in vivo extrapolation (QIVIVE) (Louisse et al., 2017; Paini et al., 2019).

PBK models have been developed for various OPs including CPF (Timchalk et al., 2002; Bouchard et al., 2005; Mosquin et al., 2009; Lu et al., 2010; Zhao et al., 2019), malathion (Bouchard et al., 2003; Bogen and Singhal, 2017; Bouchard et al., 2017), parathion (Sultatos, 1990) and diazinon (Poet et al., 2004). At the start of this thesis work, no PBK model had been built for the OP PFF, despite its widespread use in developing countries and reported cases of human accidental poisoning (Gotoh et al., 2001; Eddleston et al., 2009). In addition, PFF was the most frequently encountered pesticide residue in vegetables sampled in peri-urban Nairobi, Kenya at the initial stages of this study (Chapter 2). Therefore, in the present thesis a PBK model was developed for PFF in rat and human (Chapter 3). The rat PBK model was evaluated against literature data on urinary excretion of conjugated 4-bromo-2-chlorophenyl (BCP) (Cho et al., 2002). To facilitate PBK model based quantitative in vitro to in vivo extrapolation (QIVIVE), concentration-dependent inhibition of rat and human AChE was determined in vitro.
and these data were translated with the PBK models to predicted dose-dependent AChE inhibition curves in rats and humans in vivo. When the predicted dose-response curve for PFF-induced AChE inhibition in rats was compared to literature data, the prediction of the in vivo effect levels appeared accurate. Comparison of rat predictions (the BMDL10 of the predicted dose-response curve being 0.45 mg/kg bw) and human predictions (the BMDL10 of the predicted dose-response curve being 0.01 mg/kg bw) suggested humans to be more sensitive than rats. The PBK models revealed that this difference appeared to be mainly due to higher catalytic efficiencies for microsomal, cytosolic and plasma biotransformation of PFF to BCP in rats as compared to humans. PFF, being an oxon, is mainly detoxified through hydrolysis by hepatic and plasma paraoxonase 1 (PON1) and cytochrome P450 (CYP450)-mediated detoxification, resulting in the production of BCP (JMPR, 2007; EPA, 2016; Dadson et al., 2013). Interspecies differences in activities between human and rat PON1 have indeed been reported, with human PON1 having lower catalytic activity as compared to rat PON1 (Kaliste-Korhonen et al., 1996). Another possible reason for the differences in PFF detoxification may be related to quantitative differences in B-esterases in rats and humans, which may affect the metabolism and disposition of ester compounds including OPs (Ecobichon and Comeau, 1973; Maxwell et al., 1987). B-esterases, such as carboxylesterase (CaE), butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE), detoxify oxons, but these enzymes are inhibited by the oxons as a consequence (Chanda et al., 1997). In this way, B-esterases may play a protective role in rats but not humans. It has been reported that rat plasma contains almost all types of esterases including CaE, PON1, BChE, and AChE (Bahar et al., 2012; Satoh and Hosokawa, 2006), whereas humans are deficient of plasma CaE (Williams et al., 2011; Berry et al., 2009; Li et al., 2005) and plasma AChE (Ecobichon and Comeau, 1973). The absence of CaE in human plasma in addition to low PON1 activity may therefore be responsible for lower PFF
clearance resulting in higher sensitivity of humans to PFF as compared to rodents (Kaliste-
Korhonen et al., 1996).

As earlier indicated, human exposure to OPs originates mainly from ingestion via residues on
food (Bradman et al., 2003; Suratman et al., 2015; EFSA, 2019a). Since a variety of pesticides
is being used, environmental, occupational and dietary exposures are primarily to pesticide
mixtures. Consequently, there is lifelong combined exposure to various pesticides from, for
example, one food item containing multiple compounds or combinations of food items, each
containing different residues (Boobis et al., 2008). If these pesticides have a similar mechanism
of action and toxic endpoint, assessing the dietary risk of exposure for each pesticide separately
may lead to underestimation of the health risk (Boon et al., 2008). Therefore, current approaches
in pesticide risk assessment include cumulative and probabilistic approaches in order to include
the amount and variety of pesticide residues likely to be present in the vegetable sample (Jensen
et al., 2013; Boon et al., 2015; Elgueta et al., 2019). The first step in assessing effects of
combined exposure to pesticide mixtures is to identify substances with a similar mechanism
underlying their toxicity (Gallagher et al., 2015; EFSA, 2019a). For chemicals in the same
cumulative assessment group (CAG), the current scientific and regulatory recommendations for
the risk assessment of mixtures follows a test strategy based on a component-based assessment,
a concept with dose addition as the default model (EFSA, 2019; Bopp et al., 2015; EFSA, 2013;
Kortenkamp et al., 2009). As reported in Chapter 2 of this thesis, PFF and CPF were the most
frequently detected pesticide residues in commonly consumed vegetables in Kenya (Omwenga
et al., 2021a). In the same study, co-occurrence of PFF and CPF was reported in some of these
vegetables including tomatoes (Omwenga et al., 2021a). PFF and CPF are both OPs assigned
to the CAG related to brain and/or red blood cell (RBC) AChE inhibition (EFSA et al., 2019).
Consequently, consumers can be concurrently exposed to these OPs and knowledge on adverse
effects upon combined exposure is desirable. In **Chapter 4**, combination effects of PFF and
CPF were determined, by studying the combined effects of PFF and CPF’s toxic metabolite CPF oxon (CPO) on AChE inhibition in vitro, as well as the effects of CPF and CPO on PFF biotransformation (detoxification) by human liver microsomes, cytosol, and human plasma. AChE inhibition was shown to be 199-fold more potent by CPO than by PFF, and combined exposure to CPO and PFF resulted in effects that are in line with the principles of dose addition.

CPF and CPO appeared to affect PFF detoxification to its main metabolite (BCP) in a non-competitive manner at high concentrations, with Ki values of 120, 256 and 473 μM for CPF, and 80, 63 and 326 μM for CPO, for liver microsomes, liver cytosol and plasma, respectively, concentrations far higher than in vivo relevant concentrations. The PBK model of PFF (Chapter 3) was extended to include the description of CPF kinetics, using in vitro kinetic data from the literature and in silico calculations. PFF concentrations in the model were expressed in CPO-equivalents allowing prediction of total internal CPO-equivalents upon combined exposure to PFF and CPF. The model adequately predicted the AChE inhibition in a hospitalized person with CPF poisoning as reported in the literature (Drevenkar et al., 1993). Combined exposure to PFF and CPF at their ARfD (0.005 mg/kg bw; NB: the latest reported ARfD of PFF (EFSA, 2019b) was used in this study, being lower than the ARfD applied in chapter 2) was predicted to not affect AChE activity.

In developing the PBK models, pooled human liver fractions and plasma were used to derive the in vitro kinetic data for the detoxification of PFF, hence the resulting predictions were for ‘an average human’. Therefore, we could not take interindividual differences into account, which may occur as a result of differences in kinetic processes between individuals. In general, a default uncertainty factor of 3.16 is applied to account for human variation in toxicokinetics (IPCS, 2005). However, having more detailed insights in possible interindividual variation might provide risk assessors a more science-based approach to derive factors accounting for intraspecies and interspecies differences in toxicokinetics, which may be applied to define
chemical specific adjustment factors (CSAFs) for chemicals. The final experimental chapter (Chapter 5) of this thesis therefore aimed to predict interindividual differences in PPF detoxification. To that end, PPF conversion to BCP was studied in in vitro incubations with liver S9 fractions of 25 different Caucasian donors and with plasma samples of 25 different Caucasian donors. The obtained information on the variation in the in vitro kinetic constants Vmax and Km was combined with the PBK model developed in Chapter 3 using a Monte Carlo simulation modelling approach. Analysis of the predicted internal maximum concentrations of PPF in the simulated population indicated a 1.4-, 1.4- and 1.5-fold difference between the geometric mean (GM) and the 90th, 95th and 99th percentile, respectively, of the simulated population. These factors are below the default uncertainty factor accounting for human variability in toxicokinetics of 3.16. Concentration-response curves for inhibition of human AChE determined in vitro were translated with the PBK models to predicted dose-dependent AChE inhibition in humans in vivo. In line with the differences in Cmax values, the 99th percentile of the population was predicted to be 1.5-fold more sensitive to PPF-induced AChE inhibition than the GM of the population based on the BMDL10 values of predicted dose-response data for the virtual populations. Comparing the predicted BMDL10 of 0.0057 mg/kg bw for the 99th percentile with health based guidance values proposed by the regulatory bodies reveals a close similarity to the ARfD reported by EFSA, (2019) of 0.005 mg/kg bw, based on a German evaluation, and being slightly higher than the ARfD adopted by EPA, (2016) of 0.002 mg/kg bw. It is, however, 200-fold lower than the ARfD of 1 mg/kg bw adopted by JMPR, (2007). Interestingly, EFSA (2019 b) mentioned that “Due to the limited details available in the JMPR Report and the German evaluation, a final conclusion on the acceptability of the toxicological reference values derived by the two bodies cannot be made”. The results from this thesis would support the use of the ARfD of 0.005 mg/kg bw rather than the ARfD of 1 mg/kg bw, as at 1 mg/kg bw clear PPF-induced AChE inhibition was predicted in humans. Altogether,
the results obtained demonstrate that integrating PBK modelling with Monte Carlo simulations using human in vitro data provides a powerful strategy to quantify human interindividual variation in kinetics, which can be used to refine the hazard characterization of OPs.

Given the results of the present thesis, several topics are discussed to a further extent in the next sections, including:

- Pesticide residue levels and their health concerns following exposure via vegetables from urban areas of Kenya
- Use of alternative testing strategies and how they can be used to develop PODs to set health based guidance values for OPs
- Use of PBK modelling coupled to Monte Carlo analysis to study inter-individual human kinetic differences in metabolism and toxicity of OPs
- Risk assessment of combined exposure to OPs and to OPs together with other types of pesticides
- OPs and long term effects considering neurodegenerative diseases including Parkinsonism
- Future perspectives

6.2 Pesticide residue levels in vegetables from urban areas of Kenya and their health concerns following exposure

Studies worldwide reveal that infants, adults, and the elderly are exposed to pesticide residues as a consequence of their presence in food (Smegal, 2000; Risher and Navarro, 1997). The OPs and carbamates produce their effects by inhibiting acetylcholinesterase (AChE), the enzyme that terminates the action of the neurotransmitter acetylcholine (ACh) within neuromuscular junctions and nerve tissue, leading to overstimulation of the post-synaptic membrane (Timchalk
and poet, 2008). Reported effects related to exposure to OPs vary from mild short-term impacts such as nausea and headaches to chronic effects such as infertility, birth defects, blood disorders, nerve disorders, endocrine disruption and reproductive effects (Mansour, 2004; Alavanja et al., 2013).

Due to their health effects, OP residues in crops, food, and food by-products especially residues exceeding the Maximum Residue Levels (MRL) can be a threat to health and international trade (Zhang et al., 2008). Consequently, pesticide monitoring programmes have been implemented in various countries of the world. However, this is not in place in Kenya, and as a result few data are available on the presence and levels of pesticide residues in vegetables consumed in Kenya (Ngatia and Kabaara, 1976; Karembu, 1991; Karanja et al., 2012; Mutai et al., 2015; Kunyanga et al., 2018).

In chapter 2, this thesis reports OP residues in tomatoes, kales, spinach and French beans and the associated dietary exposure and potential health risks to children and adults upon acute and chronic exposure. PFF and CPF were among the most frequently encountered OPs among the screened vegetables. These findings corroborate those of previous studies involving pesticide screening in vegetables in peri urban Nairobi that reported PFF (Karanja et al., 2012) and CPF (Kunyanga et al., 2018) as the most frequently detected pesticides among others. Kunyanga et al., (2012) reported PPF levels of 4100 µg/kg in kales. These levels are four fold higher compared to those reported in tomatoes in our study (960 µg/kg) collected from peri-urban Nairobi. However, no PFF was detected in kales in this study. Furthermore, Kunyanga et al., (2012) reported CPF levels of 30 µg/kg in amaranth leafy vegetable, levels lower as compared to those from our study in the range of 78 to 107 µg/kg in tomatoes (11 % of samples), 26 to 315 µg/kg in kales (7% of samples), and 24-1,343 µg/kg in spinach (8% of samples), respectively. Another study by Karanja et al., (2012) reported levels of PFF, diazinon,
cypermethrin and bitertanol above EU permissible limits in kales in peri-urban Nairobi. Routine monitoring of OPs in vegetables is recommended to minimize consumer’s potential health risks. In order to characterize health risks associated with consumption of the vegetables in children and adults, chapter 2 determined the hazard quotients (HQs) for the detected pesticides. CPF was found to have an acute HQ of 3.3 and 2.2 for children and adults, respectively, implying that potential health risks with respect to acute dietary exposure cannot be excluded (Chapter 2). When using the JMPR ARfD of 1 mg/kg for determination of the HQ of PFF in tomatoes, all HQs were below 1, implying no risk to consumers. However, when the recent EFSA-reported ARfD of 0.005 mg/kg was used, the HQs were 2.33 and 1.53 for children and adults respectively, again calling for urgent monitoring of pesticide residues in Kenyan vegetables. This therefore indicates the variability in risk assessment when different human health based guidance values from different regulatory authorities are used. In future, for a more harmonized risk assessment, the PODs should be harmonized. EFSA (2019b) mentions that “a final conclusion on the acceptability of the toxicological reference values derived by the two bodies cannot be made”. The present study supports the use of the ARfD of 0.005 mg/kg bw, showing the added value of this NAM-based approach for the hazard characterization. When risk assessment of PFF in kales was conducted in this thesis based on reported PFF levels in the study of Kunyanga et al. (2012) was conducted, HQ values of 9.98 and 6.56 were obtained for children and adults, a finding that urgently calls for monitoring of the pesticide levels since kales are among the commonly consumed vegetables in Kenya. In addition, training of farmers on better use of PFF should be conducted in order to reduce PPF residues levels in kales.

Pesticide residues need to comply with MRLs which are based on Good Agricultural Practice (GAP). Since GAP may differ in different countries, also MRLs can differ. Exceedance of local MRLs are an indication that local GAP is not well followed. There are no national MRLs in Kenya, and this could lead to inadequate monitoring of pesticide residues in vegetables. Failure
to follow GAP may lead to exposure of consumers to higher than maximum allowable limits, which may lead to adverse health effects (Zhang et al., 2008). In addition, MRL exceedances may impede trade leading to reduced export of the vegetable produce to the EU and other trade partner countries (Ngolo et al., 2019). For example, Kenya is one of 14 countries listed in the 2017 European Food Safety Agency report (2019) in which Maximum Residue Limits (MRLs) were exceeded in more than 10 % of samples tested. In that report, high residues above the European MRLs were detected in kales, tomatoes and water (Ngolo et al., 2019).

The MRL exceedances reported in chapter 2 could be due to failure to adhere to the withdrawal intervals, which may lead to increased human pesticide exposure (Ntow et al., 2006; Darko & Akoto, 2008; Akoto et al., 2015; Bujwa and Sandhu, 2014). Failure to adhere to pre-harvest intervals and other indiscreet agricultural practices like pesticide use above recommended doses may be linked to high illiteracy amongst the farming communities in Kenya. A recent report indicated that vegetable farming in Kenya is mostly conducted by woman, and that Kenyan women tend to have lower levels of education than men, making it impossible for them to read labels and instruction manuals (Horna et al., 2008; Policy Department for External Relations, 2021). Ngigi et al., (2011) made a similar observation in Kenya among 85 percent of peri-urban farmers. High literacy skills in pesticide regulation and application is more adequate in the large-scale commercial export farms. It should however be noted that in Kenya, smallholders constitute up to 80 % of horticultural products, half of which are for export markets (Ridolfi et al., 2018). Moreover, it has been a challenge to create awareness for pesticide residue issues among this largely dispersed population by government agencies. Similar observations have been reported in other African countries such as Ghana where farmers were involved in indiscreet practices such as application of higher than recommended doses of pesticides on crops and failure to implement the pre-harvest time frame after application (Akoto et al., 2015;
FAO, 2014). Therefore capacity building and training of small holder farmers on GAP should be prioritized to minimize risks of OP residues in the food chain.

Although the Kenyan pesticide regulation regime has been considered as one of the most rigorous on the African continent and closest to global benchmarks, a few challenges still exist (Talk Africa, 2019). Currently, Kenyan pesticide industry is regulated by Chapter 346 of the Pest Control Products Act (PCPA) issued in 1985. In this regulation, new products by companies must first go through the trial conducted by the Pest Control Products Board (PCPB), followed by application for a certificate that is valid for three years (Kenya Law Reports, 2012). It should, however be noted that during the registration, only the purity and efficacy of the product are tested, and there is no mention of the potential threats to the environment, human health, or biodiversity by the PCPA. This is a serious pitfall as human risk assessment remains unaddressed, considering that OPs of environmental and human health concern that have been banned in developed countries such as EU, USA and Canada are still used in Kenya and other developing countries (Hertz-Picciotto et al., 2018). Indeed, a recent report by the directorate-general for external policies of the EU parliament mentioned Kenya as a major destination for pesticides that have been banned for use within the EU (Policy Department for External Relations, 2021). In chapter 2, the pesticides detected in vegetables such as chlorpyrifos, profenofos, acephate, metamidophos, dimethoate and omethoate are all banned in Europe while they still remain in use in other countries including Kenya (PCPB, 2019).

Comparing the MRLs set by various regulatory authorities, MRLs set by the EU are in general lower than those in North America. For example, MRLs of cypermethrin on strawberries was set twice lower by the EU as compared to Canada, while in the USA, carbaryl MRLs on apples are 1200 times higher than those in EU, partly because the MRLs in the EU is set to a default 0.01 mg/kg given that they are no longer registered for use. Also, MRLs for malathion and diazinon are 25 to 400 times higher in North America than in Europe (Nguyen et al., 2020).
However, in some cases, MRLs from the EU and US are comparable, such as those for permethrin in potato or DDT and glyphosate in tomato. Rarely, lower MRLs are imposed in the US than in Europe, an example being glyphosate in strawberry and potato, deltamethrin in potato and cypermethrin in tomato (Nguyen et al., 2020). This variation in MRLs between countries may lead to challenges in case there is a need for universal enforcement to promote international trade. Therefore, it is recommended, where possible, that harmonized MRLs are set that are universally accepted and enforced jointly for promotion of public health and international trade.

A bottleneck in a common approach in enforcement of MRLs is the selective use of some pesticides in some countries while they remain banned in others. For example, sometimes pesticides that are banned in Canada or the US, are still permitted in Europe or Africa and vice versa.

Due to extensive use of OPs to control pests in vegetable farming, one expects consumer exposure to insecticide mixtures. Indeed, a number of biomonitoring studies have reported the presence of several dialkyl phosphate metabolites resulting from OP metabolism in urine and inhibition of AChE in plasma of agricultural workers (Nishihama, et al., 2021). Therefore, many studies begin to characterize the toxicological effects of exposures to concurrent or sequential OP mixtures (Timchalk & Poet, 2008; Reffstrup et al., 2010). In Chapter 2 of the thesis it was also shown that some vegetables contained more than one type of pesticide residue. The presence of multiple residues could be a result of plant uptake of persistent pesticides (Zhang et al., 2015), spray drift (Coronado et al., 2011) and poor agricultural practices that involve mixing of more than one kind of pesticide during application based on the conception that as a mixture they will be more potent, as has been observed among Nepalese farmers (Bhandari et al., 2018). Indeed, the practice of using pesticide cocktails that sometimes include unapproved or banned pesticides is worrying but in practice among some farmers in Africa. Exposure to
two or more pesticides may result in additive and/or interactive effects (Saha and Zaman, 2012; Reffstrup et al., 2010).

6.3 Use of alternative testing strategies and how they can be used to derive PODs to set health based guidance values for OPs

In chapter 3 of this thesis PBK models for PFF were developed for rats and humans and successfully applied to predict dose-dependent in vivo AChE inhibition using PBK modeling-facilitated reverse dosimetry of in vitro data on PFF-induced AChE inhibition,. This allowed interspecies comparisons and provided a proof-of-principle that OP-induced AChE inhibition can be predicted for both rats and humans without the need for in vivo studies. Furthermore, chapter 4 assessed the combination effects of PPF and CPO, the toxic metabolite of CPF, on human recombinant AChE activity in vitro also translating these effects upon combined exposure to the in vivo situation, while Chapter 5 predicted human interindividual differences in PPF detoxification based on a combined in vitro-in silico approach. These studies add to previous work that reported the suitability of PBK models to predict OP dose-dependent in vivo AChE inhibition using PBK modeling-facilitated reverse dosimetry of in vitro data, for example for malathion CPF (Zhao et al., 2019) and diazinon (Zhao et al., 2021). In order to allow risk assessors to implement this alternative testing strategy, more proofs-of-principle using this approach with more OPs would be of use and provide a topic for future work in which the approach may prove to be of general use for OP risk assessment.

In this thesis, a chemical-specific PBK model was developed in order to predict the levels of PFF in various compartments. However, to allow chemical assessors to implement this alternative strategy in a broader way, there is need to develop generic OP PBK models for increased efficiency. In most cases the generic PBK models are built on IT platforms (Madden et al., 2019), allowing computing several chemicals with the same type of input data and similar assumptions and limitations. Furthermore the simulation of more than one chemical can be
carried out at the same time when generic PBK models are used. Such generic models hence simplify the task of carrying out a mixture risk assessment provided they also enable modelling of kinetic interactions as done in Chapter 4 of this thesis (Desalegn et al., 2018; Pletz et al., 2020). Moreover, the application of generic PBK models provides a more homogenous way of comparing various chemicals thereby eliminating biases. In this thesis, the PFF PBK model was developed based on a generic PBK model structure first developed by Jones and Rowland-Yeo, (2013). The developed PFF model was then extended to include CPF since all chemical-specific input data were already available (Chapter 3). This model can form the basis for PBK models of other OPs.

For quantifying relevant toxicodynamic effects of PFF, in vitro experiments using recombinant AChE for humans and red blood cell (RBC) AChE from rats were conducted to define the concentration-response curves. The obtained curves were translated into in vivo dose-dependent AChE inhibition curves in rats and humans using the PBK modelling-facilitated reverse dosimetry approach, after which the predictions for rats could be compared to in vivo data for PFF-induced AChE inhibition in RBCs and in the brain of rats (JMPR, 2007). In chapter 2, the derived BMDL10 was compared to the US EPA reported BMDL10 of 1.99 mg/kg bw for PFF-induced RBC AChE inhibition in adult rats upon a single exposure to PFF, with this EPA value being 4 times higher than the BMDL10 obtained from the predicted dose-response data for rats in our study (0.45 mg/kg bw). Furthermore, comparison to the JMPR NOAEL value of 100 mg/kg revealed a 200-fold difference for the point of departure based on AChE inhibition as compared to the BMDL10 value obtained from our predicted dose-response data in rats (0.45 mg/kg bw). This indicates that the NOAEL may represent a POD that may be too high and may not be protective to all segments of the population including the sensitive group. Indeed, when studying the interindividual differences in profenofos induced AChE inhibition based on in vitro kinetic data and a PBK modelling approach coupled to a Monte
Carlo simulations (Chapter 5), it became evident that exposure to the JMPR ARfD of 1 mg/kg bw PFF may lead to significant levels of AChE inhibition in the virtual human population, whereas the predicted AChE inhibition is minimal when exposed to 0.005 mg/kg the EU reported ARfD (EFSA, 2019). The predicted BMDL10 in humans for the sensitive part of the population amounted to 0.0057 mg/kg bw. Therefore, this thesis supports the use of the ARfD of 0.005 mg/kg bw rather than the one of 1 mg/kg bw in future PFF risk assessment studies. This is an example where a NAM-based assessment can aid in selection of the most appropriate POD when more than one option is presented.

The use of RBC AChE as a surrogate for brain AChE inhibition is based on the fact that RBC AChE is biochemically similar to the AChE present in the neuromuscular junction and the central nervous system, and this has been supported by various regulatory bodies (EPA, 2016, Carlock et al., 1999; EPA, 2008, 2012). The US EPA considered RBC AChE inhibition to be more suitable to derive a POD for human safety assessments, since it is more sensitive than brain AChE inhibition in case of PFF exposure (EPA, 2016). In addition, RBC AChE is easier to sample compared with AChE in other target organs like the spinal cord, brain and the peripheral nervous system (EPA, 2011). Indeed, the points of departure (POD) in risk assessment of OPs such as a benchmark dose (BMD), its lower confidence limit (BMDL) or a no observed adverse effect level (NOAEL) have been derived from data obtained from the inhibition of RBC AChE activity as the surrogate for brain AChE activity. Human cholinergic effect data or RBC AChE inhibition should, when available, take precedence over animal data for determination of PODs (Carlock et al., 1999). Since there are no adverse effects associated with a limited (10 or 20%) inhibition of RBC AChE, the use of a 10-fold uncertainty factor from the POD based on RBC AChE inhibition is considered adequate when RBC AChE inhibition data from either animal or human studies are used to assess human risk (Clegg et al., 1999; Carlock et al., 1999). Moreover, a default uncertainty factor of 100 is considered adequate.
when the POD is derived from animal studies for brain AChE inhibition and cholinergic effects, with a possibility for lower uncertainty factors on a case-by-case basis (Clegg et al., 1999; Carlock et al., 1999). In addition, a POD based on cholinergic effects derived from human studies may only require an uncertainty factor of 10 for interindividual variability, since an interspecies extrapolation factor from animals to humans is not necessary (Clegg et al., 1999; Carlock et al., 1999). However, recent epidemiological studies have consistently identified associations between OP exposure and neurodevelopmental outcomes in human, for example attention problems, autism spectrum disorder in early childhood, delays in mental development in infants (24-36 months) as well as intelligence decrements in school age children. Consequently, there is a need for protection of children from OP exposures that could cause these effects. The mode of action of OPs related neurodevelopmental effects is thought to be associated with AChE inhibition. Indeed, a study by Suarez-Lopez et al. (2013) reported associations between decreased AChE activity and lower overall neurodevelopment, inhibitory control, attention, and memory. In that study, the associations were reported to be gender specific, with correlations present in boys but not in girls. It should also be noted that neurodevelopmental effects have been reported to occur at OP dose levels below levels that cause overt AChE inhibition (US EPA, 2014; Abreu-Villaca and Levin, 2017). Given that the current derivation of HBGVs is based on animal data using 10% AChE inhibition as the critical effect, this implies that HBVGs derived from PODs based on animal models may not be sensitive enough and provide for full protection against adverse effects of OPs, when using a default uncertainty factor of 100. Currently, the extra Food Quality Safety Act (FQPA) safety factor of 10 for interindividual variability has been retained for some OPs including CPF and PFF for the population subgroups consisting of infants, children, women of childbearing age and youth for all exposure scenarios. Novel approach methods (NAMs) may play a future role...
in defining interindividual differences in sensitivity towards OPs including also sensitive subpopulations.

In the in vitro AChE inhibition study used in this thesis, a static approach was used to determine the AChE inhibitory effect concentrations, using a single preincubation time point (15 minutes). When including more time points, information on the time-dependent inhibition kinetics can be obtained. However, a previous study with CPF oxon showed that human recombinant AChE active sites were 100% inhibited after a pre-incubation period of 11 minutes (Kaushik et al., 2007). One would expect that effect concentrations would decrease with longer incubation times until 100% of the binding sites is inhibited, as shown before by Aurbek et al., (2006) and Krstić et al., (2008). With a relatively long pre-incubation time of 15 minutes as used in the present study and also in other studies (e.g. Aurbek et al., 2006; Kasteel et al., 2020), it is expected that a relevant and conservative estimation of the effect concentrations will be obtained, as also indicated by the small difference between the BMDL10 value obtained with the predicted rat dose-response data and the BMDL10 value from a reported in vivo study in rats (Chapter 3).

This thesis mainly addressed risk associated with AChE inhibition upon a single exposure. However, chronic poisoning may occur in agricultural workers with daily exposure to OP compounds as well as consumers upon daily consumption of OP-contaminated food. Some OPs have the capacity to induce organophosphate-induced delayed neuropathy (OPIDN), a symmetrical sensorimotor axonopathy, with severe effects reported in long axons, and encountered 7 to 14 days following acute high dose exposure or repeated low dose exposure. OPIDN is initiated by phosphorylation and subsequent aging of >70% of the functional neuropathy target esterase (NTE) in peripheral nerves or depletion of ornithine decarboxylase in spinal cord (Balali-Mood and Saber, 2012). In risk assessment for longer exposures, one must also take the time-dependent de novo AChE production into account to adequately
estimate the AChE activity upon a second and further exposure. In that regard a phenomenon referred to as steady state AChE inhibition is of interest, which is the situation when the degree of AChE inhibition reaches equilibrium with the production of new enzyme at which AChE inhibition remains constant at a specified dose over the exposure period (EPA, 2016). Adequate prediction of these processes based on only in vitro data, as applied in the present study, is an interesting challenge for future studies. Furthermore, one must consider that OPs inhibit detoxifying enzymes, such as CaE and BuChe, which may result in a decrease in metabolic clearance, and related higher internal concentrations and increased sensitivity upon repeated dosing.

6.4 Use of PBK modelling coupled to Monte Carlo analysis to study inter-individual human kinetic differences in metabolism and toxicity of OPs

In chapter 5, the effect of inter-individual human kinetic variation in PFF-induced AChE inhibition was predicted by linking Monte Carlo simulations with PBK modelling. Careful literature review indicates that the studies on inter-individual human kinetic differences described in the present thesis are the first attempt to use PBK modelling to identify inter-individual kinetic differences in detoxification of OPs, especially PFF and thus sensitivity towards AChE inhibiting OPs and carbamates. The Monte Carlo sampling approach for generating a ‘virtual population’ was applied in order to characterize the response for a representative population. In this thesis, a total of 10,000 simulations was performed, where in each simulation, the Vmax and Km of PFF detoxification in the liver and of PFF detoxification in plasma were randomly taken from a log-normal distribution. In previous studies on simulations considering the general population, Monte Carlo simulations with a sample size of 10,000 is often used (Slob, 2006; Sprandel et al., 2006; Goutelle et al., 2009; Punt et al., 2016, Ning et al., 2019). Another study on the number of replications required in Monte Carlo simulations considering a total of 22 studies concluded that the minimum recommended number
of replications (also considered as the sample size) is less than 10,000 (Mundform et al., 2011). In general, about 7500 to 8000 replications can produce robust results, while in some instances a total number 5000 replications may be enough (Mundform et al., 2011).

The developed PBK model for PFF in humans was based on parameters gathered for the Caucasian population (Chapter 5). In risk assessment, inter-individual differences including interethnic differences are taken into account by applying an uncertainty factor of 10 for human variability in kinetics (factor of 3.16) and in dynamics (factor of 3.16) (IPCS, 2005). However, having more detailed insights in possible interindividual variation might provide risk assessors a more science-based approach to derive factors accounting for intraspecies and interspecies differences in toxicokinetics, which may be applied to define chemical specific adjustment factors (CSAFs). In the future applications of this approach, variability in other parameters such as for example body weight, age and gender can be included. Moreover, previous studies have demonstrated the capability of PBK modelling to address age-related changes in physiology and their resulting influence on pharmacokinetics, mainly to predict age related variation between adults and children or to simulate life-time chemical exposures (e.g. Haddad et al., 2001; Price et al., 2003; Pelekis et al., 2003; Clewell et al., 2004; Beaudouin et al., 2010; Bosgra et al., 2012). In most approaches, a mathematical description of the changes of average organ sizes and other parameters with age are included in the PBK model in order to reflect the expected variation by using Gompertz growth curves, polynomial or biexponential functions (Bosgra et al., 2012).

In this thesis, exposure assessment conducted in chapter 2 focused on the situation in Kenya. However, in chapters 3, 4 and 5, the human liver subcellular fractions and plasma used to derive the kinetic parameters for the PBK models were from the Caucasian population. Previous studies have, however, reported interethnic differences between the Caucasian and African population in expression of kinetic enzymes such as PON1 (Davis et al., 2009). Indeed,
knowledge of PON1 enzymatic activities as related to phenotype, genotype, sex, race, and age within a population may provide a useful explanation for some of the disparities in OP metabolism among the various demographic groups (Davis et al., 2009). In the absence of the African kinetic data due to the lack of commercial availability of plasma and liver samples, the African American population data may be applied to compare the interethnic differences in metabolism, since they share a common ancestry. For example, it has been reported that PON1R192 hydrolyses CPO faster than PON1Q192 (Mohammed Ali and Chia, 2008; Eyer et al., 2009; Mutch et al., 2007). Various studies have found that African Americans have a weighted PON1Q192 allele frequency of 0.37 and a weighted PON1R192 allele frequency of 0.63, while the Caucasians have a weighted PON1Q192 allele frequency of 0.73 and a weighted PON1R192 allele frequency of 0.27 (Chen et al., 2003; Scacchi et al., 2003). A higher efficiency of CPO hydrolysis in the Caucasian population could be due to a relatively higher frequency of the RR genotype in the Caucasian population as compared to the African population. In future studies, it is recommended that in vitro kinetic studies should be conducted using human liver and plasma subcellar fractions from the Kenyan African population in order to derive HBVGs specific to the study population, and/or to evaluate whether the default uncertainty factor for interindividul differences in kinetics adequately covers the differences between these ethnic groups.

A risk assessment approach that employs Monte Carlo simulation taking inter-individual variability (caused by inherent genetic variability as well as random variability as a result of external factors) into consideration is key to a better understanding of the risks of pesticide exposure which could cause unexpected dose response outcomes that might happen with rare frequency among the sensitive segment of the population. This is particularly evident in individuals with a low PON1 status leading to an increased susceptibility to OP toxicity in humans (Costa, 2013). In future risk assessment using PBK models, in vitro input data based
on recombinant enzymes that represent the sensitive segment of the population should be included.

Considering all these, one must be prudent during interpretation of the simulation outcomes because of the uncertainties related to other sources of variability. Generally when performing model-based risk assessment, some assumptions are necessary because not all of the information pertaining all parameters of the compound under consideration is available. In future, it would be of use to build mathematical models and run various simulations under several assumptions with uncertainties and to identify the key components that play key roles by sensitivity analyses. In so doing, the toxicity of various compounds can be well studied as this approach provides quantitative answers to fundamental questions regarding the worst-case scenario based on current knowledge and helps to prioritize the uncertainties and assumptions that should be solved.

6.5 Risk assessment of combined exposure to OPs and to OPs and other types of pesticides

Assessment of exposures to pesticide mixtures is important in the assessment of the aggregate risk (Hernandez et al., 2017), hence the initiative to conduct studies to examine the effects of combinations of OPs. Chapter 4 provides insights into the combination effects of two selected OPs (PFF and CPF), by studying the combined effects of PFF and CPF’s toxic metabolite CPF oxon (CPO) on AChE inhibition in vitro, as well as the effects of CPF and CPO on PFF biotransformation (detoxification) by human liver microsomes, cytosol, and human plasma using in vitro and in silico methods. In addition, in vivo AChE inhibition as a result of the combined exposure was determined using PBK modelling-facilitated reverse dosimetry of the in vitro data. The results reveal that AChE inhibition upon combined exposure to these OPs follows the concept of dose addition, and that at reported exposure levels, no toxicokinetic interactions of CPF on PPF detoxification are expected. These findings resonate with those
reported by Timchalk et al., (2008) where binary exposure to CPF and diazinon was found to follow dose addition in cholinesterase inhibition, using a physiologically based pharmacokinetic and pharmacodynamic model. Again, this provides another proof-of-principle that approaches that combine in vitro studies and PBK modelling-facilitated reverse dosimetry are promising tools for risk assessment upon combined exposure to pesticide mixtures. Indeed, since a variety of pesticides is being used, environmental, occupational and dietary exposures to pesticide mixtures are likely to occur. Consequently, there is lifelong combined exposure to various pesticides from, for example, one food item containing multiple compounds or combinations of food items, each containing different residues (Boobis et al., 2008; Hernández et al., 2017). These findings therefore support the current scientific and regulatory recommendations for the risk assessment of mixtures that recommend a test strategy based on a component-based assessment, and dose addition as the default model for chemicals in the same cumulative assessment group (EFSA, 2019; Bopp et al., 2015; EFSA, 2013; Kortenkamp et al., 2009).

For pesticides with different modes of action, however, the various mixture effects can be evaluated by determining chemical interactions at both kinetic and dynamic level as well as the cellular or molecular targets of individual pesticides (Hernández et al., 2017). In addition, the complexity of toxicological interactions can lead to unpredictable effects of pesticide mixtures. In general, the interactions on metabolic pathways affecting the biotransformation of pesticides is by far the most common mechanism of synergism. For example, in a study to evaluate the combined effect of a binary mixture of CPF and diazinon, the metabolic interactions between CPF and DZN at the level of their CYP450 mediated conversion were evaluated in vitro, showing that each insecticide was found to inhibit the other’s in vitro metabolism in a concentration-dependent manner (Timchalk et al., 2008). However, that synergism is rare at dietary exposure levels, and is likely to occur at experimentally unrealistic high dose levels and
concentrations (Timchalk et al., 2008; Larsen et al., 2019). A similar observation was made in chapter 4, where interactions between PFF and CPF and its metabolite, CPF-oxon were predicted to occur only at relatively high dose levels, largely exceeding expected daily intakes (EDIs). Obviously PBK modeling provides an adequate way to evaluate the consequences of such interactions at realistic low dose levels.

Although PBK modelling is promising in evaluating combined effects of chemicals that follow the principles of dose addition, it cannot be applied as such when combined effects of chemicals do not follow the concept of dose addition, but when other combination effects, such as synergism or antagonism apply. Most synergistic interactions are thought to result from interactions at the level of metabolic processes (Cedergreen, 2014), making it possible to potentially screen synergists using either in vitro assays on for example CYP P450 enzyme activity or esterase inhibition potential, or determination of kinetics in in vivo studies using representative test species. However, the in vivo studies would be labour intensive (Cedergreen, 2014), and may be difficult to extrapolate to the human situation and especially to low dose exposure regimens. In another study, several specific binary combinations of AZM-oxon and CPF-oxon caused a synergistic effect on the ChE inhibition in *P. corneus* homogenates. The degree of synergism tended to increase as the ratio of AZM-oxon to CPF-oxon decreased. These results suggest that synergism is likely to occur in *P. corneus* snails exposed in vivo to binary mixtures of the OPs AZM and CPF (Cacciatore et al., 2012). Consequently, predicting effects of mixtures would be more complex in case of less than dose addition or more than dose addition. It should, however, be noted that deviations from predicted additivity are considered to be rare (Kortenkamp et al., 2009; Cedergreen et al., 2014).
6.6 OPs and long term effects considering neurodegenerative diseases including Parkinsonism

Neurodegenerative diseases are diseases linked with a wide variety of pathological and clinical conditions associated with aging. Examples include diseases such as Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) or Alzheimer’s disease (AD) (Costa, 2018). Although the etiology of these diseases is unknown, it is believed that both genetic and environmental factors may play a role. Several genes implicated as monogenic causes of parkinsonism are only responsible for approximately 10% of cases (Ball et al., 2019), while the remaining 90% of the cases are idiopathic, with different environmental exposures being implicated as either risk factors (pesticides exposure and heavy metals) or protective factors (such as caffeine intake and tobacco smoking) (Schneider Medeiros et al., 2020). OPs constitute the largest group of insecticides currently used in farming despite being responsible for about 3 million cases of poisonings and about 300,000 deaths annually worldwide, according to Robb and Baker, (2020) and others (Buckley et al., 2004; Terry, 2012; Costa, 2006). Furthermore, some human subjects that survive acute OP poisoning have been found to develop signs of parkinsonism, suggesting that OPs may have a negative effect on the striatal dopaminergic system (Bhatt et al., 1999; Hashim et al., 2011). These lesions are similar to the main pathological lesions in PD, where there is a slow and progressive degeneration of dopaminergic neurons in the substantia nigra of the brain, with clinical signs such as resting tremor, gait disturbances and bradykinesia appearing with the degeneration of about 80% of dopaminergic neurons. Pathologically it has been reported that neuroinflammatory processes and oxidative stress are prominent in most neurodegenerative diseases such as PD (Costa, 2018; Wani et al., 2017), and some OPs have indeed been reported to cause these (Naughton and Terry, 2018; Pope, 1999; Wani et al., 2017). Moreover, previous studies have linked acute exposure to OPs with causation of Parkinsonism (Muller-Vahl et al., 1999; Baldi et al., 2003). Chuang et al. (2017) recently reported an increased
risk of PD following OP and carbamate poisoning. Indeed, a positive association between chronic exposure to OPs and PD has been reported (Wang et al., 2014), especially in individuals with particular paraoxonase-1 (PON1) genotypes that affect proper PON-1 functioning (Paul et al., 2017). With all these associations being reported, the Board for the Authorisation of Plant Protection Products and Biocides (Ctgb) and EFSA have expressed interest in conducting research to establish the link (if any) between exposure to plant protection products including OPs and the development of Parkinsonism (https://www.ctgb.nl/documenten/brieven/2021/03/23/efas-reply-on-possible-relation-ppp-and-parkinson). On their part, EFSA has undertaken activities by the PPR Panel culminating in the development of adverse outcome pathways (AOP) for Parkinsonian disorders. The measurable key events (KEs) included in the AOP could be used to test and identify chemicals with potential to contribute to the disease via the identified pathway. An AOP approach is key in the study of mechanisms of toxicity required in linking those mechanisms through epidemiological studies to neurological disorders such as parkinsonism. The mechanistic understanding enables the development of tools necessary for a predictive toxicology approach, which is essential for regulatory decisions.

Other pesticides such as organochlorine insecticides, maneb, paraquat and rotenone may have neurotoxic actions that potentially play a role in the development of PD, with previous epidemiological studies showing a relation between these pesticides and PD (Dick, 2006; Brown et al., 2006; Wright et al., 2005). Since these pesticides have been linked to PD, and considering that they have different modes of action, there is need to also better characterize and understand the consequences of such combined exposures.
6.7 Future perspectives

The present thesis provided proofs-of-principle that PBK modelling-based reverse dosimetry of in vitro data is able to predict in vivo acute OP-induced AChE inhibition (PFF and CPF) in a quantitative way. In order to increase the applicability and impact of this novel approach, one may consider to provide proofs-of-principle for endpoints other than OP-induced AChE inhibition, including especially examples on compounds with different target organs and different AOPs also including in addition to effects of acute exposure effects of chronic low dose exposure. For example, it would be interesting to study the sub-chronic to chronic adverse effect of OPs, resulting from long-term repeated exposure to low concentrations using recombinant AChE with an in vitro system capable of mimicking the de novo synthesis of the enzyme as well as metabolic enzyme activities in order to predict AChE inhibition and other endpoints of OPs upon daily low dose exposure. Besides the AChE inhibition in the brain and RBC, other toxic endpoints and target tissues should be investigated. For example, results following inhibition of enzymes like neuropathy target esterase (NTE) (Costa, 2018), acylpeptide hydrolase (APH) (Richards et al., 2000), fatty acid amide hydrolase (FAAH) (Quistad et al., 2001; Buntyn et al., 2017) muscarinic M2 receptors (Costa, 2006), and a variety of lipases (Quistad et al 2006) have not been analysed for their in vivo relevance. Already, SH-SY5Y human neuroblastoma cells have shown promise in development as in vitro assay to measure OP effects on NTE activities (Sogorb et al., 2010). Some studies have reported the endocrine disrupting effect of OPs (Yang et al., 2019; Ortiz-Delgado et al., 2019), which may play a role in the mode of action responsible or neurodevelopmental effects. Consequently, in vitro assays employing novel human stem cell models have been developed for testing developmental neurotoxicity (Bal-Price et al., 2018; López-Tobón et al., 2018; Lupu et al., 2020). For example, human induced pluripotent stem cells derived neuro-progenitor cells (Human iPSC-derived NPC) from different brain regions have been used to develop in vitro
assays with capability to measure the relevant neurodevelopmental effects including neurite, differentiation, network formation and activity as well as migration during early embryonic development (Bal-Price et al., 2018; López-Tobón et al., 2018; Lupu et al., 2020). In addition, in order to understand the molecular mechanisms of OP-induced neurobehavioral deficits such as observed in PD (see section 6.6), various models have been developed to study the molecular effects of OPs in relevant cell types. For example, some studies have investigated molecular responses following in vivo exposures, and attempted to correlate these findings with behavioral outcomes without inducing overt toxicity related to AChE inhibition activity in isolated tissue or cell culture systems. Furthermore, it has been demonstrated that OPs induce neuronal damage or death at levels that do not ablate AChE activity (Voorhees et al., 2017). Another example of an in vitro system is that of a cortical culture system where hippocampal slice cultures were treated with CPO at levels that reduced hippocampal AChE activity by 50% after 3 and 7 days of exposure, showing also neuronal injury that was both concentration- and time-dependent (Zimmer et al., 2000). Development of in vitro models to measure OP effects on APH, FAAH, muscarinic M2 receptors and lipases are yet to be developed.

Once these in vitro systems are developed, PBK model based reverse dosimetry could be applied to translate the in vitro data to the in vivo situation and allow their use in hazard characterization and risk assessment.

The present thesis studied the inter-individual variations in kinetics of OP metabolism, whereas the effect of inter-individual dynamic differences remains to be elucidated in future studies. A recent in vitro study suggested limited interindividual differences in OP-induced AChE inhibition (Kasteel et al., 2020). Studies in this thesis also reported similar AChE inhibition patterns in both human and rat AChE, concluding that the differences between rats and humans in PFF-induced AChE inhibition are mainly driven by differences in kinetics. Therefore, the current PBK models could be extended to physiologically based dynamic (PBD) models, in
which for example AChE inhibition could be integrated. Combining the current PBK model with an equation describing the concentration-dependent AChE inhibition of OPs and carbamates in different human individual RBC samples, as well as an extension of the PBK models coupled to Monte Carlo simulation to also predict toxicodynamics, could provide a way forward to fully predict the interindividual differences in in vivo dose-response curves for OP- and carbamate-induced AChE inhibition and resulting toxicity in humans.

Another important point that can be considered in the future when using PBK modelling-based reverse dosimetry of in vitro data for risk assessment is the uncertainty factor to be used when a POD for risk assessment is defined by a QIVIVE approach. This requires insight in the uncertainties inherent to the approach and the model applied. Uncertainty comes, for example, from the level of inaccuracy in the various model parameters. In the present thesis, a sensitivity analysis was performed to evaluate the impact of model parameters on the model output so that the effect of small changes in parameter values on the model outcome can be evaluated. Furthermore, the PODs derived in the present thesis were based on a human PBK model and human recombinant AChE derived in vitro data, hence human specific physiology, metabolism and inhibitory effects were taken into account. Consequently, the UF of 10 for inter-species differences would no longer be required. Then an extra UF of 10 could be applied because the POD was derived by an alternative in vitro-in vivo testing strategy. This would still result in an uncertainty factor of 100 to be applied when a POD is derived using the combined human based in vitro-in silico NAM approach, to account for the uncertainties brought about by the in vitro-in silico QIVIVE approach (factor 10) and the interindividual differences (factor 10). For the OPs studied in the present thesis, differences in predicted toxicity values of PFF and those values derived from rat in vivo toxicity studies were within 4-fold (EPA, 2016) while for average humans the predicted BMDL10 value was 2-fold higher than EFSA’s ARfD value (EFSA, 2019) (chapter 3), indicating that an extra uncertainty factor of for example 10 would
be by far sufficient to cover for the uncertainties related to use of the QIVIVE approach. Earlier studies have shown that the PODs for developmental toxicity predicted with the in vitro PBK approach were within 0.2 to 10-fold difference compared to the corresponding values derived from in vivo data (Louisse et al., 2015; Louisse et al., 2010; Strikwold et al., 2017; Strikwold et al., 2013). Thus, based on the available data one would conclude that an uncertainty factor of 10 may be used when a POD is derived with the combined in vitro PBK modelling approach to predict developmental toxicity. To further substantiate the uncertainty factor to be used when using PBK modelling based reverse dosimetry to perform QIVIVE and predict in vivo dose response curves to define PODs for risk assessment, more examples and proofs-of-principles for other chemicals and other endpoints would be required to make this proposed UF more robust. In such assessments predictions made for experimental animals can be compared to animal toxicity data for evaluation of the approach and predictions in humans can be compared to currently available health based guidance values, to provide better insight into what uncertainty factor is considered adequate to apply when defining HBGVs using PBK modelling-based QIVIVE of in vitro toxicity data to provide similar protective HBVGs for humans as those currently derived based on animal toxicity data.

Taking it all together it can be concluded on the basis of the currently available data that when the combined in vitro PBK modelling approach would be based on an adequate human in vitro model and a human PBK model describing respectively the dynamics and kinetics directly for humans, it might be advocated to replace the default uncertainty factor 10 for inter-species differences by the uncertainty factor required when a POD for risk assessment is defined by a QIVIVE approach. Assuming that a factor of 10 would be sufficiently protective to cover the uncertainties of the QIVIVE approach the overall default uncertainty factor could then still be 100. However, the default factor of 10 is used if no data on interindividual differences are
available and may be replaced by a possible chemical specific adjustment factor (CSAF) when data on interindividual differences are available (IPCS, 2005).

6.8 Conclusion
In conclusion, the present thesis showed novel insights into hazards and risks following exposure to OPs via residues present in vegetables in Kenya. The assessment of the levels of OPs in vegetables in Kenya revealed that PFF and CPF were the most frequently encountered pesticide residues, and that CPF and PPF (when applying EFSA’s latest ARfD) had for some situations an acute HQ higher than 1, implying that potential health risks with respect to acute dietary exposure cannot be excluded. Therefore, routine monitoring of OPs and carbamates in vegetables is recommended to minimize consumers’ health risks.

Upon development of a PBK model for PFF, adequate predictions were obtained for dose levels leading to in vivo AChE inhibition upon acute exposure in rats providing another proof-of-principle that with this new approach methodology (NAM) in vivo effects of chemicals can be predicted without the use of in vivo studies. Moreover, the combined exposure to PPF and CPF at their ARfD was predicted to not affect AChE activity, and the AChE inhibition upon combined exposure to these OPs follows the concept of dose addition. Furthermore, at reported exposure levels, no toxicokinetic interactions of CPF on PPF detoxification are expected. Moreover prediction of interindividual differences in PFF detoxification using PBK modelling linked to Monte Carlo simulation followed by PBK modelling based reverse dosimetry revealed a close similarity between the predicted BMDL10 of the sensitive segment of the population and the latest ARfD reported by EFSA (2019) based on German evaluation, and that adopted by EPA (2016). The predicted BMDL10 was however 200-fold lower than the ARfD derived by JMPR (2007), which appeared to be non-protective as it was predicted to lead to AChE inhibition in humans.
Finally, the present thesis has provided further proofs-of-principle that the PBK model-facilitated reverse dosimetry solely based on in vitro assays and in silico data, together with a relative potency factor methodology or Monte Carlo simulation, can be adequately used to derive PODs and provide data that may be used to derive a chemical specific adjustment factor (CSAF) value for defining inter-species and inter-individual differences in OP-induced RBC AChE inhibition resulting from the variability in toxicokinetics following acute oral exposure to an OP. The current and next generation human health risk assessors for OPs may utilize data generated in the present thesis on directly predicted PODs for the human situation based on the combined in vitro and in silico approach without the need for in vivo animal studies. Altogether, the current work supports the implementation of the 3Rs principle, the application of NAMs in next generation OP-human risk assessment and regulatory decision making.
REFERENCES


Bouchard, M., Carrier, G., Brunet, R.C., Bonvalot, Y., Gosselin, N.H. 2005. Determination of


Chiu, Y.H., Williams, P.L., Gillman, M.W., Hauser, R., Rifas-Shiman, S.L., Bellavia, A.,


260

http://dx.doi.org/10.1016/S0300-483X(00)00452-2


European Food Safety Authority (EFSA) 2019b. Scientific Report on scientific support for

https://doi.org/10.2903/j.efsa.2019.5797


FIFRA, Scientific Advisory Panel. (2012). Transmittal of the Meeting Minutes from the FIFRA


General discussion and future perspectives


General discussion and future perspectives


Ortiz-Delgado, J.B., Funes, V., Sarasquete, C., 2019. The organophosphate pesticide -OP-


Talk Africa – Association for Freelance Journalists, Agriculture Stakeholders Support Kenya Government’s Upgrade of Pesticide Legislation, online publication, 2019.


Timchalk, C., Poet, T.S., 2008. Development of a physiologically based pharmacokinetic and
pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat. Neurotoxicology. 29(3):428-43.


Disease, Archives of Environmental & Occupational Health, 60:1, 32-38,


CHAPTER 7.

Summary
Summary
The use of chemical pesticides is indispensable in Kenya due to the hot and humid tropical environmental conditions that are conducive to the development of pests, weeds, and disease vectors. Currently, OPs are among the most widely used pesticides in agriculture, and their residues have been found in various foods. Currently, PODs have been derived from data on OP-induced AChE inhibition from animal studies, and this is undesirable due to economical, ethical and scientific limitations. The main aim of this thesis was to develop non-animal approaches in OP risk assessment and application of these novel methods to predict the potential of the OPs to inhibit AChE in vivo upon acute exposure, also taking combined exposure into account. Furthermore, this thesis aimed to obtain data on the occurrence of OPs on commonly consumed vegetables in Kenya, as such data, and related estimations of human exposure, are lacking. Chapter 1 of the thesis provides background information on OP use in agriculture, the exposure of non-target species to OPs and a description of the characteristics and toxicity of the OPs studied in this thesis, profenofos (PFF), and chlorpyrifos (CPF). This chapter also presents background information on the hazard assessments for PFF and CPF and presents the concepts of PBK modelling-based reverse dosimetry and approaches used to assess combined exposure. Chapter 2 analyses the occurrence of OPs in commonly consumed vegetables in Kenya and assesses the accompanying exposure and health risks. A total of 90 samples were analysed by liquid chromatography/high-resolution tandem mass spectrometry. Residues of acephate, CPF, methamidophos, omethoate and PFF were found in 22% of the samples, at levels ranging from 10 to 1343 μg/kg. The EU MRL for these OPs was exceeded in 21%, 10%, 8% and 22% of the samples of French beans, kales, spinach, and tomatoes, respectively. CPF in spinach had an acute Health Quotient (HQ) of 3.3 and 2.2 for children and adults, respectively, implying that potential health risks with respect to acute dietary exposure cannot be excluded. For chronic
dietary exposure, all chronic HQs were below 1. The Health Index (HI) for the pesticides, i.e. the sum of the chronic HQs, was 0.54 and 0.34 for children and adults, respectively.

**Chapter 3** proposes a combined in vitro-in silico approach to predict AChE inhibition by the OP profenofos in rats and humans by applying PBK modelling-facilitated quantitative in vitro to in vivo extrapolation (QIVIVE). A PBK model was developed for both species. Parameter values for profenofos conversion to 4-bromo-2-chlorophenol (BCP) were derived from in vitro incubations with liver microsomes, liver cytosol, and plasma from rats and humans whereas other chemical-related parameter values were derived using in silico calculations. The PBK model predictions were evaluated by comparison to literature data on profenofos kinetics in rats following oral exposure (Cho et al., 2002). To facilitate PBK model based quantitative in vitro to in vivo extrapolation (QIVIVE), concentration-dependent inhibition of rat and human AChE was determined in vitro and these data were translated with the PBK models to predicted dose-dependent AChE inhibition curves in rats and humans in vivo. When the predicted dose-response curve for PFF-induced AChE inhibition in rats was compared to literature data, the prediction of the in vivo effect levels appeared accurate. Comparison of rat predictions (the BMDL10 of the predicted dose-response curve being 0.45 mg/kg bw) and human predictions (the BMDL10 of the predicted dose-response curve being 0.01 mg/kg bw) suggested humans to be more sensitive than rats. The PBK models revealed that this difference appeared to be mainly due to higher catalytic efficiencies for microsomal, cytosolic and plasma biotransformation of PFF to BCP in rats as compared to humans. Another possible reason for the differences in PFF detoxification may be related to quantitative differences in B-esterases in rats and humans, which may affect the metabolism and disposition of ester compounds including OPs. B-esterases, such as carboxylesterase (CaE), butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE), detoxify oxons, but these enzymes are inhibited by the oxons as a consequence. In this way, B-esterases may play a protective role in rats but not humans. It has
been reported that rat plasma contains almost all types of esterases including CaE, PON1, BChE, and AChE, whereas humans are deficient of plasma CaE and plasma AChE. The absence of CaE in human plasma in addition to low PON1 activity may therefore be responsible for lower PFF clearance resulting in higher sensitivity of humans to PFF as compared to rodents. Altogether, the results demonstrate that in vivo AChE inhibition upon acute exposure to profenofos was closely predicted in rats, indicating the potential of this novel approach method in chemical hazard assessment.

**Chapter 4** investigates the combination effects of two selected OPs (PFF and CPF), by studying the combined effects of PFF and CPF’s toxic metabolite chlorpyrifos oxon (CPO) on AChE inhibition in vitro, as well as the effects of CPF and CPO on PFF biotransformation (detoxification) by human liver microsomes, cytosol, and human plasma. The PFF physiologically based kinetic (PBK) model developed in chapter 3 was extended to include the description of CPF kinetics, using also in vitro kinetic data from the literature and in silico calculations. The PFF concentrations in the model are expressed as CPO-equivalents (i.e., using a TEF/RPF approach) allowing prediction of total internal CPO-equivalents (and related effects on AChE activity) upon combined exposure to PFF and CPF. AChE inhibition was shown to be 199-fold more potent by CPO than by PFF, and combined exposure to CPO and PFF resulted in effects that are in line with the principles of dose addition. CPF and CPO appeared to affect PFF detoxification to its main metabolite (BCP) in a non-competitive manner at high concentrations, with Ki values of 120, 256 and 473 μM for CPF, and 80, 63 and 326 μM for CPO, for liver microsomes, liver cytosol and plasma, respectively, concentrations far higher than in vivo relevant concentrations. The model adequately predicted the AChE inhibition in a hospitalized person with CPF poisoning as reported in the literature (Drevenkar et al., 1993). Combined exposure to PFF and CPF at their ARfD (0.005 mg/kg bw) was predicted to not affect AChE activity. Altogether, this study reveals that AChE inhibition upon combined
exposure to these OPs follows the concept of dose addition, and that at estimated exposure levels, no toxicokinetic interactions of CPF on PFF detoxification are expected.

**Chapter 5** aimed to predict human interindividual differences in PFF detoxification based on a combined in vitro-in silico approach to account for human variability in toxicokinetics. To that end, PFF conversion to BCP was studied in in vitro incubations with S9 liver fractions of 25 different Caucasian donors and with plasma samples of 25 different Caucasian donors. The obtained information on the variation in the in vitro kinetic constants Vmax and Km, was applied in the PBK model developed in Chapter 3 using a Monte Carlo simulation modelling approach. Internal concentrations were estimated for the geometric mean (GM), the 90th, 95th and 99th percentiles of the simulated virtual population. The model was then used for reverse dosimetry of the in vitro data on PFF-induced AChE inhibition of Chapter 3. Also, the interindividual variability in PFF toxicokinetics was quantified by dividing the internal Cmax concentrations of profenofos for the 90th or 99th percentile by that of the GM, which was compared to the default uncertainty factor for interindividual differences in kinetics (IPCS 2005). The predicted BMDL10 for the 99th percentile was compared to PODs of the regulatory bodies. Analysis of the predicted internal maximum concentrations of PFF in the simulated population indicated a 1.4-, 1.4- and 1.5-fold difference between the geometric mean (GM) and the 90th, 95th and 99th percentile, respectively, of the simulated population. These factors are below the default uncertainty factor accounting for human variability in toxicokinetics of 3.16. Concentration-response curves for inhibition of human AChE determined in vitro were translated with the PBK models to predicted dose-dependent AChE inhibition in humans in vivo. In line with the differences in Cmax values, the 99th percentile of the population was predicted to be 1.5-fold more sensitive to PFF-induced AChE inhibition than the GM of the population based on the BMDL10 values of predicted dose-response data for the virtual populations. Comparing the predicted BMDL10 of 0.0057 mg/kg bw for the 99th percentile
with health based guidance values proposed by the regulatory bodies reveals a close similarity to the ARfD reported by EFSA, (2019) of 0.005 mg/kg bw, based on a German evaluation, and being slightly higher than the ARfD adopted by EPA, (2016) of 0.002 mg/kg bw. It is, however, 200-fold lower than the ARfD of 1 mg/kg bw adopted by JMPR, (2007). The results from this thesis would support the use of the ARfD of 0.005 mg/kg bw rather than the ARfD of 1 mg/kg bw, as at 1 mg/kg bw clear PFF-induced AChE inhibition was predicted in humans. Altogether, the results obtained demonstrate that integrating PBK modelling with Monte Carlo simulations using human in vitro data provides a powerful strategy to quantify human interindividual variation in kinetics, which can be used to refine the hazard characterization of OPs.

Finally, **Chapter 6** of the present thesis discusses the general discussion of the results of the previous chapters and highlights on the future perspectives for research in the use of alternative methods in risk assessment of OPs.

In conclusion, the present thesis showed novel insights into hazards and risks following exposure to OPs via residues present in vegetables in Kenya. The assessment of the levels of OPs in vegetables in Kenya revealed that PFF and CPF were the most frequently encountered pesticide residues, and that CPF and PPF (when applying EFSA’s latest ARfD) had for some situations an acute HQ higher than 1, implying that potential health risks with respect to acute dietary exposure cannot be excluded. Therefore, routine monitoring of OPs and carbamates in vegetables is recommended to minimize consumers’ health risks.

Upon development of PFF PBK model adequate predictions were obtained for dose levels leading to in vivo AChE inhibition upon acute exposure to single or combined OPs, providing another proof-of-principle that with this new approach methodology (NAM) in vivo effects of chemicals can be predicted without the use of in vivo studies. In addition, the prediction of interindivdual differences in PFF detoxification using PBK modelling linked to Monte Carlo simulation followed by PBK modelling based reverse dosimetry revealed a close similarity
between the predicted BMDL10 of the sensitive segment of the population and the latest ARfD reported by EFSA (2019) based on German evaluation. Finally, the present thesis has provided further proofs-of-principle that the PBK model-facilitated reverse dosimetry solely based on in vitro assays and in silico data, together with a relative potency factor methodology or Monte Carlo simulation, can be adequately used to derive PODs and provide data that may be used to derive a chemical specific adjustment factor (CSAF) value for defining inter-species and inter-individual differences in OP-induced RBC AChE inhibition resulting from the variability in toxicokinetics following acute oral exposure to an OP. The current and next generation human health risk assessors for OPs may utilize data generated in the present thesis on directly predicted PODs for the human situation based on the combined in vitro and in silico approach without the need for in vivo animal studies. Altogether, the current work supports the implementation of the 3Rs principle, the application of NAMs in next generation OP-human risk assessment and regulatory decision making.
Appendices

Acknowledgements
Lists of Publications
About the author
Overview of Completed Training Activities
Acknowledgements

I would like to express my sincere gratitude and appreciation to all people who encouraged and supported me throughout my PhD journey to get to where I am now. Without you, the journey would have been more difficult.

First I would like to sincerely thank you my promoter Prof. Dr. Ivonne Rietjens for your support, guidance and encouragement throughout the period of study. Thank you Ivonne for the opportunity to join the Division of Toxicology as a PhD student. Apart from the scientific knowledge, I have learnt many positive attributes, such as working in a smart and efficient way.

I also highly appreciate your quick and constructive feedback during the writing process, especially at the last stage of my thesis. Despite the pandemic posing a new challenge last year, thank you Ivonne for your help in tackling one of the most critical and difficult moments of a PhD project. From you I learnt the meaning of a good scientist.

To my co-promoter Dr. Jochem Louisse, thank you so much for your dedicated support during the scholarship application process. We actually knew each other long before we met. I am grateful for your patience, guidance and critical comments throughout this journey. I appreciated and enjoyed the meetings we had and the discussions we had along the way, especially when we figured out the way forward after encountering challenges. I really appreciate your dedicated support and guidance on modelling. You challenged me to always learn more. All along, you were always ready and willing to help, and I highly appreciate you for that. I admired your thorough and diligent working style. I sincerely appreciate you for all you did to and the advice you provided.

To my co-promotor Dr. Hans Mol, thank you so much for your valuable advice and guidance throughout this journey. I really appreciate you critical comments on my publications and thesis. I am also grateful for the meetings we had to figure out risk assessment approach for my first paper. All your contributions are highly appreciated.
I would also like to thank the PhD thesis committee Prof. Dr. Violette Geissen, Dr. Jessica Broeders, Dr. Paul Scheepers and Dr. Remco Westerink, for the effort and time you expended to critically review this PhD thesis.

To everyone at TOX, thank you so much for your support and comradery. Sebas, thank you so much for your assistance and help in the ordering of products, setting up the methods of UPLC and being so patient to teach me how to use the machines. Thank you so much for the conversations we had about the Dutch lifestyle, family and your beautiful cat. I really appreciate you for your time, effort, and positive energy. Bert, thank you for helping me solve challenges related to the running of the UPLC. Thank you also for very well organized AChE practicals.

I enjoyed the conversations we had in the lab and thank you for sharing your family pictures and stories of grandchildren. Me thank you for the great time! Nico and Hans, thanks for the nice talks during the coffee breaks/lunch, and the constructive questions during my research in progress presentations. Letty, thanks for your help in arranging PET courses. Laura, it was working with you in organizing for practical courses and for the chats from time to time. Lidy, thank you so much for all your help since my resumption of my studies until your last day at TOX. Carla and Gerda, thank you so much also for all your help with all administrative matters.

To all the Intoxicated PhDs (old and new), I am so happy and grateful to have shared this time with you (birthdays, Sinterklaas, dinners, BBQs, etc). I’m grateful to all of my former and current office mates for the time we shared, I really had a wonderful time with you all. Felicia, Danlei, Bohan, Edit and Jing, thank you so much for being so cheerful, you made the office warm and a fun place be. I thank you for the good chats and encouragements during this journey. To all the former and current PhDs I have been privileged to meet;

Aafke, Akanksha, Annelies, Artem, Ashraf, Aziza, Biyao, Bohan, Chen, Danlei, Diana, Diego, Edith, Felicia, Frances, Gogo, Ixchel, Jia, Jiaqi, Jin Jing, Jing, Jingxuan, Katharina, Katja, Lenny, Liang, Lu, Maartje, Marta, Mebrahtom, Mengying, Menno, Merel, Miaoying, Nacho,
Nina, Orsolya, Pim, Qianrui, Qiu hui, Shensheng, Shuo, Suparmi, Tessa, Veronique, Weija, Yasser and Yiming, I wish you all a wonderful time and for those who already finished, all the success in the future! To Felicia, Diana, Annelies, Ixchel, Aziza, Menno, Mebrahtom, Sheng sheng, Edith, Miaoying, and Diego, thanks for the friendship and it was great to have worked (and talked) with you. To all current, and new PhDs not included here, I wish you the best!

To Shensheng, thank you so much for the long hours of work we did together, for the enlightening discussions and laughs we had as we worked on our pet subject of pesticides. The constant support and encouragement we gave to each other was important.

To the Kenyans in WUR, Joshua, Faith, Shaphan, Asaph, Alex, Jared, Jane, Jasper, Kirina, Boit, Emma, Emily, Jackie, Hellen, Jasper, Mendi, Nyokabi, Shikuku, Ojos, Asaah, Migose, Richard, DK, Esther, Nathaniel, Mercy and Brian, thank you all for the hearty laughs, the chats, diners, the BBQs and all the moments we shared, you are amazing! The constant support we gave to each other was important.

Finally, the most important to me, my family: My love and best friend Elcah, daughter Briella and son Omwenga junior, thank you for the love and the patience during this treacherous journey. To my all-time cheerleaders; Dad Samson Omwenga, Mom Marcellah Kemunto, brothers Ben and Andrew, sisters Judy and Evelyn, I love you all. Your constant prayers and support is highly appreciated. I couldn’t have done all this without you!
List of Publications


**Omwenga I**, Zhao S, Mol H, Rietjens IMCM, Louissee J. Prediction of in vivo acetylcholinesterase inhibition upon acute combined exposure to profenofos and chlorpyrifos by using a combined in vitro and in silico approach. *(Submitted)*

**Omwenga I**, Zhao S, Mol H, Rietjens IMCM, Louissee J. Predicting interindividual differences in profenofos detoxification based on in vitro kinetic data and a physiologically based kinetic (PBK) and Monte Carlo modelling approach. *In preparation*
About the Author

Isaac Omwenga was born on 31 December 1985 in Nyamira, Kenya. He studied Veterinary Medicine and Surgery at the University of Nairobi, Kenya. After obtaining his BVM in 2010, he was awarded a University of Nairobi scholarship to pursue his MSc studies in Pharmacology and Toxicology in the same university. Thereafter, he was awarded the Netherlands Universities Foundation for international Cooperation (NUFFIC) scholarship under the Netherlands fellowship program (NFP) to pursue a PhD in Toxicology at the Division of Toxicology, Wageningen University and Research under the supervision of Prof. Dr. Ivonne Rietjens, Dr. Jochem Louisse and Dr. Hans Mol. The results of the research program are presented in this thesis. During his PhD he followed a postgraduate education in Toxicology (PET) as part of the training required for the registration as European Toxicologist.
Overview of Completed Training Activities

**Discipline specific courses**

<table>
<thead>
<tr>
<th>Name of Course</th>
<th>Organising Institute and Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutagenesis and Carcinogenesis</td>
<td>Postgraduate Education in Toxicology (PET), 2019</td>
</tr>
<tr>
<td>Cell Toxicology</td>
<td>PET, 2019</td>
</tr>
<tr>
<td>Molecular Toxicology</td>
<td>PET, 2019</td>
</tr>
<tr>
<td>Pathobiology</td>
<td>PET, 2020</td>
</tr>
<tr>
<td>Organ Toxicology</td>
<td>PET, 2020</td>
</tr>
<tr>
<td>Introduction Laboratory Animal Science</td>
<td>PET, 2020</td>
</tr>
<tr>
<td>Medical and Forensic Toxicology</td>
<td>PET, 2019</td>
</tr>
</tbody>
</table>

**Conferences**

- Society of Toxicology 59th Scientific conference (SOT) 2020 (Virtual) - California, 2020
- SOT 60th Annual Meeting (Virtual) - 2021

**General Courses**

<table>
<thead>
<tr>
<th>Course</th>
<th>Organising Institute and Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk assessment</td>
<td>Wageningen University and Research (WUR), 2018</td>
</tr>
<tr>
<td>Brain Training</td>
<td>WUR, 2019</td>
</tr>
<tr>
<td>Introduction to R</td>
<td>WUR, 2019</td>
</tr>
<tr>
<td>Scientific Writing</td>
<td>WUR, 2020</td>
</tr>
<tr>
<td>Start to teach</td>
<td>WUR, 2019</td>
</tr>
<tr>
<td>Philosophy and Ethics of Food Science and Technology</td>
<td>WUR, 2020</td>
</tr>
</tbody>
</table>

**Optional**

- General Toxicology - WUR, 2018
- Food Toxicology - WUR, 2019
- Environmental Toxicology - WUR, 2019
- Preparation of Research proposal - WUR, 2015
- Introduction to Epidemiology and public health - WUR, 2020
- Scientific presentations at Division of Toxicology - WUR, 2018-2021

---

**Approved by Graduate School VLAG**
In Vitro-In Silico Methods For Risk Assessment Of Organophosphate Pesticides (OPs) As Found In Commonly Consumed Vegetables In Kenya

Isaac Mokaya Omwenga

IN VITRO-IN SILICO METHODS FOR RISK ASSESSMENT OF ORGANOPHOSPHATE PESTICIDES (OPS) AS FOUND IN COMMONLY CONSUMED VEGETABLES IN KENYA – ISAAC OMWENGA

INVITATION
For the public defence
of my thesis entitled:
IN VITRO-IN SILICO METHOD FOR RISK ASSESSMENT OF ORGANOPHOSPHATE PESTICIDES (OPS) AS FOUND IN COMMONLY CONSUMED VEGETABLES IN KENYA

On Friday 7th Jan 2022 at 13:30
in the Aula of Wageningen University,
Generaal Foulkesweg 1,
Wageningen

Isaac Omwenga
dr.isaacomwenga@gmail.com

Paranymphs:
Annelies Noorlander
annelies.noorlander@wur.nl
Menno Grouls
menno.grouls@wur.nl